Patient preferences of genomic testing in precision cancer medicine by Fulton, Ben Alexander
 
 
 
 
 
 
 
 
Fulton, Ben Alexander (2020) Patient preferences of genomic testing in 
precision cancer medicine. MD thesis. 
 
http://theses.gla.ac.uk/81435/ 
 
Copyright and moral rights for this work are retained by the author  
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge  
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author  
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author  
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses  
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
 
  
 
Patient preferences of genomic testing in 
precision cancer medicine 
 
 
 
 
Ben Alexander Fulton 
MBChB, FRCP, FRCR 
 
 
 
 
Application in support of the degree of Doctor of Medicine 
University of Glasgow 
College of Medical, Veterinary and Life Sciences 
May 2020 
ii 
 
Declaration 
I declare this thesis has been written by myself and has not previously been submitted for a 
higher degree. The thesis was undertaken during my post as a Clinical Research Fellow at 
the University of Glasgow. All chapters were written by myself. Where others have been 
involved, this has been acknowledged. 
 
 iii 
 
Table of Contents 
 
Declaration ................................................................................................................... ii 
Table of Contents ........................................................................................................ iii 
List of Figures ............................................................................................................ vii 
List of Tables............................................................................................................. viii 
Abstract ....................................................................................................................... ix 
Acknowledgements ..................................................................................................... xi 
Abbreviations. ........................................................................................................... ixii 
Chapter 1. Introduction .............................................................................................. 15 
1.1. Overview of precision medicine ...................................................................... 15 
1.2. The role of bioinformatics and genomics in precision medicine .................... 17 
1.3. The role of genomic sequencing ..................................................................... 18 
1.4. Evolution from evidence-based to precision medicine ................................... 19 
1.5. Precision medicine in cancer ........................................................................... 20 
1.6. Barriers to clinical adoption of genomic testing ............................................. 24 
1.7. Health economic assessment of genomic testing in PCM ............................... 25 
1.8. Current landscape of UK clinical trials in PCM .............................................. 27 
1.9. Role of patient preferences for genomic testing .............................................. 33 
1.10. Conclusions ................................................................................................... 35 
Chapter 2. Assessing patient preferences of genomic testing .................................... 37 
2.1. Introduction ..................................................................................................... 37 
2.2. Mixed methods research in defining and rating attributes .............................. 37 
2.3. Consensus methods research ........................................................................... 42 
2.3.1. Background of consensus research ........................................................... 42 
2.3.2. The Delphi Technique .............................................................................. 43 
2.3.3. The Nominal Group Technique ................................................................ 46 
2.3.4. Discussion ................................................................................................. 48 
2.4. Conclusions ..................................................................................................... 51 
Chapter 3. Assessing patients’ preferences of genomic testing in PCM: A Systematic 
Review........................................................................................................................ 52 
3.1. Introduction ..................................................................................................... 52 
3.2. Systematic Review Methods ........................................................................... 52 
3.2.1. Background ............................................................................................... 52 
 iv 
 
3.2.2. Search strategy .......................................................................................... 53 
3.2.3. Selection criteria ....................................................................................... 54 
3.2.4. Data extraction .......................................................................................... 56 
3.2.5. Critial appraisal ......................................................................................... 56 
3.3. Results ............................................................................................................. 58 
3.4. Discussion ....................................................................................................... 66 
3.5. Conclusions ..................................................................................................... 70 
Chapter 4. Methodology............................................................................................. 72 
4.1. Overview ......................................................................................................... 72 
4.2. Research Aims ................................................................................................. 72 
4.2.1. Hypotheses ................................................................................................ 72 
4.2.2. Ethical approval ........................................................................................ 72 
4.3. Nominal Group design considerations ............................................................ 73 
4.3.1. Participant selection and group composition ............................................ 74 
4.3.2. Introduction to the Nominal Group process ............................................. 75 
4.3.3. Silent generation of ideas .......................................................................... 76 
4.3.4. Round robin .............................................................................................. 77 
4.3.5. Clarification .............................................................................................. 77 
4.3.6. Rating of preference attribute themes ....................................................... 78 
4.3.7. Data management ..................................................................................... 79 
4.3.8. Data analysis ............................................................................................. 79 
4.4. Conclusions ..................................................................................................... 81 
Chapter 5. Results ...................................................................................................... 81 
5.1. Pilot study ........................................................................................................ 81 
5.1.1. Participant demographics .......................................................................... 81 
5.1.2. Preference attribute themes and ratings for pilot group ............................ 83 
5.1.3. Lessons learned from pilot study .............................................................. 83 
5.1.4. Discussion ................................................................................................. 84 
5.2. Main Study participant demographics ............................................................. 85 
5.3. Nominal group A results ................................................................................. 88 
5.3.1. Participant demographics .......................................................................... 88 
5.3.2. Preference attribute themes ....................................................................... 90 
5.3.3. Preference attribute theme ratings ............................................................ 92 
5.4. Nominal Group B (radical treatment completed more than 2 years prior) results
 ................................................................................................................................ 94 
 v 
 
5.4.1. Participant demographics .......................................................................... 94 
5.4.2. Preference attribute themes ....................................................................... 97 
5.4.3. Preference attribute theme ratings ............................................................ 99 
5.5. Nominal group C (palliative treatment intent) results ................................... 100 
5.5.1. Participant demographics ........................................................................ 101 
5.5.2. Preference attribute themes ..................................................................... 103 
5.5.3. Preference attribute theme ratings .......................................................... 105 
5.6. Summary of Nominal Group results.............................................................. 106 
5.7. Discussion of results ...................................................................................... 108 
5.7.1. Introduction ............................................................................................. 108 
5.7.2. Defining preference attribute themes of genomic testing in PCM ......... 109 
5.7.3. Effect of clinical treatment intent on preference attributes and ratings .. 115 
5.7.4. Effect of time since completion of treatment on preference attribute themes 
 and ratings ........................................................................................................ 122 
5.8. Conclusions ................................................................................................... 127 
Chapter 6. Benchmarking patient preferences of genomic testing in the ATLANTIS 
clinical trial............................................................................................................... 131 
6.1. Introduction ................................................................................................... 131 
6.2. ATLANTIS trial ............................................................................................ 133 
6.2.1. Aims and objectives of ATLANTIS ....................................................... 133 
6.2.2. Study design ............................................................................................ 135 
6.2.3. Patient population and eligibility criteria................................................ 137 
6.2.4. Statistical considerations......................................................................... 140 
6.3. Benchmarking patient preferences of genomic testing in ATLANTIS ......... 141 
6.3.1. Aims of benchmarking exercise ............................................................. 142 
6.3.2. Methods .................................................................................................. 142 
6.3.3. Identification of patient population......................................................... 144 
6.3.4. Selection of ‘best practice’ benchmark ................................................... 144 
6.4. Results ........................................................................................................... 145 
6.5. Discussion ..................................................................................................... 151 
6.6. Conclusions ................................................................................................... 154 
Chapter 7. Discussion and Conclusions ................................................................... 156 
7.1. Introduction ................................................................................................... 156 
7.2. Revisiting the thesis research questions ........................................................ 157 
 vi 
 
7.2.1. How are patient preferences of genomic testing in PCM defined and rated?
 .......................................................................................................................... 157 
7.2.2. Do current clinical trial designs incorporate patient preference attributes of 
genomic testing in PCM? .................................................................................. 159 
7.3. Implications for policy and clinical practice ................................................. 161 
7.4. Study strengths and limitations ..................................................................... 162 
7.4.1. Study strengths ........................................................................................ 162 
7.4.2. Study limitations ..................................................................................... 163 
7.5. Future research .............................................................................................. 165 
7.6. Conclusions ................................................................................................... 166 
References ................................................................................................................ 167 
Appendix 1 – PRISMA checklist ............................................................................. 178 
Appendix 2 – Data extraction tables of studies included in systematic review ....... 182 
Appendix 3 – Mixed Methods Appraisal Tool (MMAT) methodological quality .. 185 
Appendix 4 – Patient preference attribute summary tables ..................................... 191 
Appendix 5 – Pilot Nominal Group Study Guide (v1.0) ......................................... 194 
Appendix 6 – Main Nominal Group Study Guide (v2.0) ........................................ 197 
Appendix 7 – Ethics approval .................................................................................. 201 
Appendix 8 – Participant consent form .................................................................... 202 
 
 
 vii 
 
List of Figures 
Figure 1 – Search strategy for systematic review of the literature ............................. 54 
Figure 2 – PRISMA flow chart for systematic review ............................................... 59 
Figure 3 – Flow diagram of participant recruitment to NGT study ........................... 75 
Figure 4 – SPIRIT diagram of ATLANTIS study design ........................................ 136 
 viii 
 
List of Tables 
Table 1 – Examples of healthcare studies using the Nominal Group Technique ................ 49 
Table 2 – Examples of healthcare studies using the Delphi Technique ............................... 50 
Table 3 – PICOS criteria applied to systematic review ....................................................... 55 
Table 4 – Criteria for studies included in systematic review ............................................... 57 
Table 5 – Pilot study participant demographics ................................................................... 82 
Table 6 – Results of preference attribute rating for pilot Nominal Group ........................... 83 
Table 7 – Summary participant demographics across all Nominal Groups ......................... 86 
Table 8 – Group A participant demographics ...................................................................... 88 
Table 9 – Preference attribute themes for each group A subgroup ...................................... 91 
Table 10 – Group A preference attribute theme ratings ....................................................... 92 
Table 11 – Group B participant demographics .................................................................... 95 
Table 12 – Preference attribute themes for each group B subgroup   .................................. 98 
Table 13 – Group B preference attribute theme ratings ....................................................... 99 
Table 14 – Group C participant demographics .................................................................. 101 
Table 15 – Preference attribute themes for each group C subgroup  ................................. 104 
Table 16 – Group C preference attribute theme ratings ..................................................... 105 
Table 17 – Summary of preference attribute theme ratings across all Nominal Groups ... 107 
 
 ix 
 
Abstract 
Aims: The aim of this thesis was to identify and rate themed patient preference attributes 
of genomic testing in precision cancer medicine (PCM).  The effect of clinical treatment 
intent and time since completing treatment was examined as a novel hypothesis that these 
factors influence identified preference attribute themes and/or ratings.  This thesis then 
benchmarked the identified preference attributes against the ATLANTIS clinical trial 
design, in order to assess how a current clinical trial incorporates patient preferences.  
Methods: A narrative review of current cancer treatment paradigms was undertaken 
alongside systematic review of the literature assessing patient preferences of genomic 
testing in PCM.  In addition, mixed methods research, using Nominal Group Technique 
(NGT), identified and rated preference attribute themes of genomic testing amongst cancer 
patients.  These preference attributes were then benchmarked against genomic testing 
undertaken within the ATLANTIS clinical trial, to determine how a novel PCM study 
design incorporated the attributes.   
Results:  Patient preferences of genomic testing in PCM are influenced by clinical 
treatment intent and time since completing treatment.  Patients undergoing cancer 
treatment with radical intent demonstrated higher preference ratings for test sensitivity 
(true positive) and specificity (true negative).  Invasiveness of testing and test turnaround 
time were higher rated preference attributes amongst patients undergoing treatment with 
palliative intent.  Ten preference attribute themes of genomic testing were identified: 
regulatory/NHS approval, test turnaround time, invasiveness of testing, physician approval, 
test sensitivity (true positive), test specificity (true negative), prevalence of variant, 
distance to travel, implications for family and family endorsement for testing.  The novel 
adaptive design of the ATLANTIS trial incorporated many of the preference attribute 
themes of genomic testing demonstrated in this thesis. 
 x 
 
Conclusions: Patient preferences of genomic testing in PCM are influenced by clinical 
treatment intent.  This thesis identified and rated preference attribute themes of genomic 
testing for patients, as well as benchmarking these against a current UK PCM clinical trial.  
The adaptive design of the ATLANTIS trial incorporated many of the preference attributes, 
but does not allow for assessment of interaction between multiple inter-related attributes.  
The results of this thesis augment novel clinical trial design for studies incorporating 
genomic testing in order they retain patient-centred values at their core.  
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Chapter 1. Introduction  
1.1. Overview of precision medicine 
The last century has seen a marked evolution in healthcare from physician preference 
approaches to a largely evidence-based one.  Whilst this has resulted in improved clinical 
outcomes for patients, it remains a mechanism whereby treatments are based on 
stratification by phenotypic markers and average response across a population that, to a 
large extent, ignores the variation between individuals.  Precision medicine is an emerging 
approach in multiple disease treatment and prevention strategies, taking into account 
individual variability in genes, lifestyle and environment (Berger & Van Allen, 2016).  The 
precision medicine approach subdivides individual patients into groups based on their risk 
of developing specific diseases or their response to particular therapies.   
 
There are many inter-related variables influencing an individual’s response to treatment 
(Schmidt, Chau, Price, & Figg, 2016).  These include disease delineation and stratification, 
early detecting, monitoring, modelling around dynamics of disease evolution, improved 
surveillance and management (Beckmann & Lew, 2016).  Precision medicine aims to 
provide adapted surveillance and therapies to delay onset of disease and, where possible, 
prevention strategies.  This may lead to a paradigm shift in the focus of healthcare as well 
as development of new taxonomies for health conditions.  
 
Distinct genetic variants cause conditions that respond to different treatments yet share 
similar symptoms.  Precision medicine aims to provide a mechanism to determine the 
underlying genetic cause of a set of symptoms or disease.  One such example lies in the 
understanding that many genetic lesions can lead to increased risk of cardiomyopathy and 
sudden cardiac death, but only patients with mutation in GLA gene respond to enzyme 
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replacement therapy (Morel & Clarke, 2009).  Even in situations where the genetic cause 
of a disease is known, unrelated genomic variants can affect treatment efficacy by altering 
mechanisms for drug metabolism or increased likelihood of adverse events.  This is 
demonstrated, for example, when some patients treated with conventional doses of 
Azathioprine, an immunosuppressive medication, are at risk of developing life-threatening 
myelosuppression if they harbour genetic variants preventing the drug being properly 
metabolized (Relling, 2013).  These examples demonstrate the importance of identifying 
an individuals’ genomic profile for providing optimal care. 
 
Precision medicine has grown rapidly over recent years, fuelled globally by the Precision 
Medicine Initiative (PMI) launched in the United States in 2015.  The PMI represents a 
$215 million investment aimed at accelerating biomedical research.   The initiative has two 
main components: a near-term focus on cancers and a longer-term aim to generate 
knowledge applicable to a wider range of health and illnesses (Allen, 2015).  Both 
components are now within reach due to scientific advances including molecular biology, 
genomics, proteomics and bioinformatics, made possible by the Human Genome Project 
(Lander et al., 2001). 
 
In the United Kingdom (UK), the 100,000 genomes project was launched in 2013 to 
establish the use of genomic sequencing within the National Health Service (NHS), drive 
change within health services and more widespread adoption of the technology 
(Rabesandratana, 2014).  Genomics England was setup to deliver this national genomics 
project in partnership with the NHS.  Rare diseases and cancer were selected as the areas 
with immediate potential for clinical benefit of genomic analysis.  The previous UK 
Biobank and Deciphering Developmental Disorders framework highlighted the UK’s role 
as a leading influence in human genomics (Sudlow et al., 2015).   Such projects have the 
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aim of up-scaling population-based genomic sequencing and pivotal integration with 
clinical data.  Previous treatment paradigms have targeted ‘causative mutations’ within just 
one gene segment at a time.  Recent scientific advances in next generation sequencing 
allow for the sequencing of millions of DNA fragments simultaneously (Blumenthal, 
Mansfield, & Pazdur, 2016).  This allows scientists to perform genetic testing for many 
more individuals and test many thousands of genes at a time.  The initial sequencing of the 
human genome took 13 years to perform and cost over £2billion, where an individual 
genome can now be sequenced in around a day at a cost of less than £700 (Watson, et al. 
1990).  
 
1.2. The role of bioinformatics and genomics in precision medicine  
The capacity to create and interpret large volume data, produced by technological and 
scientific innovations, is having a profound effect on the scientific community by 
deepening understanding of disease biology (Auffray et al., 2016).  These advances 
facilitated genome sequencing from hundreds of thousands of individuals to define allele-
specific compositions and relative abundances of RNA transcripts in numerous cell types 
and conditions, allowing exploration of protein and metabolite profiles.  These genome 
sequences promote understanding of molecular, cellular and physiological mechanisms as 
well as integral pathways and networks.  This comprehensive data, including both multi-
scale and multi-level genomics requires increasingly complex multidimensional analyses 
to convert datasets into clinically meaningful information.  Clinical bioinformatics refers to 
the multidisciplinary approach  to the utilisation and integration of laboratory and clinical 
data and other resources (Breit, Baumgartner, Netzer, & Weinberger, 2016).  This is an 
essential component of data-driven precision medicine, bridging the gap between clinical 
and laboratory research. 
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The production of high volume data from ‘omics, imaging, clinical and emerging data 
types, including data ranging from single cells to organs, provides a wealth of information.  
This ever-expanding volume of data generated by such transformative tools will lead to an 
inevitable shift in healthcare.  This will be contingent on the data eventually being 
translated into clinical benefits for patients and populations.  This may provide synergistic 
opportunities for integrative approaches and a shift from traditional organ-based treatment 
paradigms to a more inclusive and systemic assessment of health and disease based on 
large scale genomic data sets (Auffray, Chen, & Hood, 2009; Hood & Tian, 2012). 
 
1.3. The role of genomic sequencing  
Recent years have witnessed the decreasing fiscal cost of next-generation sequencing 
(NGS) technologies.  This led to increased clinical application of these techniques.  
Targeted exome sequencing of a panel of genes for hotspot mutations, selected according 
to their relevance to specific disease, is the most common molecular profiling tool utilized 
at present.  There are several advantages with this approach; being more cost and time 
efficient, as well as more manageable bio-informatic and computational requirements 
(Lopez, Harris, Roda, & Yap, 2015).  NGS uses parallel sequencing arrays to interrogate 
DNA coding regions (whole exome sequencing) or entire eukaryotic genome (whole 
genome sequencing).  Whole genome sequencing offers the most comprehensive strategy 
for tumour genomic analysis, though it is currently limited in clinical application by cost 
and turnaround time of sequencing and analysis.  The sequencing of exome regions by 
whole exome sequencing may provide a more practical technique for use in clinical 
practice (Lopez et al., 2015).  Drillon et al (Drillon, Wang, & Arcila, 2015) demonstrated 
whole exome sequencing identified actionable genomic alterations in a further 65% of non-
small cell lung cancers, originally tested negative for mutations by non-NGS methods.  
Some groups incorporate whole exome sequencing into their patient selection strategies in 
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clinical trial units (Roychowdhury & Chinnaiyan, 2014).  The ultimate selection of 
technique is likely to be driven by the specific scientific hypothesis.  
 
As the cost-effective balance changes, NGS is shifting from being a research tool to 
frontline clinical practice.  The application of NGS principles led to discovery of 
mendelian diseases in foetal-derived plasma DNA, such as foetal aneuploidies (Beaudet, 
2016).  The majority of current NGS focuses on DNA sequencing, though there is 
increasing awareness that whilst this can be informative and valuable, our genomic DNA 
sequences do not encapsulate the comprehensive information defining individual or 
population health status.  The road from genomic to phenotypic health status is fraught 
with uncertainties.  This is reflected in the fact that, besides germ line variants, somatic 
variants need to be considered given potential somatic mosaicism (Lupski, 2013).  Venter 
and colleagues maintain the presence of the “dynamically changing nature of our genomes 
throughout our life.”  (Telenti, Perkins, & Venter, 2016).  The potential for monitoring 
such dynamic genomic changes may necessitate repeated sequencing of an individuals’ 
genomic profile throughout their disease process. 
 
1.4. Evolution from evidence-based to precision medicine 
Current treatment paradigms in medicine focus on organ-specific and disease phenotypic 
factors.  This was propagated by data from population studies, from which statistical 
interpretations are applied to infer treatment recommendations applied across that 
population.  This method means, for most traits, an individual may fall within the mean 
estimates, but may be an outlier for other traits which predispose towards poor response.  
Under these circumstances, current evidence-based medicine may fail to provide adequate 
response for a particular individual.  This contrasts with the premise of precision medicine, 
where the focus is around an individual and production of large volume multi-faceted data.  
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The precision medicine approach, however, also has limitations, with the multiplicity of 
data producing a wealth of unique outputs that may put the patient in to an “n of one” 
category (Ciardiello et al., 2014).  This may, in turn, lead to a significant reduction in the 
statistical power to define appropriate evidence-based guidelines.   
 
The roles of evidence-based and precision medicine are, though, potentially 
complementary.  There is added value gained from merging the strengths of both 
approaches and relies on an ability to perform analysis of large cohorts of patients with a 
wealth of genomic data.  Conversion from single cases to an evidence-based precision 
medicine approach requires collation and meta-analysis of large-scale datasets from multi-
institutional registers and cohorts.  This facilitates detailed analysis and aggregation of 
similar “n of one” cases, resulting in reliable inferences made from such stratified 
subgroups. 
 
1.5. Precision medicine in cancer 
Oncology is the clear choice for enhancing the near-term impact of precision medicine.   
Cancers aggregate as a common disease process and are amongst the leading causes of 
death worldwide (Schmidt et al., 2016).  Much of cancer biology is based on the central 
premise that it is a genetic disease, caused by a clone of cells proliferating in an 
unregulated fashion due to somatically-acquired mutations.  We now understand that many 
malignant tumours display heterogeneity both within and between tumours (Yap, 2012).  
Further classifying tumours into more precise subgroups, by powerful methods and 
analytical tools, enables clinicians to develop more accurate diagnostic, prognostic and 
therapeutic strategies (Jamal-Hanjani, Quezada, Larkin, & Swanton, 2015). 
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The concept of precision cancer medicine (PCM) creates opportunities for innovative 
therapies with clinical benefit, whilst challenging current models of clinical practice.  The 
application of the precision medicine concept, provides powerful methods for delineating 
individual patient characteristics supported by advances in proteomics and metabolomics 
(McShane, 2013).  The application of these scientific principles herald a rapid increase in 
the number and diversity of precision medicine clinical trials which, it is hoped, will 
transfer into clinical practice in future (Sleijfer, Bogaerts, & Siu, 2013).  The overriding 
premise of PCM is delivery of the ‘right drug to the right patient at the right time’ with the 
expectation that therapeutic selection based on individual tumour profiling may produce 
durable clinical benefits (Biankin, Piantadosi, & Hollingsworth, 2015).   
 
PCM moves beyond previous models of cancer therapeutics based on clinical trials of 
largely unselected patients, beyond a simple phenotypic marker, to profiling an 
individual’s cancer genome to optimize their clinical management (Chin, 2008).  PCM 
offers the potential to deliver safe and effective cancer treatment that is individualized, 
targeted and biologically rational.  One such example is the characterization of germline 
mutations that predict cisplatin-induced oto-toxicity and potentially provide a mechanism 
for prospective identification of at-risk patients (Ross, 2009). 
 
The concept of oncogene addiction was first proposed by Weinstein in 2002, with ensuing 
innovative approaches to cancer treatment (Weinstein, 2002).  The emergence of imatinib, 
the BCR-Abl tyrosine kinase inhibitor has revolutionised treatment of chronic myeloid 
leukaemia (Druker et al., 2006).  This was the first targeted ‘precision medicine’ agent to 
illustrate proof of concept that treating the principle driving oncogene can have a powerful 
impact on response.  The initiation of the ‘Cancer Genome Project’ at the Wellcome Trusts 
Sanger Institute, using exon Sanger sequencing, quickly identified somatic mutations in the 
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BRAF gene for the majority of malignant melanoma tumours (Flaherty et al., 2012).  This 
opened a window into the biology of these tumours and clinical translation with 
development of novel BRAF-targeted tyrosine kinase inhibitors demonstrating clinical 
activity in melanoma.    Subsequent generations of targeted agents have subcategorized 
tumours into molecular subsets, such as EGFR and ALK inhibition in non-small cell lung 
cancer (Maemondo et al., 2010; Shaw, 2013).  One further example, trastuzumab, has 
demonstrated efficacy for gastro-oesophageal and breast cancers over-expressing HER2, 
challenging conventional organ-specific treatment paradigms (Schmidt et al., 2016). 
Targeting actionable mutations has potential to transcend tumour histology, effectively 
categorizing tumours based on an individual molecular profile rather than anatomical 
tumour origin. 
 
The identification of genomic drivers of cancer progression has improved outcomes in 
many cancer subtypes.  Scientific consensus from the ‘Consensus of precision medicine for 
metastatic cancers Molecular Analysis for Personalised Therapy (MAP) Conference’ 
suggests that it is best to assess the molecular profile of tumours at the time of treatment 
and avoid archival samples (Swanton C, Soria JC, et al, 2016).  This is particularly relevant 
for genomic alterations involved in resistance to prior therapy, such as EGFR T790M 
mutations in lung cancer.  There remains, though, a lack of robust clinical evidence around 
the validity of many of these genes, leading to the advent of molecular screening clinical 
trials and large collaborative data sets attempting to place molecular data within a clinical 
context. 
 
Genomic testing provides information on cancer aetiology, prognosis and potential 
therapeutic responsiveness.   Abbosh et al outline the potential role of PCM in sequencing 
circulating tumour DNA (ctDNA) to identify tumour recurrence in advance of 
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conventional imaging (Abbosh et al., 2018).  This has potential to impact decisions on 
adjuvant therapy alongside development of therapeutic resistance.  Precision medicine is 
emerging as a natural extension that integrating research disciplines and clinical practice, 
building a knowledge base that can guide individualized patient care.  This occurs at a 
crucial time when efforts such as the UK 100,000 Genomes project (Rabesandratana, 
2014) and the US Precision Medicine Initiative seek to scale up population-based genome 
sequencing and integrate it with clinical data (Abrams et al., 2014).  The 100,000 Genomes 
project has driver the UK transformation process, leading to the established NHS Genomic 
Medicine Service.  This aims to perform 500,000 whole genome sequences deployed in 
routine care for rare diseases and cancer, based on annual review by the NHS Genomic 
Test Directory (Samuel and Farsides, 2017).   
 
The UK Stratified Medicine Paediatrics (SMPaeds) research study aims to test somatic and 
germline DNA and RNA tumour samples for genetic and gene-expression changes in 
children with cancer.  This aims to identify children who may be eligible for new targeted 
precision medicine cancer therapies.  Eligible patients include those with 
relapsed/refractory progressive solid tumours who undergo biopsy as part of their standard 
care.  Testing on formalin fixed paraffin embedded tumour biopsy tissue will include 
customised next generation sequencing (NGS) panels and methylation sequencing.  
Testing on fresh frozen biopsy material includes whole exome sequencing (WES), RNA-
sequencing (RNASeq) and low coverage whole genome sequencing (lcWGS).  Circulating 
tumour DNA (ctDNA) will also undergo NGS panel testing, digital polymerase chain 
reaction (PCR) and germline exome or genome sequencing.  This study will assess 
feasibility of delivering PCM testing within clinical timelines and proportion of patients 
with molecular alternations in tumour for whom a recommendation can be made of 
molecularly targeted therapy (George, SL., Izquierdo, E., et al, 2019). 
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In recent years, both medical research and legal landscape evolved as a result of 
developments in information technology.  Medical researchers are collecting, re-using and 
linking health-related genomic data on an unprecedented scale, based on the presupposition 
that research will significantly improve patient outcomes.  This has, however, led to an 
increasing concern about the effectiveness of existing data protection law and the need for 
more protection of personal data recognized by the European Union (EU)  (Mostert, 
Bredenoord, Biesaart, & van Delden, 2016). 
 
1.6. Barriers to clinical adoption of genomic testing 
The widespread adoption of genomic testing is mired in complexity, with considerable 
challenges needing addressed.  The widespread introduction of genomic sequencing 
challenges current clinical paradigms as they exist.  For an individual patient, such factors 
include tumour heterogeneity, technical feasibility or validity of biomarkers, integration 
and interpretation of ever-increasing volume of data, associated information technology 
needs, as well as multiple dimensions of value and cost-effectiveness (Ciardiello et al., 
2014). 
 
Cancers are known to express significant heterogeneity both between and within tumours, 
driving phenotypic variation posing significant challenge to precision cancer medicine (R. 
Burrell, McGranahan, & Bartek, 2013).  The extensive heterogeneity of common cancers, 
seen by expression of protein biomarkers and at multiple genetic and epigenetic levels, 
complicates our understanding of cancer pathways and potentially confounds biomarker 
validation through cancer sampling bias.  It is evident the classical view of clonal 
architecture in cancers, manifest as driver mutations followed by linear accumulation of 
mutational insults, is too simplistic and there remains significant variation in genetic 
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profile of an individual tumour (R. A. Burrell & Swanton, 2014).  A cancer may not 
comprise a single dominant clone, but contain multiple co-existing sub-clones with the 
implication that these can be spatially separated or intermixed within the same biopsy 
specimen.  There is also co-existent tumour heterogeneity appreciated over the lifetime of 
cancer, with varying patterns of genetic changes from initiation through to formation of 
metastasis and relapse.  Longitudinal tumour sampling approaches are an important factor 
aiding clinicians deciphering the impact of cancer evolution.  This necessitates 
development of non-invasive methods of tumour profiling (Swanton, 2014). 
 
The large volume of data produced by genomic testing must be validated, standardised, 
reproducible and delivered in a timeframe compliant with clinical care.  An important 
component of this is the need for large, collaborative, translational research projects that 
link clinical, demographic and outcome data to histology and molecular profiles.  This 
enriches clinical application of data within a rigorous evidence-based framework.  Existing 
collaborations include the EORTC SPECTAcolor pan-European biomarker screening 
platform for patients with advanced colorectal cancer (SPECTAcolor).  Other examples 
include the AURORA international programme developed by the Breast International 
Group (BIG) and Lungspace, run by the European Thoracic Oncology Platform (ETOP) 
(Aurora; LungScape).  These platforms demonstrate importance of effective information 
transfer between laboratory and clinical research.  The European Consensus Conference 
has published guidelines for external quality assessment of molecular genomics to ensure 
consistency of testing (van Krieken, Siebers, & Normanno, 2013). 
 
1.7. Health economic assessment of genomic testing in PCM 
Genomic testing and PCM have potential to improve health outcomes and cost-
effectiveness in a healthcare system, though methods for economic assessment of the 
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approach are fraught with challenges (Ciardiello et al., 2014).  PCM has attractive health 
economic principles because, in theory, only those patients who are likely to benefit 
receive treatment and avoids treating patients with potentially toxic therapy for which there 
is little clinical benefit. 
 
The current cost-effectiveness analysis framework of using health gain to describe the 
value of complex health technology such as PCM is not likely to sufficiently capture all of 
its benefits (Buettner & Heydt, 2013).  There remains a need for appropriate health 
outcome models for PCM.  In the UK, patients receive health care provided by the 
nationally-funded NHS.  In this setting, access to new cancer therapies and accompanying 
diagnostic testing may be restricted, such as cases where cost exceeds the applied cost-
effectiveness thresholds.  This is further confounded that regulatory pathways for drug and 
genomic diagnostic approval are disparate, paired often with different funding streams.  
Previous economic modelling of upfront KRAS testing in patients with metastatic 
colorectal cancer suggested cost savings could be made and spare patients from toxic and 
ineffective therapies (Nelson, 2009).  A previous cost-effectiveness analysis of crizotinib 
for ALK-positive non-small cell lung cancer highlighted that this was not cost-effective 
due to the low frequency of the marker in this patient population and high cost of the drug, 
despite its clinical effectiveness (Djalalov, Beca, & Hoch, 2014). 
 
As the cost of genomic sequencing continues to reduce, the costs of education, training and 
infrastructure as well as new clinical pathways need to be considered.  The costs of any 
genomic test or new drug must continue to balance supporting innovation and investment 
with what an individual healthcare system can afford.  There remains a need for innovative 
means around assessing cost-effectiveness of genomic testing in PCM with greater 
research to provide evidence of increased healthcare quality. 
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1.8. Current landscape of UK clinical trials in PCM 
The over-riding principle of PCM is to match molecular, genomic and clinical data with 
underlying therapeutic mechanisms, providing biologically rational and clinically effective 
anti-cancer strategies.  Despite the remarkable successes in understanding novel drivers of 
oncogenic processes, success rates for approval of therapeutics remains low.  There 
remains a chasm between discoveries in laboratory-based research and development of 
successful therapeutics within the clinical arena.  There is a tangible need for creative 
strategies to bridge this gap.  One key element is the application of novel clinical trial 
designs and incorporation of predictive genomically defined biomarkers early in the 
process.    
 
Despite the increasing recognition around genomic testing in cancer, evaluating targeted 
therapies presents a formidable challenge, especially when mutations are rare and can 
transcend tumour histology.  Some eminently targetable tumour mutations may be so rare 
they are only discovered in the context of a negative trial.  Such examples include durable 
clinical benefits for everolimus, a novel mTOR inhibitor, in patients with bladder and 
thyroid cancer.  This study was negative for primary efficacy endpoints across the 
population, but exceptional clinical responders were subsequently discovered to harbour 
specific genomic signatures in mammalian target of rapamycin (mTOR) signalling 
pathways, rendering them uniquely sensitive to everolimus (Iyer, Hanrahan, et al, 2012).  If 
a clinical trial had the ability to identify patients with similar genomic signature, it may 
well lead to enrichment regardless of tumour histology or anatomical origin. 
 
A review by Roper et al in 2015 demonstrated an increase in proportion of clinical trials 
requiring a genomic alteration for enrolment.  The review showed an increase in utilization 
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of PCM from 3% in 2006 to 16% in 2013 across all clinical trials in the UK (Roper, 
Stensland, Hendricks, & Galsky, 2015).  Molecular biomarkers for precision medicine 
were included in 39% of global oncology trials in 2018 (Awad, K., Dalby, M., et al, 2019).  
Randomised clinical trials are an important tool for evidence-based medicine, historically 
incorporating a broadly defined population, representative of a specified primary cancer 
site and histology.  The heterogeneous nature of tumours from the same anatomical subsite 
and histology, though, challenging existing clinical trial design.  PCM offers the potential 
to tailor therapeutics to patients in order that more of the treated population will benefit.  
The average benefit across the population will be greater, with fewer patients exposed to 
cancer therapies without benefit.  This led to novel clinical trial designs, such as umbrella 
and basket design trials (Berry, 2012). 
 
Basket trial designs incorporate multiple tumour histologies sharing common genetic 
aberrations.  Basket trials can be randomised or non-randomised and incorporate single or 
multiple therapeutic agents.  Eligible patients have tumour sequencing performed, 
determining whether their tumour contains a genomic alteration with ‘actionable’ target.  
The basis of determining ‘actionable’ mutations may be based on clinical evidence of 
efficacy in patients with the same genomic pattern but different primary site of tumour, or 
pre-clinical tumour models demonstrating importance of the therapeutic target.  The 
standard phase 2 basket trial design ignores the heterogeneity of primary disease site and 
pool patients containing actionable mutations.  To separately analyse the patients of each 
primary site would require much larger sample sizes.  Thall (Thall et al, 2003) developed a 
Bayesian hierarchical design used for making inferences about drug activity in primary-site 
subtypes of a basket clinical trial design. 
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The vemurafenib basket trial is one such study, where patients with BRAF V600 mutations 
were treated with vemurafenib regardless of primary histology (Hyman et al., 2015).  Each 
arm of the trial had a specific histology and was analysed separately in the context of a 
Simon 2-stage design to allow for early stopping if no efficacy was seen.  This study was 
noteworthy for showing preliminary efficacy in BRAF V600-mutated non-small cell lung 
cancer, but also for highlighting that tumour lineage might influence drug sensitivity as 
underscored by the lack of responses in colorectal cancer patients harbouring the same 
mutation. 
 
Umbrella trial designs are restricted to patients with a single primary site cancer, but utilise 
therapeutic agents targeting genomic variants.  Patients with potentially actionable 
mutation for one of the available targeted agents are assigned to receive that agent or a 
matched control.  The analysis of umbrella trial designs are limited to the single primary 
site of disease. 
 
One example of umbrella trial design is the on-going UK National Lung Matrix trial 
(Middleton et al., 2015).  This trial involves multiple molecularly-targeted treatments 
against different subtypes of non-small cell lung cancer.  A patients’ tumour is molecularly 
profiled using hotspot panel within the Cancer Research UK Stratified Medicines Program 
2 study.  This determines allocated treatment arm of the trial based on detected driver 
mutations.  The trial is an adaptive design and has been designed with flexibility in mind, 
so as to add or remove treatment arms as new data comes to light.   
 
Basket and umbrella trials provide efficient designs predicated on the hypothesis that 
presence of a genomic or molecular marker predicts response to targeted therapy.  This 
hypothesis incorporates precision cancer medicine into clinical trials, including rare 
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mutations difficult to study within a histology-specific context.  This acts as proof-of-
concept validation of putative target conducted within multiple cohorts of a single study, 
rather than having to run multiple separate trials.  The success of these trial designs 
depends, in part, on the strength of data linking the genomic target with targeted therapy.  
Delivery of effective therapies relies on the tumour being dependent on the target pathway 
and that the targeted therapy reliably inhibits or promotes the target.   
 
The understanding of oncogenic mechanisms influences risk assessment, diagnostic 
categorization and therapeutic strategies, with increasing use of therapies in clinical trials.  
The WINTHER trial (Kurzrock et al, 2019) selected patients for therapy based on fresh-
biopsy derived DNA sequencing or RNA expression.  The study included 107 patients 
deemed evaluable for therapy with matching scores calculated post-hoc for each patient 
according to drugs received.  For DNA, this included the number of mutations divided by 
the total alteration number.  For RNA, it incorporated expression-matched drug ranks.  
Amongst the 107 patients in the study, 26.2% had stable disease for greater than 6 months, 
partial or complete response.  The study demonstrated that fewer prior therapies, improved 
baseline performance status and higher matching scores correlated with longer PFS.  The 
study highlighted both genomic and transcriptonomic profiling are useful for improving 
therapy and patient outcomes, expanding the horizons for PCM trials. 
 
Classical population-based clinical trials harvest a small number of measurements from a 
group, often led by a single study sponsor with single pharmaceutical company or drug 
agent.  Precision medicine clinical trials require consideration of a myriad of genomic 
factors that may be unique to that individual. Increasingly complex trial designs evolve 
with additional numbers of clinical arms, targeted therapy combinations and complex 
collaborations.  These complex collaborations may involve more than one genomic test 
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and more than one targeted agent, with potential to transcend study sponsors and 
pharmaceutical companies.  These studies will rely on new collaborations between 
academic institutions, clinicians and pharmaceutical industry.   
 
Sicklick and Kurzrock (2019) described the challenges of precision cancer medicine trials 
based on molecular matching with monotherapies and low matching rates correlating with 
low response rates.  They hypothesized that personalised treatment with combination 
therapies could improve outcomes in patients with refractory malignancies.  The I-
PREDICT study used tumour DNA sequencing and timely recommendations for 
individualised treatment with combination therapies.  Administration of multidrug 
regimens was feasible and 49% of patients received personalised treatment.  This study 
demonstrated targeting a larger fraction of identified molecular alterations, yielding higher 
matching score, correlated with significant improvement in disease control rates, paired 
with improvements in progression-free and overall survival rates when compared to 
targeting fewer somatic mutations.  The I-PREDICT study demonstrated current PCM 
clinical trial designs pairing one oncogenic driver with one drug may be optimised by 
treating molecularly complex and heterogeneous cancers with combination regimens 
(Sicklick, J.K., Kurkrock, R., et al, 2019). 
 
Patients enrolling in conventional PCM clinical trials, often involving a single genomic 
profile, face the potential of screening, potentially including invasive biopsy, for a trial 
without prospect of intervention.  Novel clinical trial designs attempt to increase efficiency 
and enrichment by linking patients in a common infrastructure for screening in the 
appropriate trial or sub-study.  This has potential to benefit patients by increasing 
prospective intervention rates and reducing delays to targeted therapeutics.  Being 
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performed under a single study design reduces the need for repeated invasive testing to 
assess tumour genomics. 
 
The TARGET study (Rothwell, D., Ayub, M., et al, 2019) demonstrated the feasibility of 
blood-based genomic profiling by matching patients with different cancer types to early 
phase clinical trials on the basis of analysis of somatic mutations and copy number 
alterations across 641 cancer-associated gene panel in a single ctDNA assay.  ctDNA from 
the first 100 patients in the study demonstrated good concordance with matched tumour, 
results being turned around within clinically acceptable timeframes for review by a 
molecular tumour board.  Data from the TARGET study demonstrated that 41 out of 100 
patients had actionable mutations and 11 of these received matched therapy.  This data 
supports the application of ctDNA in early phase clinical trials.  
 
Statistical considerations will continue to play a pivotal role in novel clinical trial design in 
PCM, incorporating small patient numbers and multiple tests.  One key challenge for 
conventional clinical trial design is generalizability of results.  Ensuring a trial design 
offers applicable results to an individual is challenging, given the ever increasing 
recognition of heterogeneity amongst cancer patient populations.  Developing therapeutics 
with candidate biomarkers is more complex than traditional practice of developing drugs 
based on broad heterogeneous populations.  Ensuring screening strategies reflect expected 
gene mutation frequencies will be a crucial calculation as complex trial designs evolve.  
Larger phase II studies with more extensive genomic profiling may be required in order to 
adequately understand the role of the candidate biomarkers in a specific disease.   
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1.9. Role of patient preferences for genomic testing 
As discussed throughout this chapter, PCM moves beyond previous models of cancer 
therapeutics, based on trials of largely unselected patients, to molecular profiling of an 
individual’s cancer genome.  This has potential to offer efficacious, cost-effective cancer 
treatment that is targeted, biologically rational and reduces under- or over-treatment, thus 
preventing toxicities associated with non-specific modes of action of chemotherapy.  PCM 
must incorporate genomic stratification with a holistic treatment approach which accords 
patient participation and preferences (Cribb & Owens, 2010).  Tutton emphasised the 
importance of genomic and social aspects of healthcare in the UK, an important component 
to maintain the lasting legacy of scientific innovation (Tutton, 2012). 
 
Novel clinical trial designs in PCM mean patients face different therapeutic and clinical 
trial decisions.  Conventional clinical trial designs incorporate a small number of molecular 
profiles and targeted therapies, opening the possibility of patients enrolling and screening 
for a study for which they have little prospect of intervention.  Patients may undergo 
further testing, including invasive biopsy, to determine eligibility.  Novel clinical trial 
designs try to optimise this efficiency.  However, with little empirical evidence around 
patients’ preferences of genomic testing, there is a gap in understanding how best to do 
this.  Without evidence of what matters to patients, it is difficult to predict uptake or 
understand what the barriers are to successful PCM implementation within clinical trials. 
 
It is anticipated genomic testing in PCM will increasingly be utilized to select patients for 
specific and clinical trials.  This has the potential to raise a number of ethical questions for 
patients beyond the provision of their cancer care.  Genomic sequencing has potential to 
reveal increased risk of cancer syndromes and other diseases.  This raises issues of privacy, 
data protection and discrimination for patients.  In such cases, reporting of results could be 
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clinically meaningful and/or life-saving.  Disclosure of such results from genetic testing 
that are clinically and analytically valid can be positive, helping patients take control of 
their lives.  One such example could be patients with BRCA 1/2 mutations, who can 
benefit from prophylactic surgery to reduce cancer risk or from surveillance to detect 
cancer earlier.  Providing feedback opportunities may also contribute to involving and 
educating patients and patient advocacy groups.  Genomic testing could highlight genetic 
mutations with potential to affect other family members or have implications for an 
individual.  In either setting, it is important to identify patients’ preferences for genomic 
testing and its wider implications.  Continuing research around developing ethical and 
legal frameworks, establish counselling recommendations and disclosure of information 
from genomic testing are paramount in this process.  Patient and advocacy group 
participation is important to ensure acceptability of PCM and improve the translation of 
genomic testing data to the overall benefit of cancer patients.  
 
Given the growing emphasis on providing patient-centred care, policy makers are 
increasingly seeking consumers’ healthcare expectations, priorities and opinions.  
Involvement of patients’ preferences is seen as an indicator of quality in modern cancer 
care (Muhlbacher, Bethge, Reed, & Schulman, 2016).  Developing deeper understanding 
of patients’ preferences around genomic testing in a rapidly emerging new era of cancer 
medicines may also allow further optimisation of patient-centred clinical trial design and 
recruitment.  The inclusion of patient preferences can have beneficial effects including 
improved treatment compliance and clinical outcomes. 
 
Within the promising scientific principles of genomic profiling, clinicians and patients will 
have to balance this plethora of information in order to make informed therapeutic 
decisions.  Previous studies demonstrate patient preferences towards cancer diagnosis and 
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treatment are affected by a number of factors unique to that individual (McQuellon et al., 
1995; Slevin, 1990; Weeks, 1998).  These include factors such as perceived prognosis, 
disclosure of information and associated risks of testing (Gray et al., 2016).  These factors 
have been studied in the pre-precision medicine era, but become of paramount importance 
in assessing the validity of precision cancer medicine and ensuring its lasting legacy 
beyond scientific promise. 
 
1.10. Conclusions 
As discussed throughout this chapter, the emergence of genomic testing in PCM challenges 
conventional clinical therapeutics and trial design, affecting clinical trialists, clinicians, 
pharmaceutical companies, regulatory and funding bodies as well as patients.  Patients are 
now faced with increasingly complex decisions around genomic testing and its role in 
clinical trials.  This thesis will identify and rate patient preferences of genomic testing 
within the rapidly evolving PCM paradigm and how these preferences are incorporated by 
a novel clinical trial design. 
 
The overall aim of the thesis was to identify and rate patient-centred preference attribute 
themes of genomic testing and benchmarked these against a current UK clinical trial, to 
assess how current PCM clinical trial designs incorporate patient preferences.  This thesis 
also explored the novel hypothesis that preference attribute themes and ratings of genomic 
testing may be influenced by clinical treatment intent and time since completing therapy. 
 
The research questions for this thesis are as follows: 
1. How are patient preference attributes of genomic testing in PCM defined and rated? 
2. Do current clinical trial designs incorporate patient preference attributes of genomic 
testing in PCM?  
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The aims of this thesis will be addressed as follows:- 
1. Conduct a narrative review of genomic testing and precision cancer medicine. 
2. Undertake systematic review of the literature examining current evidence assessing 
patient preferences of genomic testing in precision cancer medicine. 
3. Identify preference attribute themes of genomic testing for patients.  
4. Identify rating scores for identified preference attribute themes. 
5. Examine the effect of cancer treatment intent and time since completing therapy on 
identified preference attributes and rating scores. 
6. Benchmark how a current precision medicine UK clinical trial design incorporates 
the identified patient preference attribute themes and ratings.
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Chapter 2. Assessing patient preferences of genomic testing 
2.1. Introduction 
As discussed in Chapter 1, a key factor ensuring the legacy of PCM is incorporation of 
patient preferences of genomic testing in both clinical trial design (Tsimberidou, 2012) and 
widespread implementation in clinical practice (Lee & Nelson, 2012), (Fraeknel & 
McGraw, 2007), (Say & Thomson, 2003).  Understanding patient preferences will deepen 
understanding of attitudes towards genomic testing (Rogausch & Prause, 2006).  This 
chapter will consider methodologies to endorse the thesis research aims of identifying and 
rating patients’ preference attributes of genomic testing in PCM. 
 
2.2. Mixed methods research in defining and rating attributes 
Qualitative approaches to healthcare research have their roots in social science and 
humanities disciplines such as sociology, social anthropology, psychology, history and 
geography.  Health professionals have a long history of integrating social science insights 
into understanding of human health (Henderson, 1935), (Kleinman, 1973), (Helman, 
2000).  Social research methods have been adopted as part of the toolbox of approaches 
providing evidence for practitioners and policy-makers across fields such as global health, 
primary care, health promotion, health services and nursing.  Although social sciences and 
humanities disciplines have their own distinct methodological and theoretical traditions, 
what they have in common is a focus on what people do, and why, in the context of social 
relationships (Green J, 2018).  As the challenges of health policy and practice are 
increasingly recognized as rooted in the ‘social,’ it is not surprising that health care 
practitioners, managers and policy makers have turned to social enquiry to enhance 
understanding of health, health behaviour and health services (Murphy E, 2003). 
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Qualitative research has a particular role to play in generating useful knowledge about 
health and illness, from that of individual perceptions through to global systems.  
Qualitative methodologies include approaches answering questions of what happens, why 
and with what effects at different levels.  There are differing ways of characterizing 
qualitative versus quantitative research.  The most basic way of characterizing qualitative 
research is by describing the kind of data it generates (Holliday, 2002).  In this delineation, 
qualitative data are usually in the form of words, in contrast to the numbers generated by 
quantitative research.  Some have seen this division between qualitative and quantitative 
research as difficult, since many studies involve differing degrees of both.  Another way of 
characterizing qualitative research is by the methods used to generate the data.  There are 
some methods primarily associated with qualitative research, including interviews, 
ethnographic case studies and participant observation, where others, such as surveys or 
experiments, are more associated with quantitative research.  Studies in health care 
literature often employ a mixed methods approach of qualitative and quantitative 
methodologies (Fielding, 2010). 
 
Mixed methods research is becoming increasingly recognised as a third major research 
approach, along with qualitative and quantitative methodologies (Kuhn, 1962).   Mixed 
methods research exists as a synergy between ideas of both qualitative and quantitative 
research.  Within social science methodological literature, Campbell and Fiske’s article 
(Campbell & Fiske, 1959) is often viewed as formalising the practice of using multiple 
research methods.  In this article, Campbell and Fiske introduce the idea of triangulation, 
referring to “multiple operationalism.”   More than one method is used as part of a 
validation process ensuring explained variance is the result of the underlying phenomenon 
or trait and not of the method (such as qualitative or quantitative methods).  Subsequent 
authors argued the convergence of findings stemming from two or more methods 
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“enhances our beliefs that the results are valid and not a methodological artefact.” 
(Bouchard, 1976).  Denzin (Denzin, 1978) was the first to outline how to triangulate 
methods.  Denzin defined triangulation as “the combination of methodologies in the study 
of the same phenomenon.”  He outlined the following four types of triangulation:  
1 - Data triangulation, such as the use of a variety of sources within the study 
2 - Investigator triangulation such as the use of multiple different researchers 
3 - Theory triangulation, where the use of multiple perspectives and theories interpret the 
results of the study 
4 - Methodological triangulation, defined by use of multiple research methods to study a 
research problem. 
 
Although recognizing triangulation may not be suitable for all research purposes, Jick 
(Jick, 1979) noted the following advantages: 
- It allows researchers to be more confident of their results 
- Stimulates development of creative ways of collecting data 
- Can lead to thicker, richer data 
- Can lead to synthesis or integration of theories 
- Can uncover contradictions 
- May serve as the litmus test for competing theories 
 
Morse (Morse, 1991) outlined two types of methodological triangulation: simultaneous and 
sequential.  According to Morse, simultaneous triangulation represents use of qualitative 
and quantitative research where there is limited interaction between two sources of data 
during the collection stage, but findings complement one another at the data interpretation 
stage.  On the other hand, sequential triangulation is utilized when the results of one 
approach are necessary for planning the next. 
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Sieber (Sieber, 1973) outlined five reasons for combining qualitative and quantitative 
research.  This included how combinations can be effective at the design, data collection 
and data analysis stage of the research process.  Rossman and Wilson (Rossman & Wilson, 
1985) identified three reasons for combining qualitative and quantitative research.  Firstly, 
the combinations are used to enable confirmation or corroboration of each other through 
triangulation.  Secondly, combinations are used to enable or develop analysis, providing 
richer data.  Thirdly, combinations are used to initiate new models of thinking by attending 
to paradoxes emerging from different data sources. 
 
Greene et al (Greene, 1989) inductively identified the following five purposes or rationale 
of mixed methodological studies: 
Triangulation – seeking convergence and corroboration of results from different methods 
studying the same phenomenon 
Complementarity – seeking elaboration, enhancement, illustration, clarification of the 
results from one method with results from the other 
Development – using the results from one method to help inform the other 
Initiation – discovering paradoxes and contradictions leading to reframing of the research 
question 
Expansion – expanding the breadth and range of inquiry by using different methods for 
different inquiry components 
 
Most recently, Collins (Collins, 2006) identified four rationale for conducting mixed 
methods research.  They were: 
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1 - Participant enrichment – mixing quantitative and qualitative research using 
techniques including recruiting participants, engaging in activities and ensuring appropriate 
participant selection for inclusion. 
2 - Instrument fidelity – assessing the appropriateness and/or utility of existing 
instruments, creating new instruments or monitoring performance of human instruments. 
3  -  Treatment integrity – assessing fidelity of intervention 
4  -  Significant enhancement – facilitating thickness and richness of data, augmenting 
interpretation and usefulness of findings.   
 
Johnson, Onwuegbuzie and Turner (Johnson, Onwuegbuzie, & Turner, 2016) defined 
mixed methods research as “Intellectual and practical synthesis based on qualitative and 
quantitative research.  It is the third methodological or research paradigm, along with 
qualitative and quantitative research.  It recognizes the importance of traditional 
quantitative and qualitative research but offers a powerful third paradigm choice that may 
provide the most informative, complete, balanced and useful research results. ” 
 
The aim of the research presented in this thesis was to identify and rate themed patient 
preference attributes of genomic testing in PCM.  This involved initially identifying 
preference attributes and associated rating scores.  This thesis also assessed whether 
patient-centric factors such as clinical treatment intent and time since completing treatment 
affect patient preference attributes or ratings of genomic testing.  The nexus of 
contingencies in this thesis, in relation to the thesis research question, suggests that mixed 
methods research design is anticipated to provide superior research findings and outcomes 
compared to either qualitative or quantitative research methods alone. 
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2.3. Consensus methods research 
2.3.1. Background of consensus research 
Formal consensus research methods have become increasingly visible tools for solving 
problems in health and cancer research.  The main purpose is to define levels of agreement 
on controversial subjects in situations where there is insufficient evidence, or where there 
is an overload of, often contradictory, information (Rennie, 1981).  Quantitative research 
methods, such as meta-analysis, have been developed to provide statistical overview of 
clinical trials and resolve inconsistencies in the results of published studies.  Consensus 
methods are another means of dealing with conflicting scientific evidence.  They allow a 
wider range of study types to be considered than is usual in statistical reviews.  In addition, 
consensus methods research allows greater role for qualitative assessment of evidence 
(Fink, 1984).  Consensus methods are primarily concerned with deriving quantitative 
estimates through qualitative approaches.  They, therefore, complement the theory of 
mixed methods research. 
 
The aim of consensus research methods is to determine the extent to which experts or lay 
people agree about a given issue.  They seek to overcome some of the disadvantages 
normally found with decision making in groups or committees, which are commonly 
dominated by one individual or by coalitions representing vested interests (Jones & 
Hunter, 1995).  The term ‘agreement’ takes two forms, which need to be distinguished.  
First, the extent to which each respondent agrees with the issue under consideration, 
typically rated on a numerical or categorical scale.  Second, the extent to which 
respondents agree with each other, the consensus element of these studies, typically 
assessed by statistical measures of average and dispersion. 
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The focus of consensus methods research lies where unanimity of opinion does not exist 
owing to lack of evidence or where contradictory evidence exists on an issue.  Consensus 
methods attempt to assess extent of agreement (consensus measurement) and to resolve 
disagreement (consensus development) (Perry, 1987).  The most widely utilised consensus 
research methods are the Delphi Technique (DT) and nominal group technique (NGT).  
Both methods involve measuring consensus and NGT also incorporates developing 
consensus.  Both of these techniques have a relatively long history of use in healthcare 
research, with formal rules for collecting and analysing information, emphasizing 
production of immediate solutions to healthcare problems.  This chapter will discuss these 
methodologies in healthcare research and their application in this thesis study. 
 
2.3.2. The Delphi Technique 
The Delphi technique (DT) has been used widely in health research to obtain expert 
opinion in a systematic manner via highly structured group interaction.  The Delphi 
method was developed by Norman Dalkey and associates at the RAND institute in 1953 
and utilizes a multi-stage self-completed questionnaire with individual feedback (Linstone 
& Turoff, 1975).  Delbecq, Van de ven and Gustafson (Delbecq, Van de Ven, & 
Gustafson, 1975) define this as a “method for the systematic solicitation and collation of 
judgments on a particular topic through a set of carefully designed sequential 
questionnaires interspersed with summarized information and feedback of opinions 
delivered from earlier responses.”  The technique, is used to achieve the following 
objectives: 
- Determine or develop a range of possible program alternatives. 
- Explore or expose underlying assumptions or information leading to different 
judgments. 
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- Seek out information which may generate consensus on the part of the respondent 
group. 
- Correlate informed judgments on a topic spanning a wide range of disciplines 
- Educate the respondent group as to the diverse and inter-related aspects of the topic. 
 
The DT, according to Cyphert and Gant (Cyphert & Gant, 1971), attempts to overcome the 
numerous problems associated with the traditional round-table method for achieving a 
consensus.  These include factors such as influence of psychosocial factors, dominant 
group members and the band-wagon effect.   Participants within DT are polled 
individually, often anonymously.  The survey is conducted over three to five ‘rounds.’  
After each round results are elicited, tabulated and reported to the group.  The Delphi 
method is considered complete when reported outcomes saturate and develop convergence 
of opinion.   
 
Tersine and Riggs (Tersine & Riggs, 1976) point out that Delphi Technique has many 
advantages over more conventional means of gathering opinions on matters not subject to 
precise quantification.  Tersine and Riggs observed that most benefits are the result of 
keeping the identification of participants’ unknown, eliminating one form of bias.  
Participants are deemed to be less susceptible to the ‘halo effect,’ where opinion of one 
highly respected individual can influence others.  The authors observed advantages in the 
DT with face-to-face groups, where full member participation is not restrained by 
increasing group size.  DT imposes no restrictions on the number of participants. 
 
The DT has advantages enabling each participant to express views impersonally, whilst 
ultimately providing information generated by the entire group (Proctor & Hunt, 1994).  
Since DT questionnaires are completed by mail, no geographical constraints on the 
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selection of experts need be imposed.  Crawford and Cossitt (Crawford & Cossitt, 1980) 
compared three group processes, namely regular face-to-face interacting groups, the NGT 
and DT.  They point out that one of the major strengths of the Delphi process is removal of 
inhibiting effect around face-to-face interactions of the group.  This strength also proves to 
be one of its major weaknesses.  In an attempt to measure participant satisfaction, 
Crawford and Cossitt had subjects respond to eight Likert-type statements on a five-point 
agree-disagree scale.   The results supported the hypothesis that “the total removal of face-
to-face interactions from decision-making processes tends to diminish social-emotional 
satisfaction among participants.” 
 
Anderson, Ball and Murphy (Anderson, Ball, & Murphy, 1981) observed DT has three 
main weaknesses: 
  1  -  It is only the initial step and simply attempts to obtain consensus.  
  2  -  This consensus may not necessarily be the “best” judgment. 
3 - The technique entails considerable labour, including tabulations, record keeping 
and mailings. 
 
Sackman (Sackman, 1975), in critical analysis of DT, concluded its liabilities outweighed 
its assets, often being characterized by crude questionnaire design, vulnerability with 
respect to who is an ‘expert’ and obliviousness to reliability of measurement and scientific 
validation of findings.  Starkweather, Gelwicks and Newcomer (Starkweather, Gelwicks, 
& Newcomer, 1975) also highlighted the reliability of DT increases with the size of the 
group and number of rounds, but panellists sometimes become fatigued after two or three 
rounds. 
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2.3.3. The Nominal Group Technique 
NGT is a highly structured face-to-face group interaction, providing orderly procedure for 
obtaining information from target participants about a selected issue.   The NGT was 
initially devised by Van de ven and Delbecq (Van de Ven & Delbecq, 1972) as a “special 
purpose technique useful for situations where individual judgments must be tapped and 
combined to arrive at decisions which cannot be delivered by one person.  They are 
problem-solving or idea-generating strategies.” 
 
Delbecq (Delbecq et al., 1975) described the step-by-step process associated with the 
Nominal Group Technique: 
- The meeting room must be selected and prepared 
- The necessary supplies must be ready 
- The leader must make an opening statement 
- The question must be presented 
- Each member must write his or her key ideas silently and independently 
- Ideas from all group members should be recorded in a round-robin fashion on a flip 
chart that is visible to the entire group. 
- There should be serial discussion for clarification purposes.  This means there will be a 
short period allowed for discussion of each idea listed on the flip chart.  It is 
imperative that each item on the flip chart be discussed in order. 
- The preliminary vote is taken 
- The group discuss the preliminary vote.  The purpose of this discussion is two-fold: to 
examine inconsistent voting patterns and provide opportunity to re-discuss items 
which appear to have received too many or too few votes. 
- The final vote 
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Van de Ven and Delbecq further describe NGT as “a group process for generating 
qualitative insight regarding critical problem dimensions.”  Gallacher et al (Gallacher, 
Hares, Spencer, Bradshaw, & Webb, 1993) agree it is a structured procedure for gathering 
information but reinforce in their definition the importance of gathering it from ‘people 
who have insight into a particular area of interest.’  The decision of the group is the 
combined outcome of the individual votes. 
 
Subsequent authors (Pendleton & Myles, 1991), (Carney, McIntosh, & Worth, 1996), 
(Hickson, Worrall, Yiu, & Barnett, 1996) presented variations of the original technique, 
but the process up to the point of ranking or scoring items appears based on the original 
outline.  Twible (Twible, 1992) used a modified technique in which the question was 
written on a board and members called out relevant responses.  In this setting, similar 
responses were grouped together and labelled alphabetically. 
 
In their original work, Van de Ven and Delbecq (Van de Ven & Delbecq, 1972) outlined 
the advantages of NGT in allowing the target group to single out critical problems by 
means of a process which is non-threatening and depersonalized.  It allows clarification of 
meaning and exploration of both subjective and objective dimensions.  Katz (Katz, 1988) 
demonstrated that all group members can contribute effectively and feel valued by the 
process.  Hickson (Hickson et al., 1996) highlighted the prioritization process enabling the 
resulting program to reflect values of the participants.  NGT can also be used to survey a 
large number of participants and allow for efficient management of the data generated 
(Twible, 1992). 
 
There are disadvantages associated with NGT.  Pendleton and Myles (Pendleton & Myles, 
1991) felt the technique was time consuming as it can take up to two hours to complete a 
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group.  Scott and Deadrick (Scott & Deadrick, 1982) stated time can be wasted clarifying 
the question if it is not clearly stated.  Fox (Fox, 1987) highlighted that NGT makes no 
provision for inputting and review of ideas before the meeting.  The nominal group 
technique also permits only one person to input at any given time, which can create a 
‘bottleneck’ around discussion topics.  This sets a group size limit of around 10 
participants for effective operation. 
 
2.3.4. Discussion 
The choice for utilization of either Delphi Technique or Nominal Group mixed methods 
research techniques is influenced by various factors, including the primary research 
question, perception of consensus required and associated practicalities such as limitations 
of time or geography.  Examples of healthcare studies employing Nominal Group and 
Delphi Technique are shown in Table 1 and Table 2, respectively. 
 
Linstone and Turoff  (Linstone & Turoff, 1975) suggest criteria for situations where DT 
should be considered: 
- The research problem does not lend itself to precise analytical techniques but can 
benefit from subjective judgments on a collective basis. 
- The research population presents diverse backgrounds with respect to experience or 
expertise. 
- More subjects are required than can effectively interact face-to-face. 
- Time, costs and logistics would make frequent meetings of all subjects unfeasible. 
 
Cantrill, Sibbald and Buetow (Cantrill, Sibbald, & Buetow, 1996) highlight further 
advantages of the NGT lie in allowing peer support for participants identifying problems.  
NGT also has value in situations where participants value social interaction. 
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Table 1.  Examples of healthcare studies using the Nominal Group Technique (NGT) 
Authors Aim  Participants  
Prioritisation 
or ranking 
Develop 
guideline 
Generate 
ideas 
Problem 
solving 
n Size 
range 
Doctors Other 
AHP 
Policy 
makers 
Patients Public Academics 
Bissell et al •   1 8 • • •    N/A 
Bond&Watson •   1 13 • • • • •  Ranking 
Bradley et al  •  4 3-8 •     • Prioritisation 
Tully&Cantrill •   1 10 • •    • Ranking 
Rice et al  •  3 3-6     •  Mean rating 
Gastelurrutia et al   • 2 7  • •   • Mean rating 
McMillan et al  •  21 2-14  •    • Ranking 
Hutchings et al  •  6 4-9  • •  • • Ranking 
Aspinal et al • • • 10 4-12  •  • • • Ranking 
 
AHP= Allied healthcare professional 
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Table 2.  Examples of healthcare studies using the Delphi technique (DT) 
Authors Aim No of experts Experts  
Rating Develop 
guideline 
Generate 
ideas 
Invited Agreed Completing Doctors Other AHP Academics Patients 
Campbell et al •  305 305 79 • •   Yes 
Chan et al •  23 9 9 •    Yes 
McBride et al • • 164 109 47 •  • • Yes 
Taylor et al • • 179 158 158 • • •  Yes 
McDermott et al • • 58 53 48  • •  Yes 
Alahlafi&Burge • • 84 73 71 • • • • No 
Meshkat et al •  201 75 54 • •   Yes 
Masud&Blundell • • 67 53 49 •  •  No 
 
AHP = Allied healthcare professional
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2.4. Conclusions  
This chapter discussed methodological considerations to identify and rate patient 
preference attributes of genomic testing in PCM.  The primary research question required 
both qualitative identification of preference attributes and quantitative rating scores.  Given 
genomic testing and PCM remains in its clinical infancy, it is hypothesized that patients 
will have little prior experience of the modality.  The strengths of consensus research and 
NGT, in this setting, are that they support participants to better understand genomic testing 
and its role.  Previous studies in this patient population have also highlighted the 
importance of social interaction in facilitating complex discussions for patients.  Given 
these considerations, systematic review of the literature followed by mixed methods 
research methods employing NGT to identify and rate preference attributes is favoured for 
this study.  
 
The first stage of the research design was to examine, via systematic review, the current 
literature identifying and rating patient preference attributes of genomic testing in PCM.  It 
was anticipated the identified preference attributes or ratings could be utilised within the 
mixed methods study design.  Chapter 3 will explore the employed methods and identified 
patient preference attributes from the systematic review of the existing literature. 
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Chapter 3. Assessing patients’ preferences of genomic testing in 
PCM: A Systematic Review  
3.1. Introduction 
As discussed in chapter 1, understanding preference attributes will lead to greater 
understanding of patients’ preferences of genomic testing, its subsequent therapeutic 
application and role in clinical trials (Rogausch & Prause, 2006).  The aim of this 
systematic review was to identify, summarize and assess the validity of preference 
attributes and ratings of genomic testing for patients within existing literature. 
 
3.2. Systematic Review Methods 
3.2.1. Background 
Systematic reviews have become increasingly important in healthcare research (Stephens, 
2001).  Healthcare professionals use them to keep up to date in their field (Oxman, Cook, 
& Guyatt, 1994), often used as a starting point for developing clinical guidelines 
(Swingler, Volmink, & Ioannidis, 2003).  As with all research, the value of a systematic 
review depends on what was done, what was found and the clarity of reporting (Moher, 
Tetzlaff, Tricco, Sampson, & Altman, 2007).  Several early studies evaluated the quality of 
systematic review reports (Mulrow, 1987), (Sacks, Berrier, Reitman, Ancona-Berk, & 
Chalmers, 1987) and found areas of inconsistency or perceived deficiency.  In order to 
address this, the Quality of Reporting of Meta-analysis (QUOROM) statement (Moher et 
al., 1999) aimed to create international consensus on reporting and meta-analysis of 
randomised controlled trials.  The Preferred Reporting Items for Systematic Reviews and 
Meta-analysis (PRISMA) guidelines updated previous recommendations, reinforcing 
principles within systematic reviews (Moher, 2009). 
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The terminology used to describe a systematic review has evolved over time.  The 
PRISMA statement (1999) utilised the definition provided by the Cochrane Collaboration 
(S. Green & Higgins, 2005): “A systematic review is a review of a clearly formulated 
question that uses systematic and explicit methods to identify, select, and critically 
appraise relevant research, collect and analyse data from the studies that are included in the 
review.”   
 
3.2.2. Search strategy 
A systematic review was conducted for publications up until January 2018 using Cochrane 
Library, MEDLINE, EMBASE and PubMed (Moja et al., 2005).  A combination of the 
following search terms was used: ‘precision/personalised cancer medicine/genomic testing’ 
in combination with ‘patient preferences/attitudes/satisfaction.’  The initial search strategy 
was not restricted to a particular type of research design.  Articles were eligible for 
consideration if they were published in English, within peer-reviewed journal, included 
precision/personalised cancer medicine and explored patient preferences and/or attitudes 
towards genomic testing.  All retrieved studies were screened by title and abstract, 
following which the selection criteria were applied (Stephens, 2001).  If this initial search 
strategy concluded that a title/abstract met eligibility criteria for literature review, then the 
full text article was obtained.  Based on full manuscripts, studies were included for 
selection according to whether they met pre-defined eligibility criteria.  The complete 
search strategy is included in Figure 1. 
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Figure 1.  Search strategy for thesis systematic review of the literature 
1          exp Individualized Medicine/         7299   
2          exp Molecular Targeted Therapy/ 13750             
3          exp Pharmacogenetics/      10507             
4          exp Patient-Specific Modeling/     104     
5          (precision adj2 medicine).ti,ab.      370     
6          (personali?ed adj2 medicine).ti,ab.           4699   
7          ((precision or personali?ed or genomic) adj2 oncolog*).ti,ab.           107     
8          1 or 2 or 3 or 4 or 5 or 6 or 7           32620             
9          exp Attitude to Health/         323484           
10        exp Patient Preference/      4128   
11        exp Patient Satisfaction/     68555             
12        exp Patient Participation/   19631             
13        exp Patient-Centered Care/           12900             
14        (patient* adj (view* or attitude* or preference* or satisfaction or perception* or 
centered or centred)).ti,ab.           46918             
15        9 or 10 or 11 or 12 or 13 or 14        353405           
16        8 and 15        2014     
17        limit 16 to english language          1805  
 
3.2.3. Selection criteria 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
statement provides guidelines for conducting a systematic review and suggests framing 
questions with five components to facilitate the systematic review and meta-analysis 
process (Moher, 2009).  The PRISMA checklist is demonstrated in Appendix 1.  Inclusion 
criteria are presented as five PICOS components (Methley, Campbell, Chew-Graham, 
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Mcnally, & Cheraghi-Sohi, 2014), namely the patient population or disease being assessed 
(P), the intervention or exposure (I), the comparator group (C), the outcome or endpoint 
(O) and chosen study design (S).  The PICOS tool is commonly used to identify 
components of clinical evidence for systematic reviews and is endorsed by the Cochrane 
Collaboration (S. Green & Higgins, 2005).  The pre-defined criteria for this systematic 
review were applied in order to choose the final studies to be included, presented using 
PICOS criteria as shown in Table 3. 
 
Table 3. PICOS criteria applied to systematic review. 
PICOS components Inclusion criteria 
Population (P) Participants with history of cancer or healthy volunteers 
participating in hypothetical cancer-related scenarios 
Intervention (I) All precision/personalised cancer medicine/genomic testing 
studies 
Comparative (C) Any 
Outcome (O) Patient preferences, attitudes or perspectives 
Study design (S) Any study design (qualitative, quantitative or mixed 
methods) 
 
This systematic review included original research articles, review articles were excluded.  
Studies were included if they empirically assessed patient 
attitudes/perspectives/preferences of genomic testing in precision cancer medicine via any 
qualitative, quantitative or mixed methods.  Studies were excluded if they did not assess 
patient attitudes/preferences, did not involve cancer, precision medicine or genomic 
testing.  The titles, abstracts and full texts of the identified studies were reviewed. 
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3.2.4. Data extraction 
After screening, all eligible studies were reviewed and study characteristics were extracted 
to three data extraction tables (Appendix 2).  Appendix 2 contains the following elements: 
basic study characteristics (including author and year), country of study, number of 
patients and volunteer participants, recruitment criteria, study type, applied methodology 
for eligible studies, identified attributes and associated levels. 
 
3.2.5. Critical appraisal 
This systematic review applied and adopted the quality assessment list of previous reviews 
assessing patient perspectives in healthcare (Moja et al., 2005), (Stephens, 2001).  The 
critical appraisal of included studies was assessed using the Mixed Methods Appraisal 
Tool (2018) due to mixed qualitative and quantitative methods employed by studies.  The 
foundation of mixed methods research combines the strengths of qualitative research in 
providing in-depth description of complex phenomena, allied with the statistical 
generalizability of quantitative methods.  Multiple validated tools exist assessing 
quantitative methodologies as well as some validated tools for qualitative methods.  The 
MMAT was developed by Pluye et al in 2009 to address the challenges relating to 
appraisal of mixed methods studies (Pluye, P., Gegnon, M.P., et al, 2009).  The first 
iteration of MMAT was developed in line with a social constructionist world view.  This 
version of MMAT included 15 criteria for four categories of study design, namely 
qualitative, quantitative experimental, quantitative observational and mixed methods.  
Further refinement to the MMAT methods were published in 2012 (Pace, R., Pluye, P., et 
al, 2012) and latterly 2018 (Pluye, P., Garcia Bengoechea, E., et al, 2018).   
 
The 2018 MMAT version includes 25 criteria and 2 screening questions.  This appraises 
five different categories of study design: qualitative, randomised controlled, non-
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randomised, quantitative descriptive and mixed methods.  Each category contains five core 
criteria, rated as either yes, no or can’t tell.  Prior versions of the MMAT incorporated a 
summative score for each study, calculated by dividing the number of criteria met by four 
(Pluye et al, 2011).  Increasing opinion suggests single numerical values do not reflect the 
strengths or deficiencies of a study, as well as being unclear whether it should be weighted 
(Higgins and Green, 2008).  Current literature discourages use of summative scores for 
each criterion (Herbison, Hay-Smith and Gillespie, 2006; Viswanathan et al, 2012).  
MMAT has been validated in several studies, demonstrating reliability, usability and 
content validity (Hong et al, 2018). 
 
Performing MMAT involved three main steps (Hong et al, 2018).  This firstly involved 
two screening questions to determine suitability of MMAT appraisal.  Secondly, selection 
of appropriate category of study design amongst the five MMAT categories: qualitative, 
randomised controlled, non-randomised, quantitative descriptive and mixed methods.  
Each qualitative or quantitative study was assigned one category.  Studies employing 
mixed methods were assigned three categories, namely: the qualitative category, one 
quantitative category and the mixed methods category.  In assigning appropriate study 
categories based on methodological approach, the MMAT acknowledges the distinctive 
methodological characteristics specific to each component used in mixed methods studies 
(O’Cathain, 2010).  The third step of MMAT consists of rating the chosen category 
criteria.  There were three response options: ‘yes’ meaning the criterion was met, ‘no’ 
meaning the criterion was not met or ‘can’t tell’ when there is not enough information in 
the paper to judge whether criterion was met or not. 
 
The studies were critically appraised using the MMAT and independent preference 
attributes and attribute levels for genomic testing in PCM were assessed descriptively, with 
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comparison between descriptive outcomes.  This was performed due to heterogeneity of 
study design and methodologies employed within the small number of studies eligible for 
inclusion.  No studies were excluded due to limited or reduced methodological quality 
based on MMAT assessment.  The Mixed Methods Appraisal Tool quality criteria tables 
are shown in Appendix 3. 
 
3.3. Results  
The primary search strategy yielded 1805 articles.  After removal of duplicate publications, 
titles and abstracts of 1403 studies were screened resulting in exclusion of 1301 studies.  
The full text articles of the remaining 102 studies were then screened based on the previous 
inclusion and exclusion PICOS criteria, of which 3 studies were eligible for inclusion in 
the systematic review.  The PRISMA flow chart of the screening process is demonstrated 
in Figure 2.    
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Figure 2.  PRISMA flow chart for systematic review.  
 
 
This systematic search yielded three unique studies examining patient attitudes/preferences 
of genomic testing in precision cancer medicine.  These studies, the identified themed 
preference attributes and ratings are discussed in turn below. 
 
Genomic testing to determine drug response: measuring preferences of the public and 
patients using Discrete Choice Experiment (DCE) (Najafzadeh, 2013) 
Methods 
This study utilised a discrete choice experiment (DCE) to elicit preferences of both the 
public (n=1,058) and cancer patients (n=38) for differing attributes within a hypothetical 
genomic test aimed at guiding cancer treatment.  The study presented a questionnaire to 
Publications identified 
n = 1805 
Review of titles and 
abstracts 
n = 1403 
Review of full text 
articles 
N=102 
Publications included 
n = 3 
Duplicates removed 
n = 402 
Publications excluded 
n = 1301 
99 articles excluded for 
the following reasons: 
- Review articles (n =4) 
- Non-cancer (n = 57) 
- Non-patient outcomes 
(n = 38) 
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patients previously or currently being treated for lymphoma, as well as healthy volunteers.  
Participants completed discrete choice questionnaires using scenarios either involving an 
aggressive curable cancer or non-aggressive incurable cancer (571 and 525 participants 
respectively), reflecting clinical treatment paradigms in lymphoma. 
 
Factors examined 
The study identified attribute characteristics of both patient and physician preferences 
towards pharmacogenomic testing using 3 pilot studies, published literature and physician 
opinion (Najafzadeh & Davis, 2013).  The attributes selected were: genomic test 
sensitivity/specificity, severity of side effects, likelihood of side-effects, genetic test 
turnaround time, genetic test procedure and cost. 
 
Results 
This study highlighted the relative impact of attributes affecting uptake of genomically-
guided cancer testing.  It demonstrated preferences for uptake of genomic testing were 
different between the scenarios of an aggressive curable malignancy versus a non-
aggressive incurable malignancy.  The groups of patients and public within the study 
demonstrated significant variability in demographic characteristics: mean age (58.2 versus 
47.9 years respectively), household income of greater than CAN$ 125,000 (36.1 versus 6.1 
per cent respectively) and baseline education with 32.4% of patients having master or 
doctorate degree versus 3.3% in the public group. 
 
Test sensitivity 
The study demonstrated, in the case of an aggressive curable cancer, the preference weight 
of the public for a test sensitivity of 50% was -0.1686 (s.e. 0.466) and increased to 0.1748 
(s.e. 0.0266) for a test with sensitivity of 95%.  This effect is evident in the odds ratio for 
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willingness-to-pay (WTP) relative to test sensitivity, showing the odds of choosing a test 
with 95% sensitivity were 1.41 times the odds of choosing a test with 50% sensitivity.  
Respondents were willing to pay $1331 for increasing test sensitivity from 50% to 95%.   
Respondents were, however, only willing to pay $796 and $487 for increasing sensitivity 
to 80% and 65% respectively.  In the setting of a non-aggressive incurable cancer, 
preference weights for 95% sensitivity and 50% sensitivity were 0.2577 (s.e. 0.270) and -
0.2436 (s.e. 0.0479) respectively.  Increasing test sensitivity from 50% to 95% increased 
the odds ratio of choice by 1.65 times.     
 
Test specificity 
In the scenario of an aggressive curable cancer, the odds of choosing a test with 95% 
specificity were 1.24 times the odds of choosing a test with 50% specificity and the public 
were willing to pay $827 for this amount of improvement in specificity level.  The 
preference weight for 95% test specificity was more than two fold larger in the respondents 
for the scenario of non-aggressive incurable cancer (0.2452 versus 0.1008, p-value 
<0.001). 
 
Severity of side effects 
Reducing the severity of side effects from severe to mild was associated with large odds 
ratios in both aggressive curable and non-aggressive incurable cancers (2.10 and 2.24 
respectively).  Furthermore, the odds of choosing a treatment with 5% likelihood of side 
effects were 1.62 and 1.75 times the odds of choosing a treatment with 95% likelihood of 
side effects, for an aggressive curable and non-aggressive incurable cancer respectively. 
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Shortening test turnaround time 
Shortening test turnaround time from 12 to either 7 or 2 days had the smallest impact on 
preference weights and odds ratios (OR) for both scenarios.  In contrast, the invasiveness 
of testing procedure had a large impact on estimated preference weights and OR values for 
both scenarios.  Respondents offered blood sample had an OR of 1.73 and 1.88 for an 
aggressive curable and non-aggressive incurable cancer respectively, versus OR of 1 for 
liver biopsy in both groups.  This demonstrated strong preference for m less invasive 
testing modality. 
 
Comparing patients versus healthy population 
The authors of the study did attempt to compare selected subsamples of the public (n=83) 
with similar demographic characteristics of the patient group (n=38) to allow comparison 
between the groups for their preferences.  The pooled data was examined using a fitted 
conditional logit model to estimate preference weights and OR with attribute levels.  The 
study numbers within the patient group meant that for many factors, the study was 
underpowered to determine significant differences between the groups.  It did demonstrate, 
however, that the preference weight for test sensitivity of 95% was larger for patients 
compared to the public (0.8794 versus 0.2480 respectively, p-value<0.001).    
 
A national study of breast and colorectal cancer patients’ decision-making for novel 
personalized medicine genomic diagnostics (Issa, Tufail, Atehortua, & McKeever, 
2013) 
Methods 
This study employed discrete choice experiment to develop an understanding of breast and 
colorectal cancer patients decision-making and preference trade-offs around characteristics 
of specific molecular genomic tests, namely Oncotype DX and KRAS/UGT1A1 
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respectively.  The study surveyed a nationally representative sample of 300 patients with 
breast or colorectal cancer using a web-administered discrete choice instrument.  Amongst 
all respondents for the study, 76.5 % of breast and 70% of colorectal cancer patients were 
identified as having early-stage cancers. 
 
Factors examined 
The attributes and levels were allocated based on published literature and six focus groups 
of breast and colorectal cancer patients (Issa, Tufail, Hutchinson, Tenorio, & Baliga, 
2009).  The attributes were: personal cost of testing, individuals who would have access to 
results (confidentiality of results), how test results are used, chance the test will correctly 
predict patient response to treatment and what information the test will provide.  There 
were up to 6 levels within each attribute, assessed across 20 scenarios presented in a 
randomized manner.  For each participant, part-worth utilities or relative importance scores 
were computed, reflecting the influence of each attribute on participant choice.   
 
Results 
This study demonstrated all 5 preference attributes influence patient decision-making, 
however accuracy of the genomic test and cost appeared to have the most weight amongst 
both breast and colorectal cancer patients.  Amongst all patients within the study, 22.5% 
were willing to pay for genomic testing and patients sought test accuracy of greater than 
90%.  The study demonstrated both groups of patients weighted the capability of genomic 
testing diagnostics to determine probability of treatment efficacy of greater importance 
than detecting adverse events.  78.6% of breast cancer patients ranked the possibility of 
false-negative test, leading to under-treatment, higher than false-positive resulting in over-
treatment (68%).  This finding contrasted that of the colorectal cancer patient group, who 
ranked the chance of false positive as greater significance than a false negative (72.8 
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versus 63%, p=0.0024).  Overall, cancer patients demonstrated a high willingness to pay 
for these two specific genomic tests.  Amongst all respondents, willingness-to-pay falls at a 
level of $500. 
 
Cancer patients’ acceptance, understanding and willingness-to-pay for 
pharmacogenomic testing (Cuffe et al., 2014) 
Methods 
This study employed patient questionnaire followed by interviews using hypothetical 
trade-off scenarios around use of chemotherapy. The questionnaire encompassed domains 
of socio-demographic characteristics, health status, patient preference for whom should 
decide on pharmacogenomic testing and level of agreement (using Likert scales) with a 
series of novel statements designed to elicit patient values on chemotherapy and 
pharmacogenomics.  Patient preferences were determined by interviewer administered 
questionnaires and probability trade-off testing.  This included 244 patients with diagnosis 
of malignancy.  The population was divided into adjuvant (n=123) and metastatic (n=121) 
groups, based on patients self-reported perception of cancer stage.   
 
Factors examined 
Patients in the study were asked to trade off preferences against the burden of testing by 
systematically modifying the levels of attributes associated with testing.  The primary 
attribute was therapy efficacy, in the adjuvant group, and risk of adverse events in the 
metastatic group.   Other attributes included cost of testing, waiting time for results and 
prevalence of genetic variant of interest. 
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Results 
Amongst the adjuvant patient group, 72% of patients were willing to accept chemotherapy 
for a 5% absolute improvement in cure rate and risk of severe side-effects less than 5%.  A 
further 24% of patients would accept chemotherapy for a higher cure rate (median 15%, 
range 10-50%); thus only 4% refused chemotherapy at any level of benefit.  Of the patients 
accepting chemotherapy, 99% were willing to accept pharmacogenomic testing that could 
improve prediction of response to chemotherapy when the test was free, had a 1 day 
turnaround time for results and the prevalence of the genetic variation associated with lack 
of response to chemotherapy was 50%. 
 
Amongst the metastatic group, 92% were willing to accept chemotherapy for an 80% 
benefit (shrinkage or stable disease) and risk of severe side effects less than 5%.  A further 
2.5% of patients would accept chemotherapy for a higher response rate (median 95%, 
range 85-100%), where as 2.5% would accept chemotherapy for a lower risk of side-
effects (median 0%, range 0-1%).  Of the 97% of patients accepting chemotherapy, 97.4% 
were willing to accept pharmacogenomic testing that could stratify risk of toxicity when 
the test was free, had a 1 day turn around for results and the prevalence of the genetic 
variation associated with severe side-effects was 5%. 
 
The median acceptable waiting time for pharmacogenomic test results was 16 days (range 
0-90 days) for the adjuvant group and 14 days (range 1-90 days) in the metastatic group.  
Patient preferences for pharmacogenomic testing were not influenced by the prevalence of 
the genetic variant.  The median lowest prevalence at which patients would no longer opt 
for pharmacogenomic testing was 5% (range 0-80%) and 1.5% (range 0-10%) for the 
adjuvant and metastatic groups respectively.  Amongst the adjuvant patient group, 37% of 
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patients would accept testing even when the prevalence of the genetic variation of interest 
varied from 5-95%. 
   
Within the study, 85% of patients agreed reducing chance of receiving ineffective 
treatment was a high priority.  77% of patients believed any additional test offered by the 
medical profession must be of benefit.  92% of patients were agreeable to an additional 
blood test to facilitate testing, whereas only 55% of patients were agreeable to repeat tissue 
biopsy.  The median WTP for pharmacogenomic testing was CAD$2000 and CAD$1000 
in the adjuvant and metastatic setting respectively. 
 
3.4. Discussion 
To the authors’ knowledge, this is the first systematic review analysing the available 
evidence regarding patients’ preferences and attribute rating of genomic testing within the 
precision cancer medicine paradigm.  The core principles of precision cancer medicine 
remain around the concept of the ‘right drug for the right person at the right time,’ 
(Biankin, Piantadosi, & Hollingsworth, 2015) highlighting the importance of patient 
empowerment and involvement in decision making within precision medicine (Sleijfer, 
Bogaerts, & Siu, 2013),(Chin & Gray, 2008), (E. D. Green, Guyer, & National Human 
Genome Research, 2011).  This systematic review highlights the paucity of prospective 
studies examining patient preference attributes of genomic testing within precision cancer 
medicine. 
 
The study by Najafzadeh et al demonstrated the type and prognosis of cancer effect 
preference attributes for genomically-guided treatments.  In the scenario of an aggressive 
curable cancer, individuals emphasized the importance of test sensitivity versus specificity.  
In contrast, for a non-aggressive incurable cancer, individuals put similar emphasis on 
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sensitivity and specificity attributes.  The study enrolled both healthy volunteers and 
patients with previous diagnosis of lymphoma, but was limited by the small sample of 
cancer patients within the cohort, making valid conclusions for the wider cancer population 
challenging.  Historical studies demonstrate differential decision-making and priorities 
amongst patients both after a cancer diagnosis and at varying points along their cancer 
journey.  This, therefore, does make it difficult comparing this study group to the wider 
cancer population.  The scenarios in this study also reflect current treatment paradigms in 
the management of patients with non-Hodgkins lymphoma, which are not necessarily 
applicable to the wider cancer patient population.  
 
The study demonstrates the relative impact of different attributes of genomically-guided 
testing on uptake.  The change in severity and likelihood of toxicity attributes, as well as 
invasiveness of the test procedure had the largest influence on decision-making.  The study 
highlighted in the patient group that improving test sensitivity influenced patient 
preferences of genomic testing, but was underpowered to make inferences about other 
preference attributes within the patient group.   
 
The study by Issa et al employed a discrete choice methodology to determine trade-offs 
and threshold values for patient preference attributes regarding two specific genomic 
cancer tests.  The study provides insight into the relative importance of attributes affecting 
patients preferences of the two genomic tests assessed.  Overall, the study demonstrates 
high willingness for colorectal and breast cancer patients to pay for genomic diagnostic 
tests.  Since most cancer treatment decisions involve making ‘trade-offs’ between evidence 
of efficacy and potential for adverse events, this study explored patient preferences for the 
type of information provided by genomic testing.  It demonstrated patients’ high value 
genomic tests with accuracy of greater than 90%.  The decisions of both groups of patients 
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within the study about use of genomic testing are influenced more by probability of being 
cured than desire to avoid potentially serious adverse events.  It is noted within the study 
that privacy of results was not ranked highly amongst patients, but that oncologist/doctor 
recommendation was weighted strongly by both breast and colorectal cancer patients.  This 
highlights the importance of both physician and patient education around complex 
decision-making process for these genomic tests. 
 
This study identified patient preference attributes of two genomic tests testing utilised in 
clinical practice.  The study assessed tests used to make decisions on benefits of adjuvant 
chemotherapy, one in each breast and colorectal cancer.  The preference attributes used 
within this study all had weighting when assessed using the discrete choice experiment.  
The study looked at genomic testing within these two groups, but not all factors may be 
fully generalised to the wider cancer community and in particular different stages or 
anatomical subtypes of cancer.  The scenarios in this study focus on patients having 
adjuvant therapy.  The trade-offs and thresholds for patients with advanced disease may be 
different to this group and cannot be assumed to be similar to those in the study.  It is, 
therefore, difficult to extrapolate the preference attributes used in this study to patients with 
more advanced cancer, or patients with cancers other than breast and colorectal anatomical 
subsites.  This study enlisted patients willing to complete an online questionnaire, sourced 
from an independent web-based tool.  These patients may, therefore not be entirely 
representative of the wider cancer patient community and may reflect those more willing to 
respond to a questionnaire. 
 
The study be Cuffe et al included 244 patients with a cancer diagnosis, assessing 
preference attributes for pharmacogenomic testing in both the adjuvant and metastatic 
setting.  The study employed hypothetical scenarios determining preferences of primary 
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outcome, efficacy and toxicity in the adjuvant and metastatic groups respectively, relative 
to systematically modified levels of preference attributes associated with testing.  These 
attributes were: cost of testing, waiting time for results and prevalence of the genomic 
variant.  Amongst both the adjuvant and metastatic groups, willingness to accept 
pharmacogenomic testing was high (99 and 92% for adjuvant and metastatic setting 
respectively).  85% of patients identified undergoing pharmacogenomic testing in order to 
define ineffectual therapies was important. 
 
This study demonstrated patients were willing to accept and pay for pharmacogenomic 
testing when deemed clinically useful by their healthcare provider. The strength of 
patients’ desire was evidenced by the considerable out-of-pocket costs they were willing to 
pay.  This was within a universal healthcare setting, where most patients are familiar with a 
system that is reimbursed at point of use.  Several studies have demonstrated willingness-
to-pay may be a surrogate measure not only of patients perceptions of the net worth or 
benefit of a test but also their willingness to adopt novel technologies.  The two 
hypothetical scenarios within the study were limited on only one primary outcome within 
each group and it is likely that they will systematically over-estimate the willingness for 
uptake of testing within the wider oncology patient community.  This study did, though, 
elicit important preference attributes of genomic testing in PCM.  
One limitation of this study is hypothetical scenarios performed based on patients self-
reported cancer stage.  In the adjuvant group, this focused on efficacy of therapy, where as 
in the metastatic group it focused on toxicity from therapy.  Ideally, the study would have 
determined the role of both factors within each group and been able to look at trade-offs 
within these preference attributes, but the study authors felt this would lead to unacceptable 
complexity of design.  It is, therefore, likely that the hypothetical scenarios utilised in this 
study will over-estimate the actual uptake rates if translated into clinical practice.  The 
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study determined patient preferences, therefore elected not to address matters of physician 
resistance, insurance reimbursement and broader pharmacogenomic issues. 
 
The strength of this systematic review is that it is the first to critically appraise and define 
themed patient preference attributes of genomic testing from the available evidence.  It 
highlighted the sparsity of empirical studies assessing patient preferences of genomic 
testing within the clinical arena.  This involved performing a systematic review of clinical 
research publications.  One limitation of this design is that it utilised databases within 
medical and scientific literature, but did not assess the current evidence available within 
purely qualitative research databases.  This has the potential to exclude further qualitative 
studies which may add weight to themed preference attributes within the identified 
evidence.   
 
The overall aim of this systematic review was to identify preference attributes of genomic 
testing which could be utilised throughout the mixed methods design of this study.  The 
review demonstrated the paucity of empirical research identifying and defining patient 
preference attributes applicable to this study population, so these preference themes will 
not be directly utilised within the study.  This study will incorporate mixed methods 
design, in order to empirically identify themed preference attributes prior to quantitative 
rating. 
 
3.5. Conclusions 
The advent of genomic testing in precision cancer medicine relies on collective preferences 
of patients, providers and funding bodies (Greenberg, 2015).  The diffusion of genomic 
technologies has been generally slow, with comparatively little empirical research 
reporting on the expectations and experiences of patients and providers.  This systematic 
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review demonstrated the sparse empirical evidence identifying and rating preference 
attribute themes of genomic testing for patients. 
 
This systematic review identified preference attribute themes which may be applicable to 
small subsets of patients and specific genomic tests, such as Oncotype DX, or specific 
histology-related scenarios such as in lymphoma.  These attributes include predictive value 
of tests, cost of testing, efficacy of available therapy, potential toxicity and effects on 
quality of life.  These preference attributes, though, are not universal to the wider 
population of patients where PCM may be applied. 
 
The studies highlighted by this systematic review demonstrated patient preference 
attributes and trade-off thresholds of genomic testing are not homogeneous.  Patients 
making decisions on perceived risks and benefits of curative versus palliative therapy 
identified different preference attributes and trade-offs, which must be taken into account 
when considering the potential promise of genomic testing.  
 
This systematic review demonstrated patient preferences attributes and ratings of genomic 
testing across the breadth of solid tumour oncology are poorly understood.  The identified 
preference attribute themes are not wholly transferrable to the patient group being 
considered in this thesis and would not provide sufficient evidence to support the research 
questions.  The initial intention of this systematic review was to identify and describe 
themed preference attributes which could be used within the mixed methods study.  Given 
the lack of empirical evidence within the current literature, the preference attribute themes 
identified by this systematic review will, therefore, not be incorporated into the mixed 
methods study of this thesis.  The remainder of this thesis will explore the employed 
methodology and its role in addressing the research aims highlighted in Chapter 1. 
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Chapter 4. Methodology 
4.1. Overview 
The systematic review of the literature in Chapter 3 demonstrated the paucity of empirical 
evidence identifying and rating patient preference attribute themes of genomic testing in 
PCM.  As discussed in the research aims of Chapter 1, this thesis identified and rated 
patient preference attributes for genomic testing, then assessed how these attributes were 
incorporated within a novel PCM clinical trial design. Given the lack of empirical evidence 
identifying and rating themed preference attributes, consensus research methodology was 
used to answer the thesis research questions, which will be outlined in the remainder of this 
chapter. 
 
4.2. Research Aims 
4.2.1. Hypothesis 
The aim of this thesis was to identify and rate patient preference attribute themes of 
genomic testing.  These were then benchmarked against a current UK clinical trial to 
determine how current clinical trial designs incorporate patient preferences of genomic 
testing.  The study addressed the novel hypothesis that patient preference attributes and 
ratings are influenced by cancer treatment intent and time since completing therapy.  This 
thesis chapter will discuss the research methodology used to address the thesis research 
questions. 
 
4.2.2. Ethical approval 
The study received ethical approval (REC ref no.16/LO/1665) from the NHS National 
Research Ethics Service (NRES), included in Appendix 7.  Full details of the study 
methodology and copies of the study protocol, patient consent form and participant 
information sheet were submitted in parallel with the ethics application (Appendix 8).  
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Procedures of the Declaration of Helsinki and Good Clinical Practice (GCP) were 
followed.  Written informed consent was provided by all participants prior to participation 
in any study-related activities. 
 
4.3. Nominal Group Technique (NGT) design considerations 
Although there is considerable consensus on how to conduct certain aspects of NGT, there 
is variability in its application (McMillan et al., 2014).  As most studies involved small 
numbers, between one and five groups (Gastelurrutia et al., 2009), (Dening, Jones, & 
Sampson, 2012; Hiligsmann et al., 2013), there is limited information on how to conduct 
and analyse studies with larger data sets.  This thesis aimed to address the research 
questions by descriptive assessment of preference attribute themes and associated 
quantitative attribute rating.  This entailed large numbers of groups to ensure diversity with 
respect to participant demographics, such as cancer subtype, age and experience of 
previous cancer treatments.   
 
Despite the diversity in application, McMillan et al (McMillan et al., 2014) demonstrated 
general consensus on four core NGT phases: 
1  - Silent generation of ideas 
2  - Round robin 
3  - Clarification 
4  - Ranking 
 
These four stages were used in this study.  Contrary to most nominal group questions 
which are problem-focused (Tully & Cantrill, 2002), the primary question in this 
investigation asked participants to think about concepts of PCM, with which most patients 
had very little personal experience.  The phrasing of the research questions were built on 
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an appreciative inquiry approach (Gonzales & Leroy, 2011), used when participants find it 
challenging to articulate preferences due to lack of technical knowledge.  This approach 
directs participants to adopt a positive outlook, think beyond fixing problems and into 
theoretical clinical entities, thereby promoting greater engagement and creativity. 
 
4.3.1. Participant selection and group composition 
Patients attending cancer survivorship groups and outpatient department at the Beatson 
West of Scotland Cancer Centre, Scotland were invited to participate in the NGT.  Patients 
were eligible for the study if they were over 18 years of age, had a personal diagnosis of 
cancer and received treatment including surgery, chemotherapy, 
endocrine/targeted/biological therapy, radiotherapy or combination of multi-modality 
therapies.  There was no stipulation for patients to have personal experience or awareness 
of precision cancer medicine prior to involvement in this study.  Patients were offered a 
participant information sheet (Appendix 6) when they attended either the outpatient 
department or cancer survivorship groups, prior to participation and could contact the 
study chief investigator if they wished to participate.  Figure 3 demonstrates the participant 
flow diagram throughout the NGT study.  Patients were included only after they had given 
written consent at least 24 hours after receiving the study participant information sheet.   
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Figure 3.  Flow diagram of participant recruitment to NGT. 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 
 
 
  
4.3.2. Introduction to the Nominal Group process 
All groups involved two facilitators who adopted distinct roles; the primary moderator lead 
and provided directions to the group, as well as writing participant ideas on a whiteboard, 
whilst the second providing supportive care to participants throughout each group session 
(Carney, McIntosh, & Worth, 1996).  The first stage of each group entailed providing an 
overview of the study and objectives (Delbecq, Van de Ven, & Gustafson, 1975).  Some 
authors (Claxton, Ritchie, & Zaichowsky, 1980; Sink, 1983) advocate an introductory step 
prior to starting the nominal group.  This study provided a brief synopsis of the study 
Identified eligible participants 
N= 302 
302 participants received study 
information sheet 
Outpatient clinic: n=229 
Survivorship groups: n=73 
 
Participants who contacted 
study researcher 
N= 144 
Participants agreed to attend 
NGT session 
N= 121 
NGT session undertaken 
N= 108 
Dates not suitable:   n=11 
No reason offered n= 8 
Too unwell to attend: n=4 
Too unwell to attend: n=3 
Hospital appointment: n=1 
No reason offered: n=9 
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overview then clarified the procedure as each group progressed throughout the relevant 
stages. 
 
In general for NGT, one (Dening et al., 2012), (McMillan et al., 2014), (Tully & Cantrill, 
2002) or two (Hutchings, Rapport, Wright, Doel, & Jones, 2012; Potter, Gordon, & Hamer, 
2004)  questions are posed per group, with each question usually considered as a separate 
nominal group process.  This study included two main questions.  These were: 
1 - What are the features of a genomic test that are important to you? 
2 - For each of the features highlighted in question 1, are you able to rank them in order 
from most to least important to you? 
  
4.3.3. Silent generation of ideas 
The next step of the NGT design involved participants being given a pre-defined time 
period in order to consider the research question.  There is wide variety in the literature 
around the optimal time for this, with some authors advocating 5 (Aspinal, Hughes, 
Dunckley, & Addington-Hall, 2006), 10 (Carney et al., 1996), 15 (Gallacher, Hares, 
Spencer, Bradshaw, & Webb, 1993) or 20 (Claxton et al., 1980) minutes for this aspect.  
During this time, participants were asked to individually record, in silence, as many 
answers as possible.  In this study, participants were allowed a maximum of 15 minutes for 
this stage.  Any discussion was avoided.  Delbecq et al (Delbecq et al., 1975) recommend 
the facilitator models participant behaviour, including writing down and sharing their 
thoughts.  Many other authors (Tuffrey-Wijne, Bernal, Butler, Hollins, & Curfs, 2007) 
recommend facilitators simply maintain silence throughout this phase of the process.  In 
this study, the facilitators remained silent throughout and assisted participants if they 
required help with writing. 
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4.3.4. Round robin 
This phase can last from 15 (Dening et al., 2012) to 30 minutes (Potter et al., 2004), 
providing participants opportunity to contribute one idea at a time until all ideas are 
exhausted.  Delbecq et al (Delbecq et al., 1975) advised facilitators encourage participants 
to add new ideas after listening to other comments, but only when it is their individual turn.  
Discussing during idea presentation was not permitted in this study.  There is consensus in 
the literature that ideas should be recorded verbatim on a whiteboard or flipchart for 
participants to see (McMillan et al., 2014).  However, there are differences of opinion with 
respect to the facilitator’s role at this stage.  For instance, Delbecq (Delbecq et al., 1975) 
suggests the facilitator contribute ideas in the same was as participants.  In this study, the 
facilitator avoided contributing ideas, fearing that it may bias participant responses.  
Preference attribute themes identified by participants and collated on the white board 
during the round robin stage, are shown in Appendix 4. 
 
4.3.5. Clarification 
This phase ensured participants understand the meaning of each idea, thus enabling 
individuals to make informed decisions during priority rating at the next stage.  The 
ambiguity about this phase relates to whether ideas can be grouped or eliminated.  Some 
papers advocate the grouping of duplicate (Carney et al., 1996) or similar ideas (Potter et 
al., 2004; Sink, 1983)  or deletion of items (Claxton et al., 1980).  According to Delbecq 
(Delbecq et al., 1975), the facilitators’ role in this stage should be to pace the group, avoid 
argument and ensure that all ideas are discussed.  In this phase, amalgamation of ideas will 
be dependent on individual group consensus.   
 
In the NGT study, all preference attributes from the round robin stage were collated on a 
whiteboard and participants were allowed to amalgamate them into attribute themes if 
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there was consensus on grouping. If consensus was not be reached on theme grouping then 
the preference attributes remained disparate.  The preference attributes themes selected by 
participants at the end of the clarification stage are shown in Appendix 4. 
 
4.3.6. Rating of preference attribute themes 
There are different methods to conduct the attribute rating phase of NGT.  For example, 
participants could rate a number of ideas in terms of importance (Carney et al., 1996; 
Dening et al., 2012; Sink, 1983; Tully & Cantrill, 2002) or could use two-step process 
comprising secondary ranking (Allen, Dyas, & Jones, 2004; Gallacher et al., 1993)   (Jones 
& Hunter, 1995).  Delbecq (Delbecq et al., 1975) suggested public voting could instigate 
social pressure to conform to the norm, so proposed a more private voting process.  Due to 
time constraints and high cognitive burden of questioning in this study, it was decided that 
secondary ranking process by participants was not feasible. 
 
Participants in this phase were asked to select and rate preference attributes themes, which 
can range from 5 (Carney et al., 1996; Dening et al., 2012), 8 (Claxton et al., 1980) and 10 
or more options (Gallacher et al., 1993; Hiligsmann et al., 2013).  This phase lasted up to 
10 minutes (Dening et al., 2012).  Participants were allowed to rank 9 items.  This was 
done by first asking participants to individually select their top 9 themed preference 
attributes from the entire set generated at the end of clarification phase.  Participants were 
asked to rank themed preference attributes, with 9 points allocated to their top priority, 8 
points for their second priority, continuing down to zero points for their lowest priority.  If 
participants felt there are less than 9 themed preference attributes they valued then they 
started at 9 points for their highest themed attribute and stopped when they reached their 
lowest rated attribute.  To avoid errors, participants were provided with a rating sheet for 
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recording votes.  The entire rating process was completed individually, without group 
discussion. 
 
4.3.7. Data management 
As this study involved a large number of participants, data management involved a 
streamlined analysis process across multiples groups.  Microsoft Office Excel version 16.0 
was used to record scores allocated by each participant and ratings of the themed 
preference attributes for each group.  The sum scores for each attribute were then 
calculated.  This allowed for immediate reporting back of results to participants. 
  
4.3.8. Data analysis 
Initial review of the raw data from each focus group identified any anomalies or nuances 
within the data.  The raw data was used to construct attribute rating scores within each 
group and participants were offered feedback on individual group results at this time if 
they wished. 
 
Summing the votes allocated to each attribute is the most common way to analyse nominal 
group data (McMillan et al., 2014),(Dening et al., 2012; Hiligsmann et al., 2013),(Tully & 
Cantrill, 2002).  Given the number of groups and group sizes, analysis also considered the 
mean attribute rating (Gastelurrutia et al., 2009) of each preference attribute across all 
groups.  The mean attribute rating reflects the proportion (%) of all scores in the top nine 
ranking, calculated using the following equation: 
 
(Score achieved for the attribute across all groups) / (maximum possible score) x 100 
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For this method of analysis, the overall rating score for each themed preference attribute 
was calculated, the top order attribute received 9 points, the second receives 8 points, etc.  
The voting frequency of the top 9 attributes was then calculated to determine how many 
times a particular attribute was voted for, and subsequently, how popular it was amongst 
participants.  This style of analysis accommodated the fact one participant could have 
voted for two different attributes which were coded into the same higher order theme.  The 
mean and standard deviation of mean attribute rating (Kristofco, Shewchuk, Casebeer, 
Bellande, & Bennett, 2005) was calculated for each group. 
 
4.4. Conclusions 
This chapter outlined employed methodology and design considerations for this thesis 
study, which identified and rated patient preference attributes of genomic testing.  One of 
the major considerations within the methodology design was the high cognitive burden 
genomic testing placed on patients and their lack of prior experience of the modality.  The 
breadth of fields encompassed within genomic testing, including screening, diagnostics and 
therapeutics, means the study required methodology which, based on an appreciative 
enquiry approach, supports participants articulating preferences in areas of high 
complexity or lack of experience.  NGT provides a framework to support participants in 
consensus decision making addresses the high complexity and lack of participant 
experience.  The NGT also allows face-to-face interaction with group participants and 
moderator.  Given these considerations, as outlined throughout this Chapter, the research 
study employed a mixed methods research design using consensus research technique, 
namely NGT.  
 
Chapter 5 presents results of the NGT sessions which employed methodology described 
throughout Chapter 4. 
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Chapter 5. Results  
5.1. Pilot study 
5.1.1. Participant demographics for pilot group 
Six participants attended the single pilot nominal group session which assessed and 
described feasibility, alongside predicted strengths/weaknesses of the methodology, 
materials and research hypothesis.  Demographic details for each patient were collected at 
introductory meeting with group moderators.  The demographic details of the six pilot 
group participants are shown in Table 5. 
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Table 5.  Demographics of pilot study participants. 
 Total 
No of participants (n) 6 
Gender 
   Male 
   Female 
 
1 
5 
Mean Age (years) 71.4 
Age range (years) 52-80 
Relationship status 
     Never married 
     Married 
     Living with partner 
     Separated/divorced 
     Widowed 
 
0 
4 
0 
1 
1 
Highest education 
     Secondary/high school 
     College/university  
     Postgraduate degree 
 
3 
2 
1 
Employment status 
     Employed 
     Unemployed 
     Retired 
 
2 
0 
4 
Cancer diagnosis (number of participants) 
     Breast cancer 
     Colorectal cancer 
     Prostate cancer 
     CNS tumour 
 
3 
1 
1 
1 
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5.1.2. Preference attribute themes and ratings for pilot group 
The results of the pilot study highlighted six unique preference attribute themes of genomic 
testing in PCM.  The attributes and mean importance rating scores are shown in Table 6.  
Participants in the pilot group rated three attribute themes as highest order rating (score of 
nine). 
 
Table 6.  Results of preference attribute rating for pilot nominal group. 
Attribute Importance Ratings (n=6) 
1 2 3 4 5 6 7 8 9 Mean S.D. 
Sensitivity/true 
positive 
0 0 0 1 1 1 1 2 0 6.33 1.63 
Specificity/true 
negative 
0 0 0 2 1 1 0 2 0 5.83 1.83 
Test turnaround time 0 0 0 0 2 1 1 0 2 6.83 1.82 
Invasiveness of testing 0 0 0 2 0 2 2 0 0 5.67 1.36 
Physician approval 0 0 0 0 1 1 0 2 2 7.50 1.64 
Regulatory/NHS 
approval 
0 0 0 1 1 0 2 0 2 6.83 2.04 
 
5.1.3. Lessons learned from pilot study 
The primary objective of the pilot study was to descriptively assess the pilot nominal group 
guide v1.0 (Appendix 5) along with materials and methods employed in the NGT.  This 
pilot study demonstrated little direct participant experience of PCM and therefore 
importance that, in the initial synopsis of each session, this was fully explored prior to 
discussion. This prepared participants for discussion around a topic to which they had little 
or no personal experience.  The location and facilities employed in this nominal group 
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session have been employed in similar group sessions, to which some of the current 
participants have previously attended.  The setup of the pilot study reflected that which 
was familiar to some of the participants and researchers, requiring no substantial 
adaptation for the main study.  The adapted nominal group guide (v2.0), amended after 
feedback from the pilot study, and employed in the main study, is included in Appendix 6. 
 
The pilot group assessed methodology identifying and rating preference attributes of 
genomic testing in PCM.  Similar NGT methodology has been employed in previous group 
sessions and there was minimal adaptation required.  One factor highlighted during the 
pilot group was participant’s prior cancer therapeutic/diagnostic experience.  This became 
apparent throughout the pilot group session, so a decision was made to collect participant 
data on prior cancer therapies and personal experience of PCM for the main thesis study.  
This had not been prospectively collected for the pilot group participant sample and was 
included in the adapted NGT group guide v2.0. 
 
5.1.4. Discussion 
This pilot study allowed practical assessment of the research methodology and provisional 
estimation of feasibility.  The outcomes of the pilot group were reflected in the iterative 
changes in the nominal group guides (Appendix 5 and 6).  Further demographic data on prior 
cancer treatments were collected in nominal group sessions of the main study.  The research 
questions, as anticipated throughout the pilot session, reflected high cognitive burden for 
patients. 
 
 
 85 
 
5.2. Main study Participant demographics 
All participants within the main study met with eligibility criteria.  The summary 
demographics across all participants in the main study are shown in Table 7.  Total of 102 
patients enrolled in the main nominal group study.  Fifty-five participants were female 
(54%) and forty-seven (46%) were male.  The mean age across study participants was 64.2 
years with range 27-84, and inter-quartile range (IQR) 20.87 years.   
 
Participants in the study all had personal experience of cancer treatment and included 
fourteen anatomical cancer subtypes (breast, prostate, colo-rectal, sarcoma, 
gynaecological, head and neck, neuro-oncology, lung, renal, oesophageal, gastric, 
neuroendocrine, bladder and pancreatic cancers).  The top five commonest tumour 
subtypes by participant recruitment were breast cancer (19.6%), prostate cancer and colo-
rectal cancer (both 17.7%), gynaecological cancers (12.8%) and neuro-oncology (7.9%).  
 
Participants in the study all had personal experience of cancer therapies including surgery 
(53.9%), chemotherapy (63.7%), radiotherapy (55.9%), endocrine therapy (29.4%) and 
immunotherapy (15.7%).  Eight participants (7.8%) had personal experience of precision 
cancer medicine.  Characteristics of cancer treatment intent were participant-reported. 
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Table 7.  Summary participant demographics across all main study nominal groups. 
 Total (%) 
No of participants (n) 102 
Gender 
         Male 
         Female 
 
47 (46.1) 
55 (53.9) 
Mean Age (years) 64.2 
Age range (years) 27-84 
Age standard deviation 12.13 
Age IQR (years) 20.87 
Relationship status 
     Never married 
     Married 
     Living with partner 
     Separated/divorced 
     Widowed 
 
7 (6.9) 
47 (46.1) 
8 (7.8) 
20 (19.6) 
20 (19.6) 
Highest education 
     Secondary/high school 
     College/university  
     Postgraduate degree 
 
58 (56.9) 
33 (32.4) 
11 (10.7) 
Employment status 
     Employed 
     Unemployed 
     Retired 
 
29 (28.5) 
14 (13.7) 
59 (57.8) 
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 Total (%) 
Cancer diagnosis (number of participants) 
     Breast cancer 
     Colorectal cancer 
     Prostate cancer 
     Sarcoma 
     Lung cancer 
     Head&neck cancer 
     CNS tumour 
     Gynaecological cancer 
     Renal cancer 
     Pancreatic cancer 
     Gastric cancer 
     Oesophageal cancer 
     Neuroendocrine carcinoma 
     Bladder cancer 
 
20 (19.6) 
18 (17.7) 
18 (17.7) 
1 (0.9) 
6 (5.9) 
5 (4.9) 
8 (7.9) 
13 (12.8) 
4 (3.9) 
1 (0.9) 
2 (2.0) 
2 (2.0) 
3 (2.9) 
1 (0.9) 
Previous forms of treatment 
     Surgery 
     Chemotherapy 
     Radiotherapy 
     Endocrine therapy 
     Immunotherapy 
     PCM testing 
 
55 (53.9) 
65 (63.7) 
57 (55.9) 
30 (29.4) 
16 (15.7) 
8 (7.8) 
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5.3. Nominal group A (radical treatment completed within 2 years) Results 
5.3.1. Participant demographics 
All participants recruited to group A met study eligibility criteria and had received radical 
cancer therapy completing within 2 years of entering the nominal group study.  Five 
nominal groups were conducted within group A, for which demographic details are shown 
in Table 8. 
 
Table 8.  Group A participant demographics 
 Nominal Group 
A1 A2 A3 A4 A5 Total (%) 
No of participants (n) 7 6 8 6 5 32 
Gender 
         Male 
         Female 
 
3 
4 
 
3 
3 
 
5 
3 
 
2 
4 
 
2 
3 
 
15 (47) 
17 (53) 
Mean Age (years) 65.0 60.6 65.1 62.2 67.4 64.1 
Age range (years) 44-80 38-78 49-76 47-78 52-82 38-82 
Age standard deviation      11.85 
Age IQR      21.75 
Relationship status 
     Never married 
     Married 
     Living with partner 
     Separated/divorced 
     Widowed 
 
1 
4 
0 
1 
1 
 
0 
3 
1 
0 
2 
 
2 
3 
0 
2 
1 
 
0 
4 
1 
1 
0 
 
0 
3 
1 
0 
1 
 
3 (9.4) 
17 (53.1) 
3 (9.4) 
4 (12.5) 
5 (15.6) 
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 Nominal Group 
A1 A2 A3 A4 A5 Total (%) 
Highest education 
     Secondary/high school 
     College/university  
     Postgraduate degree 
 
4 
2 
1 
 
3 
3 
0 
 
5 
2 
1 
 
3 
3 
0 
 
2 
2 
1 
 
17 (53.1) 
12 (37.5) 
3 (9.4) 
Employment status 
     Employed 
     Unemployed 
     Retired 
 
2 
1 
4 
 
3 
0 
3 
 
3 
0 
5 
 
2 
1 
3 
 
1 
0 
4 
 
11 (34.4) 
2 (6.3) 
19 (59.3) 
Cancer diagnosis (number of 
participants) 
     Breast cancer 
     Colorectal cancer 
     Prostate cancer 
     Sarcoma 
     Lung cancer 
     Head&neck cancer 
     CNS tumour 
     Gynaecological cancer 
     Renal cancer 
     Pancreatic cancer 
 
 
2 
1 
1 
0 
0 
0 
1 
1 
1 
0 
 
 
1 
2 
0 
1 
1 
0 
1 
0 
0 
0 
 
 
1 
2 
1 
0 
1 
1 
0 
1 
0 
1 
 
 
0 
0 
2 
0 
1 
1 
0 
1 
1 
0 
 
 
1 
1 
1 
0 
1 
0 
0 
1 
0 
0 
 
 
5 (15.6) 
6 (18.7) 
5 (15.6) 
1 (3.1) 
4 (12.5) 
2 (6.3) 
2 (6.3) 
4 (12.5) 
2 (6.3) 
1 (3.1) 
 
Mean duration since 
treatment (months) 
17.4 19.8 16.3 21.1 16.5 18.2 
Range of duration since 
treatment (months) 
3-22 5-23 4-24 7-24 6-19 3-24 
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 Nominal group 
A1 A2 A3 A4 A5 Total (%) 
Previous forms of treatment  
     Surgery 
     Chemotherapy 
     Radiotherapy 
     Endocrine therapy 
     Immunotherapy 
     PCM testing 
 
4 
5 
5 
3 
0 
0 
 
4 
3 
3 
1 
0 
0 
 
6 
4 
5 
1 
0 
0 
 
3 
2 
2 
1 
0 
0 
 
3 
2 
3 
2 
0 
0 
 
20 (62.5) 
16 (50.0) 
18 (56.3) 
8 (25) 
0  
0 
 
Participants within group A (n=32) had mean age of 64.1 years (s.d. 11.85) with range 38-
82 years. Fifty-three percent were female and forty-seven percent were male.  Participants 
within group A included those with previous diagnosis across ten cancer subtypes.  These 
included breast (15.6%), prostate (15.6%), colo-rectal (18.7%), lung (12.5%), 
gynaecological (12.5%), sarcoma (3.1%), neuro-oncology (6.3%), renal (6.3%), head and 
neck (6.3%) as well as pancreatic cancer (3.1%).  Participants had personal experience of 
cancer treatments including surgery (62.5%), chemotherapy (50.0%), radiotherapy (56.3%) 
and endocrine therapy (25%).  There were no participants included in group A with 
personal experience of cancer therapy utilising either immunotherapy or precision cancer 
medicine.  The mean duration since completing therapy across group A was 18.2 months 
(range 3-24). 
 
5.3.2. Preference attribute themes 
Nine themed preference attributes emerged from the data generated by the five group A 
nominal groups.  The attribute themes for group A are shown in Table 9 and preference 
attribute theme summary tables are shown in Appendix 4. 
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Table 9.  Preference attribute themes for each group A subgroup. 
 Nominal Group 
Attribute A1 A2 A3 A4 A5 
Sensitivity/true positive X X X X X 
Specificity/true 
negative 
X X X X X 
Prevalence of variant X X X X 
 
 
Invasiveness of testing X X X X X 
Physician approval X X X X 
 
X 
Implications for family X X   X 
Regulatory/NHS 
approval 
X X X X X 
Test turnaround time X X X X 
 
X 
Distance to travel X    X 
 
The 9 themes generated (percentage of groups selecting theme) by group A were 
sensitivity/true positive (100%), specificity/true negative (100%), prevalence of variant 
(80%), invasiveness of testing (100%), physician approval of test (100%), implications for 
family (60%), regulatory/NHS approval for testing (100%), test turnaround time (100%) 
and distance to travel for testing (40%). 
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5.3.3. Preference attribute theme ratings 
The group A preference attribute theme ratings are shown in Table 10, including mean 
importance rating and standard deviation.   
 
Table 10.  Group A preference attribute theme ratings. 
Attribute Importance Ratings (n=32) 
1 2 3 4 5 6 7 8 9 Mean S.D. 
Physician approval 2 3 1 2 5 1 9 5 7 6.75 2.49 
 
Sensitivity/true 
positive 
0 2 0 5 4 5 4 5 7 6.40 2.11 
Specificity/true 
negative 
0 0 2 7 0 8 3 7 5 6.38 1.95 
Regulatory/NHS 
approval 
1 2 2 3 9 2 4 5 5 6.03 2.27 
Prevalence of variant 0 0 3 4 4 4 4 5 3 5.12 1.94 
 
Invasiveness of 
testing 
2 3 7 5 3 2 5 3 3 5.06 2.42 
Test turnaround time 4 5 4 3 4 8 2 1 2 4.56 2.33 
 
Implications for 
family 
2 3 5 3 2 2 0 1 0 2.03 1.85 
Distance to travel 5 
 
3 1 0 1 0 1 0 0 0.81 1.96 
 
The preference attribute theme giving rise to the highest attribute rating score in group A 
was physician approval, with mean importance rating of 6.75 (s.d. 2.49).  It was selected as 
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highest order attribute by 7 participants (21.9% of total participants).  The preference 
attribute theme with second highest rating was test sensitivity/true positive, with mean 
importance rating of 6.40 (s.d. 2.11).  It was selected as the highest order attribute theme 
by 7 participants (21.9% of total participants).  The third highest preference attribute rating 
was test specificity/true negative, with mean importance rating of 6.38 (s.d. 1.95).  Test 
specificity/true negative was selected as the highest order attribute theme by 5 participants 
(15.6% of total).  The fourth highest attribute rating score was regulatory/NHS approval, 
with mean importance rating of 6.03 (s.d. 2.27).  It was selected as the highest order 
attribute theme by 5 (15.6% of total) participants.  The fifth highest attribute rating was for 
prevalence of variant, with mean importance rating of 5.12 (s.d. 1.94).  It was selected as 
the highest order attribute theme by 3 participants (9.4% of total). 
 
The sixth highest attribute theme for group A was invasiveness of testing, with mean 
importance rating of 5.06 (s.d. 2.42).  It was selected as highest order by 3 participants 
(9.4% of total participants).  The next highest rating preference attribute was turnaround 
time, with mean importance rating of 4.56 (s.d. 2.33).  This attribute theme was rated 
highest order by 2 participants (6.3% of total).  The eighth highest attribute was 
implications for family, with mean importance rating of 2.03 (s.d. 1.85).  It was rated 
highest order attribute by zero participants in group A.  The final preference attribute 
theme for group A was distance to travel for testing, with mean importance rating of 0.81 
(s.d. 1.96).  This was not selected as a highest order attribute theme by any participants in 
this group.  
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5.4. Nominal group B (radical treatment completed more than 2 years 
prior) Results 
5.4.1. Participant demographics 
All participants recruited to group B met study eligibility criteria and received radical 
intent cancer therapy completing more than 2 years prior to entering the nominal group 
study.  There were five nominal groups conducted within group B, for which demographic 
details are shown in Table 11. 
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Table 11.  Group B participant demographics 
 Nominal Group 
B1 B2 B3 B4 B5 Total (%) 
No of participants (n) 7 6 6 7 7 33 
Gender 
         Male 
         Female 
 
3 
4 
 
4 
2 
 
3 
3 
 
3 
4 
 
2 
5 
 
15 (45.5) 
18 (54.5) 
Mean Age (years) 66.4 66.8 61.6 68.4 63.4 65.5 
Age range (years) 34-84 50-76 41-76 51-82 27-83 27-84 
Age standard deviation      13.39 
Age IQR      18.5 
Relationship status 
     Never married 
     Married 
     Living with partner 
     Separated/divorced 
     Widowed 
 
1 
4 
1 
1 
0 
 
0 
2 
1 
1 
2 
 
0 
3 
0 
2 
1 
 
1 
2 
1 
1 
2 
 
0 
3 
0 
2 
2 
 
2 (6.1) 
14 (42.4) 
3 (9.1) 
7 (21.2) 
7 (21.2) 
Highest education 
     Secondary/high school 
     College/university  
     Postgraduate degree 
 
3 
2 
2 
 
4 
2 
0 
 
4 
2 
0 
 
3 
2 
2 
 
4 
2 
1 
 
18 (54.5) 
10 (30.3) 
5 (15.2) 
Employment status 
     Employed 
     Unemployed 
     Retired 
 
1 
1 
5 
 
1 
0 
5 
 
2 
1 
3 
 
2 
1 
4 
 
2 
1 
4 
 
8 (24.2) 
4 (12.2) 
21 (63.6) 
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 Nominal Group 
B1 B2 B3 B4 B5 Total (%) 
Cancer diagnosis (n) 
     Breast cancer 
     Colorectal cancer 
     Prostate cancer 
     Oesophageal cancer 
     Head&neck cancer 
     CNS tumour 
     Gynaecological cancer 
     Renal cancer 
 
 
1 
2 
1 
0 
1 
1 
1 
0 
 
 
 
0 
2 
2 
0 
1 
0 
0 
1 
 
 
 
2 
0 
1 
1 
0 
1 
1 
0 
 
 
 
1 
2 
1 
0 
1 
1 
0 
1 
 
 
1 
1 
1 
1 
0 
1 
2 
0 
 
 
 
5 (15.1) 
7 (21.2) 
6 (18.2) 
2 (6.1) 
3 (9.1) 
4 (12.1) 
4 (12.1) 
2 (6.1) 
Mean time since treatment 
(months) 
44.2 51.1 39.6 60.1 59.4 51.2 
Range of time since 
treatment (months) 
28-88 30-84 30-68 41-94 29-71 28-84 
Previous forms of 
treatment (number) 
     Surgery 
     Chemotherapy 
     Radiotherapy 
     Endocrine therapy 
     Immunotherapy 
     PCM testing 
 
 
4 
4 
4 
2 
0 
0 
 
 
3 
1 
2 
1 
0 
0 
 
 
4 
4 
5 
2 
1 
0 
 
 
5 
3 
3 
1 
0 
0 
 
 
5 
4 
4 
1 
0 
0 
 
 
21 (63.6) 
16 (48.5) 
18 (54.5) 
7 (21.2) 
1 (3.0) 
0 
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Participants in group B (n=33) had mean age of 65.5 years (s.d. 13.39) with range 27-84 
years. Fifty-four percent of participants were female and forty-seven percent were male.  
Participants had diagnosis across eight cancer subtypes.  These included breast (15.1%), 
colorectal (21.2%), prostate (18.2%), oesophageal (6.1%), head and neck (9.1%), neuro-
oncology (12.1%), gynaecological (12.1%) and renal (6.1%) cancer.  Participants had 
personal experience of cancer therapies including surgery (63.6% of group B participants), 
chemotherapy (48.5%), radiotherapy (54.5%), endocrine therapy (21.2%) and 
immunotherapy (3.0%).  No participants included in group B had personal experience of 
cancer therapy utilising precision cancer medicine.  The mean duration since completing 
therapy was 52.1 months (range 28-84).  
 
5.4.2. Preference attribute themes 
Ten preference attribute themes emerged from the data generated by the five group B 
nominal groups.  The attribute themes for group B are shown in Table 12 and preference 
attribute theme summary tables are shown in Appendix 4. 
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Table 12.  Preference attribute themes for group B subgroups. 
Attribute B1 B2 B3 B4 B5 
Sensitivity/true positive X X X X X 
Specificity/true negative X  X X X 
Prevalence of variant X 
 
X  X  
Invasiveness of testing  X X X X 
Physician approval X 
 
 X  X 
Implications for family X     
Regulatory/NHS approval X X X X X 
Test turnaround time X 
 
X X X X 
Distance to travel  
 
X  X X 
Family approval    X 
 
 
 
Ten preference attribute themes were generated (percentage of groups selecting theme) by 
Group B: sensitivity/true positive (100%), specificity/true negative (80%), prevalence of 
variant (60%), invasiveness of testing (80%), physician approval of testing (60%), 
implications for family (20%), regulatory/NHS approval for testing (100%), test 
turnaround time (100%), distance to travel (60%) and family approval of testing (20%).  
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5.4.3. Preference attribute theme ratings 
The group B preference attribute theme ratings are shown in Table 13, including mean 
importance rating and standard deviation.   
 
Table 13.  Group B preference attribute theme ratings. 
Attribute Importance Ratings (n=33) 
1 2 3 4 5 6 7 8 9 Mean S.D. 
Regulatory/NHS approval 0 0 2 2 5 4 5 6 9 6.88 1.89 
Sensitivity/true positive 0 0 1 5 6 6 4 5 6 6.39 1.84 
Test turnaround time 0 1 1 3 7 5 7 5 4 6.27 1.81 
Specificity/true negative 0 0 1 4 5 5 3 5 4 5.18 1.82 
Invasiveness of testing 0 0 0 7 2 4 6 4 3 4.94 1.76 
Physician approval 0 0 1 3 0 3 5 4 4 4.12 1.85 
Prevalence of variant 0 0 1 4 4 4 2 3 2 3.61 1.79 
Distance to travel 0 2 8 5 1 0 1 0 1 2.09 1.72 
Implications for family 0 0 2 0 2 2 0 1 0 1.09 0.77 
Family approval 0 5 2 0 0 0 0 0 0 0.48 0.47 
 
The attribute theme for group B (n=33) giving rise to the highest rating score is 
regulatory/NHS approval, with mean importance rating of 6.88 (s.d. 1.89).  It was selected 
as highest order attribute by 9 participants (27.3% of total).  The preference attribute with 
second highest mean importance rating was test sensitivity/true positive, with mean 
importance rating of 6.39 (s.d. 1.84).  It was selected as the highest order attribute theme 
by 6 participants (18.2% of total).  The third highest attribute rating score was test 
turnaround time, with mean importance rating of 6.27 (s.d. 1.81).  It was selected as the 
highest order attribute theme by 4 participants (12.1% of total).  The fourth highest 
preference attribute theme rating score was test specificity/true negative, with mean 
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importance rating of 5.18 (s.d. 1.82).  Test specificity/true negative was selected as the 
highest order attribute theme by 4 (12.1% of total) participants.  The fifth highest 
preference attribute theme rating score was invasiveness of testing, with mean importance 
rating of 4.94 (s.d. 1.76).  It was selected as highest order attribute by 3 participants (9.1% 
of total). 
 
The sixth highest preference attribute theme for group B was physician approval, with 
mean importance rating of 4.12 (s.d. 1.85).  This was selected as highest order by 4 
participants (12.1% of total participants).  The next highest attribute theme was prevalence 
of variant, with mean importance rating of 3.61 (s.d. 1.79).  This attribute theme was rated 
highest order by 2 participants (6.1% of total).  The eighth highest preference attribute was 
distance to travel for testing, with mean importance rating of 2.09 (s.d. 1.72).  It was rated 
as highest order by 1 participant (3.0% of total) in group B.  The ninth highest preference 
attribute was implications of testing for family, with mean importance rating of 1.09 (s.d. 
0.77).  This was not selected as a highest order attribute theme by any of the participants in 
Group B.  The final attribute theme from group B was family approval for testing, with 
mean importance rating of 0.48 (s.d. 0.47).  This was not rated highest order by any 
participants in group B. 
 
5.5. Nominal group C (palliative treatment intent) Results 
5.5.1. Participant demographics  
All participants recruited to group C met study eligibility criteria and received, or were still 
receiving, palliative intent therapy prior to entering the nominal group study.  Six nominal 
groups were conducted within group C, for which demographic details are shown in Table 
14. 
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Table 14.  Group C participant demographics. 
 Nominal Group 
C1 C2 C3 C4 C5 C6 Total (%) 
No of participants (n) 5 6 6 7 6 7 37 
Gender 
         Male 
         Female 
 
3 
2 
 
2 
4 
 
3 
3 
 
3 
4 
 
3 
3 
 
3 
4 
 
17 (45.9) 
20 (54.1) 
Mean Age (years) 54.1 62.0 68.7 65.3 58.7 67.3 63.1 
Age range (years) 31-75 41-79 48-81 48-79 42-76 46-79 31-81 
Age standard deviation       12.47 
Age IQR       23.1 
Relationship status 
     Never married 
     Married 
     Living with partner 
     Separated/divorced 
     Widowed 
 
0 
3 
0 
1 
2 
 
1 
2 
1 
1 
1 
 
0 
3 
0 
2 
1 
 
0 
4 
0 
1 
2 
 
1 
2 
1 
2 
0 
 
0 
3 
0 
2 
2 
 
2 (5.4) 
17 (45.9) 
2 (5.4) 
9 (24.4) 
7 (18.9) 
Highest education 
     Secondary/high             
school 
     College/university  
     Postgraduate degree 
 
3 
2 
0 
 
4 
1 
1 
 
3 
2 
1 
 
3 
3 
1 
 
5 
1 
0 
 
5 
2 
0 
 
23 (62.2) 
11 (29.7) 
3 (8.1) 
Employment status 
     Employed 
     Unemployed 
     Retired 
 
2 
1 
2 
 
1 
2 
3 
 
2 
0 
4 
 
1 
2 
4 
 
2 
2 
2 
 
2 
1 
4 
 
10 (27.0) 
8 (21.6) 
19 (51.4) 
 102 
 
 Nominal Group 
C1 C2 C3 C4 C5 C6 Total (%) 
Cancer diagnosis (n) 
     Breast cancer 
     Colorectal cancer 
     Prostate cancer 
     Gastric cancer 
     Lung cancer 
     CNS tumour 
     Gynaecological cancer 
     Neuro-endocrine cancer 
     Bladder cancer 
 
2 
1 
0 
0 
0 
0 
1 
1 
0 
 
1 
1 
2 
1 
1 
0 
0 
0 
0 
 
1 
0 
1 
0 
1 
1 
1 
0 
1 
 
2 
2 
1 
0 
0 
0 
1 
1 
0 
 
2 
0 
1 
1 
0 
1 
1 
0 
0 
 
2 
1 
2 
0 
0 
0 
1 
1 
0 
 
10 (27.0) 
5 (13.5) 
7 (18.9)  
2 (5.4) 
2 (5.4) 
2 (5.4) 
5 (13.5)  
3 (8.1) 
1 (2.8) 
Previous forms of treatment 
(number) 
     Surgery 
     Chemotherapy 
     Radiotherapy 
     Endocrine therapy 
     Immunotherapy 
     PCM testing 
 
 
3 
5 
4 
2 
3 
2 
 
 
2 
6 
4 
3 
2 
1 
 
 
1 
5 
3 
1 
2 
0 
 
 
3 
7 
4 
3 
3 
2 
 
 
3 
5 
3 
3 
3 
1 
 
 
2 
5 
3 
3 
2 
2 
 
 
14 (37.8) 
33 (89.2) 
21 (56.8) 
15 (40.5) 
15 (40.5) 
8 (21.6) 
 
Participants within group C (n=37) had mean age of 63.1 years (s.d. 12.47) with range 31-
81 years. Fifty-four percent of participants were female and forty-six percent were male.  
Participants included previous diagnoses across nine cancer subtypes: breast (27.0%), 
prostate (18.9%), colo-rectal (13.5%), gastric (5.4%), lung (5.4%), neuro-oncology (5.4%), 
gynaecological (13.5%), neuroendocrine (8.1%) and bladder cancer (2.8%).  
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Participants experienced cancer therapies including surgery (37.8% of Group C 
participants), chemotherapy (89.2%), radiotherapy (56.8%), endocrine therapy (40.5%), 
and immunotherapy (40.5%).  Eight participants (21.6% of total) in group C had personal 
experience of cancer therapy utilising precision cancer medicine. 
 
5.5.2. Preference attribute themes 
Ten preference attribute themes emerged from data generated by the five group C nominal 
groups.  The attribute themes for group C are shown in Table 15 and preference attribute 
theme summary is shown in Appendix 4. 
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Table 15.  Preference attribute themes for each group C subgroup. 
Attribute C1 C2 C3 C4 C5 C6 
Sensitivity/true 
positive 
X X X  X  
Specificity/true 
negative 
 X   X  
Prevalence of variant X 
 
   X X 
Invasiveness of testing X X X X X X 
Physician approval X 
 
X X X X X 
Implications for family   X X  X 
Regulatory/NHS 
approval 
X X X  X X 
Test turnaround time X 
 
X X X X X 
Distance to travel X 
 
X X X  X 
Family approval 
 
X 
 
 
 
X 
 
 
 
 
 
 
 
Ten preference attribute themes were generated by group C (percentage of groups selecting 
theme): sensitivity/true positive (66%), specificity/true negative (33%), prevalence of 
variant (50%), invasiveness of testing (100%), physician approval for testing (100%), 
implications for family (50%), regulatory/NHS approval for testing (83%), test turnaround 
time (100%), distance to travel for testing (83%) and family approval of testing (33%). 
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5.5.3. Preference attribute theme ratings 
Group C preference attribute theme ratings are shown in Table 16, including mean 
importance rating and standard deviation. 
 
Table 16.  Group C preference attribute theme ratings. 
Attribute Importance Ratings (n=37) 
1 2 3 4 5 6 7 8 9 Mean S.D. 
Invasiveness of testing 0 1 1 0 5 6 9 9 7 7.14 1.68 
Test turnaround time 0 0 0 4 2 10 5 8 8 6.95 1.61 
Physician approval 0 0 0 0 3 5 8 7 8 6.19 1.31 
Regulatory/NHS 
approval 
0 1 0 2 5 7 6 6 4 5.49 1.69 
Distance to travel 0 1 0 4 7 5 6 4 5 5.46 1.82 
Prevalence of variant 0 1 3 6 2 2 0 1 3 2.49 2.11 
Sensitivity/true positive 0 5 9 5 1 1 1 0 0 2.03 1.29 
Implications for family 0 0 9 1 7 1 0 0 0 1.95 1.08 
Specificity/true 
negative 
0 0 4 5 2 0 1 0 0 1.32 1.16 
Family approval 0 1 4 3 2 0 0 0 0 0.97 0.91 
 
The preference attribute giving rise to the highest rating score in group C (n=37) was 
invasiveness of testing, with mean importance rating of 7.14 (s.d. 1.68).  It was selected as 
highest order attribute by 7 participants (18.9% of total).  The preference attribute with 
second highest rating was test turnaround time, with mean importance rating of 6.95 (s.d. 
1.61).  This attribute was selected as the highest order by 8 participants (21.6% of total).  
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The third highest preference attribute rating score was physician approval, with mean 
importance rating of 6.19 (s.d. 1.31).  It was selected as highest order attribute theme by 8 
participants (21.6% of total).  The fourth highest preference attribute rating for group C 
was Regulatory/NHS approval, with mean importance rating of 5.49 (s.d. 1.69).  It was 
selected highest order attribute theme by 4 (10.8% of total) participants.  The fifth highest 
attribute theme rating score was distance to travel, with mean importance rating of 5.46 
(s.d. 1.82).  This attribute theme was selected as the highest order by 5 participants (13.5% 
of total). 
 
The sixth highest preference attribute for group C was prevalence of variant, with mean 
importance rating of 2.49 (s.d. 2.11).  It was selected as highest order by 3 participants 
(8.1% of total participants).  The next highest preference attribute was sensitivity/true 
positive, with mean importance rating of 2.03 (s.d. 1.29).  There were zero participants 
who rated test sensitivity/true positive as the highest order attribute.  The eighth highest 
attribute theme was implications of testing for family, with mean importance rating of 1.95 
(s.d. 1.08).  It was not rated as the highest order priority by any of the participants in group 
C.  The ninth highest preference attribute was specificity/true negative, with mean 
importance rating of 1.32 (s.d. 1.16).  Test specificity/true negative was not selected as the 
highest order preference attribute by any participants in group C.  The final preference 
attribute was family approval for testing, with mean importance rating of 0.97 (s.d. 0.91).  
This attribute theme was not rated as highest order by any participants in this group. 
 
5.6. Summary of Nominal Group Results 
The summary preference attribute theme ratings across all nominal groups are shown in 
Table 17, including mean importance rating and standard deviation for each attribute 
theme.   
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Table 17.  Summary preference attribute theme ratings across all nominal groups. 
Attribute Importance Ratings (n=102) 
1 2 3 4 5 6 7 8 9 Mean S.D. 
Regulatory/NHS approval 1 3 4 7 19 13 15 17 18 6.11 1.99 
Test turnaround time 4 6 5 10 13 23 14 14 14 5.98 2.19 
Invasiveness of testing 2 4 8 12 10 12 20 16 13 5.77 2.15 
Physician approval 2 3 2 5 8 9 22 16 19 5.71 2.03 
Sensitivity/true positive 0 7 10 15 11 12 9 10 13 4.81 2.23 
Specificity/true negative 0 0 7 16 7 13 7 12 9 4.16 2.92 
Prevalence of variant 0 1 7 14 10 10 6 9 8 3.68 1.99 
Distance to travel 5 6 9 9 9 5 8 4 6 2.91 2.37 
Implications for family 2 3 16 4 11 5 0 2 0 1.69 1.61 
Family approval 0 6 6 3 2 0 0 0 0 0.51 0.45 
 
The preference attribute across all nominal groups (n=102) giving rise to the highest rating 
score is regulatory/NHS approval of testing, with mean importance rating of 6.11 (s.d. 
1.99).  It was selected as highest order by 18 participants (17.6% of total).  The attribute 
theme with the second highest mean importance rating was test turnaround time, with 
mean importance rating of 5.98 (s.d. 2.19).  This was selected as highest order attribute by 
14 participants (13.7% of total).  The third highest preference attribute rating was 
invasiveness of testing, with mean importance rating of 5.77 (s.d. 2.15).  It was selected as 
the highest order attribute theme by 13 participants (12.7% of total).  The fourth highest 
attribute rating score across all groups was physician approval of testing, with mean 
importance rating of 5.71 (s.d. 2.03).  It was selected as the highest order attribute theme 
by 19 (18.6% of total) participants.  The fifth highest attribute rating score was test 
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sensitivity/true positive, with mean importance rating of 4.81 (s.d. 2.23).  This was selected 
as highest order attribute by 13 participants (12.7% of total). 
 
The sixth highest attribute theme rating across all groups was test specificity/true negative, 
with mean importance rating of 4.16 (s.d. 2.92).  It was selected as highest order rating by 
9 participants (8.8% of total participants).  The next highest attribute was prevalence of 
variant, with mean importance rating of 3.68 (s.d. 1.99).  This preference attribute theme 
was rated highest order by 8 participants (7.8% of total).  The eighth highest attribute 
theme was distance to travel for testing, with mean importance rating of 2.91 (s.d. 2.37).  
This was rated highest order by 6 participants (5.9% of total).  The ninth highest preference 
attribute theme was implications of testing for family, with mean importance rating of 1.69 
(s.d. 1.61).  It was not selected as a highest order attribute theme by any of the participants 
across the groups.  The final attribute theme across all groups was family approval for 
testing, with mean importance rating of 0.51 (s.d. 0.45).  It was not rated highest order by 
any participants across the nominal groups. 
 
5.7. Discussion of results 
5.7.1. Introduction  
The aim of this thesis was to add to current knowledge by exploring how, using mixed 
methods research techniques, patient preference attributes of genomic testing in precision 
cancer medicine can be identified and rated.  Building on the work of previous studies, 
identified by the systematic review in Chapter 3, the aim of this thesis chapter was to: 
1 – Identify patient preference attribute themes of genomic testing in PCM. 
2 – Identify rating scores for patient preference attribute themes of genomic testing. 
3 – Examine the effect of clinical cancer treatment intent and time since completing 
treatment on identified patient preference attribute themes and ratings. 
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5.7.2. Defining preference attribute themes of genomic testing in PCM 
This thesis study identified patient preference attributes themes of genomic testing 
including regulatory/NHS approval, test turnaround time, invasiveness of testing, physician 
approval, sensitivity/true positive, specificity/true negative, prevalence of genomic variant, 
distance to travel for testing, implications of testing on other family members and family 
approval of testing. 
 
Regulatory/NHS approval for testing 
The UK provides a uniform package of healthcare irrespective of income.  In the UK, 
fiscal sustainability of health care financing remains a key public policy concern 
(Aggarwal & Sullivan, 2013).  Attempts to control the provision of medicines not deemed 
cost effective by health technology assessment (HTA) agencies such as NICE and SMC 
have been met with patient and public discontent (Dyer, 2002; Mayor, 2009).  Such HTA 
agencies are designed to ensure all patients receive equitable healthcare in the UK, basing 
their value judgements on a thorough consultation and health economic impact modelling.  
In a previous survey of societal preferences for NHS funding, respondents agreed with the 
premise of value based-pricing, but the majority did not believe that extra value should be 
placed on specific groups such as children, cancer patients or those with reduced life 
expectancy (Linley & Hughes, 2013).   
 
Across all participants (n=102) in this study, the highest preference attribute rating score 
was regulatory/NHS approval for testing.  All participants within this study received 
cancer therapy within the National Health Service (NHS) universal healthcare system in 
the UK.  This attribute had the highest mean importance rating across all groups in the 
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study.   It was also selected as highest order preference attribute theme the second most 
times.  
 
This is the first study in the UK identifying and rating patient preferences of genomic 
testing in PCM.  This attribute theme was not readily identified in other studies, performed 
within different healthcare systems in the world.  This may reflect the different healthcare 
priorities between these populations.  This study demonstrated cancer patients readily 
identify regulatory approval within the NHS and role it may play in approval and uptake of 
genomic testing in PCM.  This was demonstrated by the high mean attribute rating and 
frequency of highest order prioritisation.  Many patients reported the robust and peer-
reviewed regulatory processes provided confidence around the utilisation of genomic 
testing and appropriate use of NHS resources. 
 
Test turnaround time 
The preference attribute theme with second highest mean importance rating across all 
groups was test turnaround time.  This attribute theme was rated highest order by 14 
participants (13.7% of total).  This demonstrated patients identify and highly rate the 
importance of test turnaround time within clinically appropriate timelines.  The previous 
study by Cuffe et al (Cuffe et al., 2014) highlighted that cancer patients were willing to 
undergo pharmaco-genomic testing and willing to pay for it, waiting several weeks for 
results.   
 
The results of this NGT study demonstrate turnaround time for test results remained a 
readily identified and highly rated patient preference attribute theme of genomic testing.  
This transcended all groups within the study, reflected by the second highest mean attribute 
rating.  Patients within clinical treatment paradigms are acutely aware of treatment 
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timelines, audited within the UK by cancer waiting times.  Patients in this study identified 
short turnaround time for results as highly rated preference attribute theme of genomic 
testing.  The complexity of genomic testing and plethora of datasets produced does 
challenge this turnaround timeframes.  The increasing advent of multi-professional 
molecular tumour board meetings helps augment the rapid turnaround of genomic data and 
its interpretation.  This study demonstrated doing so within truncated timelines remains 
important for patients.  
 
Invasiveness of testing 
The third highest preference attribute theme rating score across all nominal groups was 
invasiveness of testing.  Participants had personal history of cancer testing, diagnosis and 
treatment.  This study identified patient preference attribute themes across a breadth of 
fourteen cancer subtypes, though this did highlight many participants had heterogeneous 
experience of invasive diagnostic procedures.  Prior experiences of invasive biopsy did 
weight significantly on preference ratings for this attribute theme.  The high mean attribute 
rating reflects patient preference for less invasive genomic tests where possible. 
 
Participants in the study were increasingly aware of circulating tumour cell assays and 
many participants expressed interest in these novel minimally-invasive techniques for 
genomic testing.  There remains academic interest in minimally invasive PCM, with a 
small number of tests in clinical practice, such as circulating T790M resistance mutation 
analysis in EGFR mutated non-small cell lung cancer (Luo J, Shen L, et al, 2014).  High 
mean attribute rating scores in this study reflect patient preference for further minimally-
invasive techniques in clinical trials and practice. 
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Physician approval for testing 
The fourth highest preference attribute theme rating was physician approval of genomic 
testing.  It was rated by the highest number of participants as first order attribute theme 
throughout the study.  Hillen et al (Hillen, de Haes, & Smets, 2011) explored published 
empirical literature assessing cancer patients’ trust in their physician.  This demonstrated 
trust in physicians, facilitating communication and shared medical decision-making, 
resulting in decreased patient fear and better treatment adherence.  The authors appreciated 
the need for further empirical studies to understand the nature and impact of cancer 
patients’ trust in their physician.   
 
This thesis study demonstrated high rating patients placed on patient-physician relationship 
and influence on preference attributes of genomic testing.  Only 7.8% of patients had 
experience of PCM.  Patients, therefore, reported not to retain full confidence in their 
personal ability to determine suitability of genomic testing, subsequent reliance on 
physician advice and informed discussion.  Individual merits of genomic testing and 
balance of preference attributes in clinical practice will be guided by balanced patient-
physician consultation.  The high mean rating for this identified preference attribute 
reinforces the value patients place on this relationship. 
 
Test sensitivity/true positive 
The fifth highest preference mean attribute rating score was test sensitivity/true positive.  
This demonstrated patient preferences for genomic tests correctly identifying patients who 
may or may not benefit from therapeutic intervention.  Patients had an appreciation that 
test sensitivity/true positive could potentially lead to either over- or under-treatment. 
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This study demonstrated patient preference for high genomic test sensitivity, with concern 
reduction in sensitivity could lead to either under or over-treatment, depending on an 
individual genomic test.  The research aims of this thesis were to identify and rate 
preferences of genomic testing, rather than focusing on the potential therapies resulting 
from the test result.  Many patients found it difficult to tease these two elements out within 
NGT discussion of this preference attribute theme.  In clinical practice, the two often have 
significant overlap. 
 
Test specificity/true negative 
The sixth highest preference attribute rating was test specificity/true negative.  This had 
lower mean importance rating and selected less times as highest order attribute compared 
to sensitivity/true positive of testing.  Participants in this study identified specificity of 
testing could impact on potential over- or under-treatment, a consistent concern of genomic 
testing amongst participants.  Patients’ had higher preference rating for a genomic test to 
correctly identify individuals with specific genomic mutation.  This study demonstrated 
high cognitive burden of the sensitivity/specificity preference attribute discussions for 
patients.  Patients’ identified these preference attributes, thus the medical and scientific 
community need to ensure they are presented and addressed in a manner which patient and 
family members can comprehend within the clinical arena. 
 
Prevalence of genomic variant 
The seventh highest preference attribute theme was prevalence of genomic variant.  
Participants identified frequency of genomic variant as preference attribute with seventh 
highest mean attribute rating score.  It was rated as highest order attribute by 8 participants 
in total.  Participants identified rarity of genomic variants would affect preferences of 
testing.  The study identified this attribute theme, though it had lower preference rating 
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compared to others.  Patients initially considered genomic tests providing a single result, 
aligned with their previous experiences of clinical practice.  Patients were very engaged 
with platform approaches to genomic testing, though appreciated overall prevalence would 
still need to be high enough meet the preference attribute theme. 
 
Distance to travel for testing 
Distance to travel for testing received the eighth highest mean preference attribute rating.  
It was rated highest order preference attribute by 6 participants.  All participants within the 
study received cancer treatment within the West of Scotland, but included a wide range of 
geographical locations due regional and national cancer services.  Participants identified 
distance to travel as an attribute theme, but with low preference rating.  Participants 
considered travel to a regional cancer as entirely appropriate for testing, but travel out with 
Scotland as an adverse preference attribute. 
 
Implications for family members of testing 
The penultimate preference attribute theme rating was implications of testing for family 
members.  A small number of participants identified potential implications for family due 
to unveiling germline mutations, but with low preference rating scores.  The low number of 
groups identifying this theme demonstrated low awareness around this preference attribute 
of genomic testing.  The low frequency of identification in this study may also 
disproportionately affect mean attribute rating. 
 
The study highlighted implications for family members can have both positive and 
negative influence on preferences of genomic testing.  Some participants expressed feel 
more positive towards genomic testing facilitating family members diagnosed at an earlier 
stage or entering an appropriate cancer screening program based on the result.  Other 
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participants identified negative connotations with this preference attribute, reporting 
feeling burdened telling family members.  One participant identified feeling degree of 
responsibility if their offspring were to have an inherited germline mutation.  This remains 
a complex area for patients and this study demonstrated there not widespread awareness 
amongst patients of this attribute theme.  The low rates of attribute identification may 
reflect that only 7.8% of participants had experience of genomic testing. The design of this 
study did not allow for more comprehensive assessment of the wider implications of this 
single attribute theme amongst patients. 
 
Family approval for testing 
The final preference attribute theme was family approval of genomic testing.  It was not 
rated highest order by any participants within the study.  This study demonstrated 
participants identified preferences of genomic testing are influenced by approval of family 
members.  Some participants identified they could be convinced to undergo testing by a 
persuasive relative, where others felt family support would reinforce their personal 
decision-making processes. 
 
5.7.3. Effect of clinical treatment intent on preference attribute themes and ratings 
This thesis identified patient preference attribute themes and ratings of genomic testing in 
PCM.  It also aimed to define effect of clinical treatment intent on identified preference 
attributes and rating scores.  As discussed in Chapter 2, previous studies demonstrated 
therapeutic decision-making is influenced by clinical treatment intent.  This thesis explored 
the effect of cancer treatment intent, between patients who received radical versus 
palliative cancer treatment, on identified preference attributes and mean rating scores. 
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Patients treated with radical intent (groups A and B combined, n=65), identified the 
following preference attribute themes: physician approval, regulatory/NHS approval, 
sensitivity/true positive of test, specificity/true negative of test, prevalence of genomic 
variant, invasiveness of testing, test turnaround time, implications for family members, 
family approval for testing and distance to travel.  
 
Patients treated with palliative intent (n=37), identified the following preference attribute 
themes: invasiveness of testing, test turnaround time, physician approval, regulatory/NHS 
approval, distance to travel, prevalence of genomic variant, sensitivity/true positive of test, 
implications for family members, specificity/true negative of test and family approval for 
testing.  
 
Regulatory/NHS approval of genomic testing 
The highest preference attribute theme rating in the radical treatment group (groups A and 
B) was regulatory/NHS approval of genomic testing.  It had mean attribute rating score of 
6.39 and was selected as the highest order preference attribute by 14/65 participants.  
Regulatory/NHS approval received fourth highest mean attribute rating score amongst 
participants treated with palliative intent (n=37).  In this group, the mean attribute rating 
was 5.49 and rated highest order attribute theme by 4 participants.  
 
Regulatory/NHS approval received the highest mean attribute scores across both radical 
and palliative intent treatment groups, though rated higher for patients’ treated with radical 
intent.  It was identified across all groups within the NGT study.  This reflected high 
identification and overall rating of regulatory/NHS approval amongst patients.   Individuals 
treated with radical intent rate this attribute slightly higher than those treated with 
palliative intent. 
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Sensitivity/true positive of genomic testing 
Sensitivity of genomic testing was received the second highest rating in the radical 
treatment group, with mean attribute rating of 6.39.  There were 13/65 participants in the 
radical treatment groups who rated this as highest order preference attribute theme.  In the 
participant group treated with palliative intent, sensitivity of testing received 7th highest 
mean attribute rating (2.03) and not rated highest order by any participants. 
 
This highlighted differing preferences between individuals treated with radical versus 
palliative intent.  Patients treated with radical intent demonstrated higher preference rating 
for sensitivity of genomic testing compared to those treated with palliative intent.  This 
included risks of both under- and over-treatment depending on the genomic test. 
 
Physician approval for testing 
Physician approval for testing was rated fourth highest preference attribute theme for 
patients treated with radical intent, demonstrating mean attribute rating of 5.43.  It was 
selected by 11/65 participants as highest order preference attribute theme.  In patients’ 
treated with palliative intent, physician approval of testing received the third highest mean 
attribute rating of 6.19, with 8/37 participants selecting it as highest order attribute. 
 
Patients receiving radical and palliative cancer treatment identified doctor-patient 
relationship as a highly rated preference attribute of genomic testing.  This demonstrated 
importance patients placed on physician-patient relationship, regardless of cancer treatment 
intent. 
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Test turnaround time 
Test turnaround time received the fifth highest mean attribute rating (5.42) amongst 
participants treated with radical intent.  It was selected highest order preference attribute by 
6/65 participants in the radical treatment intent group.  This contrasts with the palliative 
treatment group, where test turnaround time received the second highest mean attribute 
rating of 6.95 and highest order attribute by 8/37 participants.   
 
Patients treated with palliative intent placed greater importance on genomic test results 
being delivered in an appropriate timeframe.  The high rates of attribute identification 
across the study demonstrated all patients remain acutely aware of timelines for testing 
across both radical and palliative intent groups.  Patients with a life-limiting cancer 
diagnosis, though, had higher preference rating for test turnaround time compared to those 
treated with radical intent. 
 
Specificity/true negative of genomic testing 
The specificity/true negative of genomic testing received the third highest mean attribute 
rating (5.78) and ranked highest order preference attribute by 9/65 participants within the 
radical treatment groups.  This contrasted significantly with patients treated with palliative 
intent, for whom specificity/true negative of testing received the ninth highest mean 
attribute rating at 1.32 and not rated as highest order attribute by any participants.   
 
Patients treated with radical intent demonstrated higher preference rating for specificity of 
genomic testing compared to those treated with palliative intent.  Patients treated with 
radical intent demonstrated significant concern about both over- or under-treatment by 
placing high preference rating on specificity of genomic testing.  Patients treated with 
palliative intent prioritised other preference attribute themes over specificity of testing and 
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displayed lower priority rating for over- or under-treatment compared to those receiving 
radical therapy. 
 
Invasiveness of testing 
Invasiveness of testing was identified across both radical and palliative treatment intent 
groups.  In participants treated with radical intent, it received sixth highest mean attribute 
rating (5.00) and rated highest order preference attribute by 13/65 participants.  This 
contrasted participants treated with palliative intent, where invasiveness of testing received 
the highest mean attribute rating at 7.14 and rated highest order attribute by 7/37 
participants.  This shows a stark contrast in how participants view preference attributes of 
invasiveness of testing between radical and palliative treatment intent.   
 
Participants in the study had personal experience of wide-ranging cancer diagnostics and 
testing, which influenced their preferences of invasive testing within the PCM arena.  
Patients treated with palliative intent demonstrated higher preference rating on less 
invasive testing compared to those treated with radical intent.  This suggested patients 
treated with radical intent are more prepared to accept short-term morbidity from more 
invasive biopsy for genomic testing.  Patients treated with palliative intent, on the other 
hand, placed greater preference on factors affecting quality of life.   
 
Prevalence of genomic variant 
This preference attribute theme received the seventh highest mean attribute rating across 
participants treated with radical intent.  It received mean attribute rating of 4.37 and ranked 
highest order attribute by 5 participants within the radical treatment group.  The prevalence 
of genomic variant attribute received the sixth highest mean attribute rating (2.49) amongst 
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participants treated with palliative intent.  It was rated highest order preference attribute by 
3 participants in this group. 
 
This demonstrated both radical and palliative treatment intent groups, had similar 
identification rates of prevalence of genomic variant but it retains relatively low mean 
attribute rating scores. 
 
Implications of testing for family members 
This preference attribute theme was identified by both radical and palliative participant 
groups.  Implications of testing for family members received the eighth highest mean 
attribute rating (1.56) across the radical treatment groups.  It received mean attribute rating 
of 1.95 amongst the palliative treatment intent group, making it the eighth highest 
preference attribute rating.  It was not rated as the highest order preference attribute theme 
by any participants. 
 
These results are consistent across both treatment intent groups.  Patients identified 
implications of testing for family members as a preference attribute theme, but it retains 
relatively priority across all participants in the study.  Treatment intent does not appear to 
have a significant impact on its mean attribute ratings. 
 
Distance to travel for testing 
This attribute received the ninth highest rating across participants treated with radical 
intent, with mean attribute rating of 1.45.  Distance to travel for testing was highest order 
preference attribute for 1/65 participants within the radical intent group.  It received the 
fifth highest mean attribute rating across the palliative intent group at 5.46.  Distance to 
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travel was the highest order preference attribute theme for 5/37 participants treated with 
palliative intent. 
 
Patients treated with radical intent identified distance to travel, but assigned lower 
preference attribute rating compared to patients treated with palliative intent.  The reasons 
under-pinning this were multi-factorial.  Participants treated with palliative intent may be 
less physically able to travel or place greater significance on spending time nearer family 
and home.  Distance to travel had low preference attribute rating for genomic testing in 
patients treated with radical intent. 
 
Family approval of testing 
Family approval of genomic testing was identified as a preference attribute theme by 1/10 
groups treated with radical and two out of six groups treated with palliative intent.  Within 
the radical intent participants, family approval for testing received mean preference 
attribute rating of 0.24 and was not ranked as highest order attribute by any participants.  
Within the palliative treatment intent groups, it received a mean preference attribute rating 
of 0.97 and was not ranked order attribute by any participants. 
 
The family approval for genomic testing was identified as a preference attribute theme by 
three out of sixteen participant groups in this study.  Within those groups, it received the 
lowest mean attribute rating and was not rated highest order attribute by any participants.  
This demonstrated family approval for genomic testing is identified by some patients but 
had lower preference rating in both radical and palliative intent treatment groups compared 
to other attribute themes. 
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5.7.4. Effect of time since completing treatment on preference attribute themes and 
ratings 
This thesis identified patient preference attribute themes and associate ratings for genomic 
testing.  It also investigated the novel hypothesis that time since completing treatment may 
influence identified preference attribute themes or ratings.  As discussed in Chapter 3, 
previous studies demonstrated patients therapeutic decisions were influenced by intent of 
cancer treatment.  It was hypothesized that increasing time from therapeutic equipoise and 
reflective thinking after completing cancer therapy may influence identified preference 
themes and ratings of genomic testing. 
 
Patients treated with radical intent (groups A and B, n=65) identified the following 
preference attribute themes: physician approval, regulatory/NHS approval, sensitivity/true 
positive of test, specificity/true negative of test, prevalence of genomic variant, 
invasiveness of testing, test turnaround time, implications for family members, family 
approval and distance to travel for genomic testing.  
 
Regulatory/NHS approval 
Regulatory/NHS approval received the fourth highest mean attribute preference rating 
(6.03) for participants treated with radical intent within the past 2 years (group A) and was 
highest order attribute theme for 5/32 participants.  It received the highest mean attribute 
rating (6.88) amongst participants treated with radical intent more than 2 years prior (group 
B).  It was rated highest order preference attribute by 9/33 participants in this group. 
 
These results demonstrated similar preference attribute theme ratings of regulatory/NHS 
approval for patients completing treatment within and longer than 2 years prior.  It 
received high mean attribute rating across both groups, reflecting its preference rating 
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amongst patients receiving cancer therapy with radical intent, regardless of time since 
completion. 
 
Physician approval 
Physician approval received the highest mean attribute rating for group A participants 
(6.75). It was highest order preference attribute for 7/32 participants treated with radical 
intent within the preceding 2 years.  Participants in group B, who completed cancer 
treatment more than 2 years prior to the study, assigned physician approval the sixth 
highest mean attribute rating (4.12).  It was rated highest order preference attribute by 4/33 
participants in this group. 
 
Patients treated within 2 years demonstrated higher preference rating for physician 
approval, compared to those treated more than 2 years prior.  Patients having completed 
treatment within two years were closer to time of therapeutic equipoise, having made 
clinical treatment decisions based on available information and often with support of their 
physician.  This data demonstrate patients placed greater preference rating on physician 
approval closer to the time of therapeutic equipoise.  
 
Sensitivity/true positive of testing 
Sensitivity/true positive of testing received the second highest mean attribute rating across 
patients from both group A and B (6.40 and 6.39 respectively).  It was rated highest order 
preference attribute by 7/32 patients in Group A and 6/33 patients in group B.  
 
Sensitivity/true positive of testing was a highly rated preference attribute theme across all 
patients treated with radical intent.  These results demonstrated duration since radical 
therapy did not affect preference attribute identification or rating of test sensitivity.  There 
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remained awareness of the importance of genomic test sensitivity/true positive in reducing 
either over- or under treatment, reflected by the high mean attribute rating and frequency 
of highest order rating. 
 
Specificity/true negative of testing 
Specificity of genomic testing received the third highest mean attribute rating (6.38) across 
participants in group A, who received radical intent treatment within two years prior to 
study entry.  It was rated highest order preference attribute by 5/32 participants.  
Participants who received treatment more than 2 years prior (group B) gave specificity of 
testing/true negative the fourth highest mean attribute rating (5.18).  It was rated highest 
order preference attribute theme by 4 /33 participants in group B. 
 
Patients receiving radical cancer treatment demonstrated similar identification and ratings 
of specificity/true negative of genomic testing, regardless of duration since completing 
therapy.  Patients treated with radical intent had similar preference rating of specificity/true 
negative and sensitivity/true positive of genomic testing.  This highlighted importance of 
under- or over-treatment for this patient group, which does not diminish with increasing 
time since completing cancer therapy. 
 
Prevalence of genomic variant 
Prevalence of genomic variant received the fifth highest mean attribute rating across group 
A (5.12).  It was rated highest order preference attribute by 3/32 patients.  Patients in group 
B assigned prevalence of genomic variant the seventh highest mean attribute rating at 3.61.  
It was rated highest order preference attribute by 2/33 patients in this group. 
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These results demonstrated the low rating prevalence of genomic variant had on patient 
preferences of genomic testing.  The mean attribute ratings were similar across all radical 
patients groups, with no demonstrable correlation between duration since completing 
radical treatment and preference attribute identification or ratings for prevalence of 
genomic variant. 
 
Invasiveness of testing 
Invasiveness of testing received the sixth highest mean attribute rating across group A 
participants (5.06) and highest order preference attribute for 3/32 participants.  Group B 
participants assigned invasiveness of testing the fifth highest mean attribute ranking (4.94).  
It was rated highest order preference attribute by 3/33 participants in group B.  Patients 
placed similar preference rating on invasiveness of testing, which was not influenced by 
time since completing radical cancer therapy.   
 
Test turnaround time 
Test turnaround time received the seventh highest mean attribute rating (4.56) amongst 
group A participants.  It was rated highest order preference attribute by 2/32 participants.  
This contrasts group B participants, for whom test turnaround time received the third 
highest mean attribute rating (6.27) and rated highest order preference attribute for 4/33 
participants. 
 
These results demonstrated patients who received cancer treatment more than 2 years prior 
assigned higher preference rating to test turnaround time compared to those patients treated 
within 2 years of study entry.  The attribute rating may be disproportionately influenced by 
the relatively small numbers assigning highest order preference rating to this attribute (2 
and 4 participants in group A and B respectively). 
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Implications of testing for family members 
This preference attribute theme was only identified by three nominal groups within group 
A and one nominal group within group B.  Implications of testing for family members 
received the eighth highest mean attribute rating (2.03) across group A participants and 
was not rated as highest order preference attribute.  It received the ninth highest mean 
attribute rating in group B (1.09).  Implications of testing for family members was not 
rated highest order attribute in group B. 
 
These results demonstrated some participants identified genomic testing can have wider 
implications for family members, but with low preference rating.  This study showed no 
correlation between the implications for family preference attribute rating and time since 
completing treatment.  
 
Distance to travel for testing 
The distance to travel preference attribute theme received lowest mean attribute rating 
(0.81) across group A participants and was not rated highest order preference attribute.  
Amongst group B participants, distance to travel for testing received the eighth highest 
mean attribute rating (2.09).  It was not rated highest order preference attribute by any 
participants in group B. 
 
Participants who received radical cancer treatment identified distance to travel for testing 
as a preference attribute theme, but it retained low mean attribute rating.  There is was no 
correlation between mean attribute rating for distance to travel and time since completing 
cancer treatment. 
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Family approval of testing  
This preference attribute theme was not identified by any participants in group A.  Family 
approval of testing was identified by a single nominal group of participants greater than 
two years since receiving radical cancer therapy.  Overall across group B, it received the 
lowest mean attribute rating (0.48) and was not rated highest order preference attribute by 
any participants. 
 
This demonstrated a single group of participants receiving radical therapy identified family 
approval of genomic testing as a preference attribute theme.  The low mean attribute rating 
(0.48) demonstrated it is not a highly rated preference attribute for patients considering 
genomic testing. 
 
5.8. Conclusions 
There is increasing recognition around emerging scientific potential of genomic testing 
providing therapies with durable clinical benefit to patients.  There have, in recent years, 
been a plethora of newly approved PCM therapies including in EGFR-mutated lung 
cancer, ALK-mutated lung cancer, HER2 testing in breast cancer amongst many others.  
Such interventions resulted in clinical, psycho-social, health and quality of life benefits to 
patients.  Policy makers in oncology advocate need to involve patients and carers in cancer 
therapy frameworks to ensure scientific progress retain patient preferences at its epicentre.  
This led to increasing acknowledgement of the need for further research assessing novel 
genomic testing in PCM and its adaption to individual patients. 
 
This thesis built on the work of previous studies by identifying and rating patient 
preference attribute themes of genomic testing, which had not previously been assessed 
within the UK healthcare setting.  This thesis also explored the novel hypothesis that 
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identified preference attributes and ratings may be influenced by cancer treatment intent 
and time since completing cancer therapy. 
 
The results from this NGT study support the novel hypothesis that patients’ preferences of 
genomic testing in PCM are not uniform and that heterogeneities can, in part, be explained 
by cancer treatment intent.  Patients who received radical intent cancer treatment placed 
higher preference rating on attributes such as sensitivity and specificity of testing.  This 
reflected concern amongst this patient group about potential for under- or over-treatment 
leading to either increased toxicity or increased risk of cancer recurrence.  Patients treated 
with palliative intent demonstrated lower preference rating for test sensitivity or 
specificity, but instead higher preference rating for factors such as invasiveness of testing 
or distance to travel. 
 
Patients treated with palliative treatment intent attached higher preference rating to 
invasiveness of testing and test turnaround time.  This may, in part, be explained by the 
fact that these patients have a life-limiting illness, influencing preferences and perceived 
benefits of genomic testing.  These individuals had a more acute awareness of the balance 
between therapeutic efficacy from testing and quality of life.  In contrast, patients treated 
with radical intent assigned lower preference rating to invasiveness of testing or distance to 
travel, demonstrating willingness to tolerate shorter term invasive procedures or travel 
compared to patients treated with palliative intent. 
 
This NGT study identified some preference attribute themes of genomic testing seen across 
all patient groups.  Patients treated with both radical and palliative intent assigned high 
preference rating to regulatory/NHS approval and physician approval of testing.  Within 
the NHS universal healthcare system, patients attached importance to genomic testing 
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receiving regulatory/NHS approval.  This reflected trust individual patients place in these 
independent regulatory systems and also awareness that tests approved by regulatory 
bodies are more likely to be available to individual patients.  Patients across both radical 
and palliative groups also assigned high preference rating to physician approval of 
genomic testing.  This may be rooted in positive experiences of doctor-patient relationship 
and element of trust that a patients’ doctor will act in their best interests.  The study 
demonstrated this preference attribute rating was uniform across participants.  
 
The other novel hypothesis of this thesis was that patients may identify different preference 
attribute themes or ratings for genomic testing with increasing duration since completing 
radical treatment.  Patients who completed radical cancer therapy within 2 years assigned 
higher preference rating to physician approval for testing compared to patients who 
completed therapy more than two years prior.  This reflected persisting doctor-patient trust 
and relationship in those less than 2 years since treatment, many of whom will still be 
attending follow-up clinics and have an ongoing clinical relationship with their physician.  
Patients with longer duration since completing radical treatment assigned lower preference 
rating to physician approval of genomic testing. 
 
Patients who completed radical intent treatment more than two years prior to entry 
assigned higher preference attribute ratings to regulatory/NHS approval of testing and test 
turnaround time.  Some attribute themes received consistent preference ratings across 
radical treatment groups, such as test sensitivity and specificity.  Patients treated within 
and greater than two years prior to study entry assigned high preference ratings to these 
attribute themes.  This demonstrated preference for accuracy genomic testing to reduce 
potential over- or under-treatment, which persisted in patients having received radical 
cancer treatment regardless of duration since its completion.  
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The premise of precision cancer medicine is delivering the right treatment to the right 
patient at the right time, based on scientific principles of individual genomic tumour 
assessment.  This study also demonstrated the promise of genomic testing also relies on 
patient-centric factors including as treatment intent and duration since completing therapy.  
This study was the first to produce empirical evidence that, across a breadth of cancer 
subtypes and treatment intent, patients’ preference attributes of genomic testing can be 
identified and rated.  The scientific advances of precision cancer medicine transcend the 
breadth of tumour subtypes and cancer stages.  The results of this study highlighted we 
should not consider genomic testing as a single homogeneous scientific entity, but retain 
factors such as treatment intent when considering its clinical application. 
 
Clinical trials play a key role in innovative cancer therapies and subsequent regulatory 
approval.  As discussed in Chapter 1, the innovations of genomic testing necessitate novel 
clinical trial designs incorporating the plethora of data provided and allow trials to 
transcend existing taxonomies of cancer.  Having identified and rated patients’ preference 
attribute themes of genomic testing, this thesis will now explore how these attributes were 
incorporated within a novel PCM clinical trial conducted in the UK. 
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Chapter 6. Benchmarking patient preferences of genomic 
testing in the ATLANTIS clinical trial 
6.1. Introduction 
This thesis identified and rated preference attribute themes of genomic testing for patients.  
Clinical trials play an important role in oncology. There is relatively sparse evidence about 
what motivates cancer patients to enrol in a clinical trial.  Participation potentially imposes 
a number of restrictions on individuals and, depending on study design, patients may be 
asked to comply with assignment randomisation, undergo additional tests and be unaware 
what treatment they are receiving for the duration of the study.  Clinical trialists have, for 
the most part, addressed mechanics and ethics involved in optimising recruitment, study 
retention and compliance.  Even within this remit, many clinical trials still fail to reach 
projected targets for recruitment in the UK (McDonald AM, 2005).  McDonald et al (2005) 
demonstrated that only 31% of UK Medical Research Council (MRC) and Health 
Technology Assessment (HTA) trials achieved their original recruitment target and that 
53% were awarded an extension to do so. 
 
Insufficient or untimely patient recruitment into clinical trials has serious consequences, 
such as extending trial recruitment length leading to increased resource and delaying 
availability of study outcomes or treatments.  The integrity and validity of clinical trial 
outcomes also rely on sample size calculations, hence studies failing to reach intended 
patient recruitment potentially increase the chance of a type II error.  Patient recruitment is 
influenced by both patient and investigator factors.  A systematic review by Abraham et al 
(Abraham et al, 2015) highlighted reasons why eligible patients may not wish to participate 
in real or hypothetical randomised controlled trials.  Understanding and addressing 
potential patient preferences is important when developing a study recruitment strategy. 
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Activated and engaged patients are empowered to participate in their own health care.  
Mullins et al (2014) suggest that ‘when it comes to research, people generally participate 
passively in the learning process, being involved in clinical trials as human subjects rather 
than as engaged stakeholders.’  Study design elements of clinical trials, intended for 
regulatory approval of therapies, traditionally do not align with the patient-centric 
healthcare approach.  Patients increasingly want to be informed, empowered and engaged 
with their healthcare.  Contemporary clinical trial methodologies helped address some 
issues of participant-related factors (such as medical research mistrust, hard-to-reach 
groups and lack of resources), contextual factors (such as cultural or language barriers) and 
research-specific factors (such as risk of receiving placebo, randomisation and risk of 
harm).  Mullins et al (2014) postulated means by which clinical trials can promote patient 
recruitment and retention in clinical trials by improving patient experience. 
 
Chapter 1 identified challenges facing clinical trials in the era of precision cancer 
medicine, necessitating innovative designs incorporating genomic testing and targeted 
therapies.  One such example is the ATLANTIS trial (ISRCTN 25859465, Eudract 2015-
003249), sponsored jointly by the University of Glasgow and NHS Greater Glasgow and 
Clyde (Chief Investigators Professor Robert Jones and Professor Thomas Powles).  
Developing the study protocol and regulatory submissions formed an element of the thesis 
author’s (BF) research fellowship under the guidance of the Chief Investigators and Cancer 
Research UK Glasgow Clinical Trials Unit.  The design of ATLANTIS was confirmed 
prior to this research identifying and rating preference attributes of genomic testing.  The 
ATLANTIS trial was selected for this study due to its novel adaptive design, exploration of 
precision medicine novel biomarkers and potential for the outcome to influence 
adaptations of study design in future, ensuring incorporation of patients’ preference factors 
of genomic testing. 
 133 
 
 
This thesis identified and rated patient preference attribute themes of genomic testing in 
precision cancer medicine clinical trials.  This started by identifying preference attributes 
themes and associated ratings for genomic testing in PCM.  In this chapter, these 
preference attribute themes were utilised to assess how the ATLANTIS clinical trial 
incorporated patient preferences of genomic testing into its design and implementation.  
This work was done in parallel with the ATLANTIS trial protocol development and this 
analysis is, therefore, retrospective though may have implications for design of future PCM 
trials.  This will provide evidence of how innovative study designs incorporate patient 
preferences of genomic testing. 
 
6.2. ATLANTIS trial 
6.2.1. Aims and objectives of ATLANTIS 
Urothelial cancer (UC), incorporating cancers of the bladder, urethra, ureter and renal 
pelvis, is the eighth most common cause of cancer related death in the United Kingdom 
(UK).  Around 5,600 people died from UC in 2016 (Cancer Research UK CancerStats, 
2016).  Cytotoxic platinum-based chemotherapy is routinely used as palliative treatment 
for metastatic or advanced UC in the first-line setting.  Although the majority of patients 
initially derive benefit, relapse is inevitable and occurs, on average, 4 months after 
completion of chemotherapy.  Once patients develop relapsed UC, survival and quality of 
life are often poor.  In recent years, immune checkpoint inhibitors, which can benefit 
around 20% of patients with durable responses and proven survival benefit, have found a 
role in second line treatment after failure of platinum-based chemotherapy (Bellmunt, J., 
Powles, T., Vogelzang, NJ., et al, 2017).  Their role in the first-line treatment of patients 
with UC is currently limited to patients whose tumour shows high PDL-1 expression who 
are not suitable for platinum-based chemotherapy.  Nonetheless there are still a majority of 
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patients with advanced UC who do not derive significant benefit from immune checkpoint 
inhibitors and for whom subsequent treatment options are very limited.  No consensus 
exists around the role of optimal systemic therapy in the second-line setting.  
Chemotherapy agents can be used, but response rates are low and benefits compared to 
best supportive care are unknown.  Therefore, maintaining response after first line 
chemotherapy may be an attractive way to improve outcomes for patients with advanced 
UC. 
 
The molecular heterogeneity of UC lends itself to the hypothesis that new treatments may 
be tailored to an individual’s tumour biology and a precision medicine approach.  Testing 
new therapies alongside conventional first-line chemotherapy has proven challenging due 
to the toxicity profile of such combinations in this patient group.  Patients requiring second 
or subsequent lines of chemotherapy often have limited survival and high symptom 
burden, meaning conducting clinical trials in this patient group can be challenging.  
Therefore, maintenance therapy after first line chemotherapy is a potential opportunity for 
single agent drug development in patients with advanced UC. 
 
The primary research question of the ATLANTIS trial is to determine whether molecularly 
defined maintenance treatment after first line chemotherapy can delay time to tumour 
progression in patients with advanced UC.  This phase II, signal-searching study may 
therefore establish clinically relevant initial evidence of activity for the novel agents tested, 
in order to justify validation in a phase III trial.  There will be a number of novel agents 
tested, each compared to placebo.  Treatment will be based on molecularly defined 
subgroups of patients, where laboratory or clinical evidence to support such enrichment is 
clear, or in a manner that allows exploration of, or provides initial evidence for, predictive 
biomarkers.   
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The primary objective of the ATLANTIS trial is to: 
Compare progression-free survival (PFS) on the interventional study arms to that on 
placebo within each biomarker/novel agent subgroup.  PFS has been chosen as it is largely 
objective, as most patients with advanced urothelial cancer will display progression in 
accordance with RECIST 1.1 criteria.  PFS is also clinically meaningful, as progression 
after first line therapy reflects transition to the lethal stage of the disease and often 
requirement for further systemic therapy. 
 
The secondary objectives of the ATLANTIS trial are: 
- Compare overall survival (OS) between the intervention arm and placebo for each 
component subgroup of the trial.  
- Evaluate the safety and tolerability of the regimens in this patient population  
- Compare the best response rate (BRR) between the intervention arm and placebo for 
each component subgroup of the trial 
- Compare the maximum reduction in size of measurable lesions between the 
component subgroups of the trial 
 
The exploratory/translational objectives of the ATLANTIS trial are to: 
- Investigate the correlation of outcome with different levels of biomarker expression, 
where possible. 
- Collect archival tissue and blood specimens for future biomarker testing. 
 
6.2.2. Study design 
ATLANTIS is a multi-centre randomised phase II signal-searching trial in biomarker-
defined subgroups of patients with advanced UC, using an adaptive design.  The study 
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team considered a Bayesian adaptive approach to biomarker identification, but this design 
was felt too developmental to include within the proposed trial.  Multiple novel agents will 
be used in parallel and patients will be entered into ATLANTIS subgroup studies 
dependent on tumour biomarker profile.  The SPIRIT diagram of ATLANTIS trial design 
is shown in Figure 3. 
 
The control arm for each comparison will be placebo and comparison will be double-blind, 
where possible.  Biomarker analysis will be performed on archival tissue during the pre-
screening trial phase, in order to define study subgroups. 
 
Figure 3.  The SPIRIT diagram illustrating ATLANTIS study design. 
 
 
The design of the ATLANTIS trial allows addition of further biomarker-defined subgroups 
throughout its lifespan.  ATLANTIS is currently exploring three novel drug comparison 
arms.  These include the MET and VEGF inhibitor cabozantinib, androgen receptor (AR) 
antagonist enzalutamide and rucaparib in patients whose tumour demonstrates DNA repair 
deficiency phenotypes due to defects in genes including BRCA1/2, BAP1, PALB2, 
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FANCD2 and ERCC2.  In addition to the current novel agents being tested within 
ATLANTIS, the trial provides a framework allowing new treatments to be introduced by 
amendment, with prospective stratification based around a molecular target. 
 
The design and implementation of ATLANTIS was undertaken by the study development 
team, supported by the Cancer Research UK Glasgow Clinical Trials Unit.  Patient 
representatives were involved from the inception stage of study design through to its 
implementation and study recruitment, via the National Cancer Research Institute bladder 
cancer Clinical Studies Groups and the Cancer Research UK Glasgow Clinical Trials Unit 
patient representatives.  This thesis explored benchmarking of preference attribute themes 
in parallel with the study design.  The results, therefore, reflect a retrospective analysis of 
preference attributes of genomic testing with ATLANTIS, but may inform design of future 
clinical trials.  The thesis author (BF) was a member of the study development team for 
ATLANTIS, involved in regulatory submissions, protocol writing and clinical conduct at 
site for the trial. 
 
6.2.3. Patient population and eligibility criteria 
The target population for ATLANTIS are patients with newly diagnosed metastatic or 
locally advanced urothelial cancer.  Patients must have achieved an objective response or 
stable disease with at least 4 cycles of first-line chemotherapy (maximum of 8 cycles).  
Patients are allowed to have received any chemotherapy regimen and does not necessarily 
need to include cisplatin.  Patients must start trial treatment at least 3, but not more than 10 
weeks after last dose of chemotherapy infusion.   Biomarker analysis will determine 
ATLANTIS subgroup allocation and can occur any time after the diagnosis of advanced 
urothelial cancer prior to randomisation, as long as the necessary informed patient consent 
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has taken place.  Archival tissue can be used and all biomarker analysis will occur 
centrally. 
 
Inclusion criteria for ATLANTIS are as follows: 
 Previously diagnosed stage IV urothelial cancer (UC) (T4b, Nany, Many, Tany N1-
3 M0, Tany Nany M1). 
 Histologically confirmed urothelial cancer.  This includes cancers of the urinary 
bladder, ureter, renal pelvis or urethra of transitional and/or squamous histology.  A 
component of either or both of these histologies is adequate for entry 
 Able to commence trial treatment within 10 weeks of completing chemotherapy 
 Adequate tissue for biomarker testing.  Testing will occur centrally. 
 Patients must have received between 4 and 8 cycles of first line chemotherapy for 
metastatic/advanced UC to be eligible.  Previous adjuvant or neo-adjuvant 
chemotherapy does not count as a line of therapy. 
 Adequate organ function as defined in drug-specific appendices 
 ECOG performance status 0-2 
 Age ≥16 years 
 Female patients of childbearing potential must agree to comply with effective 
contraceptive measures and have negative pregnancy test within one week of trial 
entry 
 Male patients with partners of child bearing potential must agree to take measures 
not to father children by using one form of highly effective contraception. 
 Written informed consent prior to admission of this trial 
 Meets all inclusion criteria for the relevant component subgroup listed in 
appendices 
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ATLANTIS study exclusion criteria: 
 Progression during first line chemotherapy for metastatic disease.  This should be 
based on a radiological comparison between the pre-chemotherapy CT and end of 
treatment CT (local review).  Patients with progression during the final 3 cycles of 
chemotherapy are potentially eligible if there is at least stable disease compared to 
baseline.  These patients should be discussed with the trial team. 
 Patient does not currently require second line chemotherapy in the opinion of the 
investigator 
 More than one line of chemotherapy for metastatic or locally advanced disease.  
Prior adjuvant/neoadjuvant chemotherapy is permitted in addition 
 Patients receiving radical/curative surgery at the end of first line treatment 
(palliative radiotherapy is allowed) 
 Significant co-morbidity or organ dysfunction as defined in the drug specific 
appendices 
 Patients receiving less than 4 or more than 8 cycles of chemotherapy before 
randomisation and initiation of trial intervention (excluding chemotherapy given 
with adjuvant or neoadjuvant intent) 
 Treatment with any other investigational agent within 28 days prior to the first dose 
of trial medication within ATLANTIS 
 Less than 3 or more than 10 weeks since the last infusion of chemotherapy for 
advanced disease at the initiation of trial interventions 
 History of another malignancy within the preceding 2 years (other than treated 
squamous/basal cell skin cancer, treated early stage cervical cancer or treated/stable 
organ confined prostate cancer not requiring on-going androgen deprivation 
therapy) 
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 On-going prohibited medication which cannot be discontinued prior to starting trial 
specific intervention (as defined in drug specific appendices) 
 Serious inter-current medical or psychiatric illness, including active infection 
which, in the opinion of the investigator, would make it inappropriate to enter the 
trial 
 Women who are breastfeeding 
 Patient meets any of the exclusion criteria listed in the relevant component 
subgroup specific appendix 
 
6.2.4. Statistical considerations 
Each ATLANTIS component subgroup will be based around a randomised phase II 
screening design to detect a certain level of improvement in median PFS with the novel 
agent compared to placebo/observation.  This will be with 90% power, at the 20% 1-sided 
level of statistical significance, or equivalent with 80% power at the 10% level of statistical 
significance.  If the observed PFS in favour of the novel agent is statistically significant at 
10%, this will be a clear signal that subsequent phase III trial is warranted.  A result that is 
statistically significant at the 20% level, but not the 10%, will require supportive data, such 
as reduction in size of measurable disease, before a subsequent phase III trial would be 
considered.   
 
The study analysis plan will be universal across all subgroups.  All analyses will be 
conducted on an intention-to-treat basis, with progression-free survival compared between 
the trial arms in the context of a Cox model incorporating baseline minimisation factors.  
The p-value for the observed hazard ratio will be determined from this model. The 
maximum percentage decrease in measurable disease will be compared using a Mann-
Whitney U test.  Progression-free survival will be illustrated using Kaplan-Meier plots and 
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worst toxicity grades during chemotherapy will be compared using the Mann-Whitney U 
test. 
 
6.3. Benchmarking patient preferences of genomic testing in ATLANTIS 
Adaptive trial designs, such as ATLANTIS, allow features of the trial to be altered as 
evidence accrues across the study.  These include changes such as participant numbers, 
processes for patient selection and modification of subgroups as participants respond to 
therapies or not.  The adaptive design has the potential to evaluate comparative 
effectiveness of different treatments during the trial, rather than waiting for its completion.  
This has relevance for rare disease states, or genomic signatures, where specific subgroups 
may be under represented in a traditional study design.  In the case of an ineffective trial 
subgroup, newly enrolled participants can also potentially still be randomised into the 
remaining cohorts where equipoise still exists.  In addition, when prior information 
indicates that a trial population should be more narrowly focused, based on genomic 
profiling, the improved target enrolment criteria have the potential to motivate participants 
because the trial more closely mirrors their unique experience.  Through the application of 
such clinical trial methods, it is possible to improve the quality of care for participants. 
 
Multiple advances in quality improvement methodologies have focused on reliability and 
validity of how clinicians, patients and organisations perform specific functions of 
healthcare.  These are reflected in process-of-care indicators such as cancer treatment 
waiting times, clinical trial recruitment rates as well as clinical outcomes of efficacy and 
morbidity from treatment.  For each of these processes, identification of a realistic, 
achievable, ‘gold standard’ performance, or benchmark, should be incorporated.  For each 
process-of-care indicator, there are inherent clinical, organisational and patient-centric 
factors meaning perfect benchmarks are unlikely to be achievable in the clinical arena.  For 
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example, preferences of patients and healthcare providers means it is unlikely there will be 
100% attainment of cancer waiting times initiatives.  It is, therefore imperative that 
established benchmarks of performance are realistic and achievable. 
 
6.3.1. Aims of benchmarking exercise 
The aim of this benchmarking exercise was to assess whether the ATLANTIS clinical trial 
incorporated patients’ preference attribute themes of genomic testing identified in this 
thesis.  In order to do this, a descriptive benchmarking exercise was performed, comparing 
the ATLANTIS trial against the identified ‘best practice’ benchmark preferences attribute 
themes of genomic testing. 
 
6.3.2. Methods 
Multiple techniques have been developed to evaluate outcomes based on effectiveness 
research methodologies (Hunsley and Lee 2007, Minami et al 2008). Benchmarking allows 
researchers to compare results of treatment conducted in natural settings to best practice 
standards (Hunsley and Lee, 2007).  Kiefe et al described benchmarking as ‘the 
identification of industry leaders so that their practices can be understood and emulated.’  
The definition and classification of benchmarking vary between authors, depending on the 
time and criteria they focus on.  The core aspects of evaluation and improvement by 
learning are embedded across the different forms of benchmarking (Ball 2000, 
Buyukozkan and Maire 1998, Carpinetti 2002, Longbottom 2000, Watson 1993). 
 
In order to be effective, benchmarking must ensure performance metrics are correlated 
with consumer needs and be part of a continual process resulting in effective outcomes.  
There is no standard system for reporting benchmarking methodology, stemming from 
differences among industries regarding the nature and complexity of its application.  For 
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example, Maleyeff et al (2001a) reported a system for benchmarking healthcare facilities 
using metrics related to patient care.  The statistical sophistication of these systems range 
from no statistical analysis to methods such as data envelope analysis (Madu and Kuei, 
1998). 
 
Analysis and reporting of benchmarking include both qualitative and quantitative 
methodologies.  The benchmarking framework developed by Hunsley and Lee (2007), 
involves comparison of variables, participant completion rates and major study outcomes 
with a ‘best practice’ benchmark.  Other benchmarking healthcare studies (Curtis et al 
2009, Minami et al 2007) also incorporate effect sizes for each intervention.   
 
Due to its theoretical nature, this benchmarking study was limited by lack of quantitative 
measurable study outcomes to assess effect sizes, so outcomes were analysed descriptively.  
This qualitative research process involved gathering and distilling extensive descriptive 
data into a few key messages or ideas (Cresswell, 1998).  This study descriptively assessed 
incorporation of preference attributes of genomic testing within the ATLANTIS trial.  
Previous benchmarking studies employed qualitative descriptive analysis to describe 
outcomes and provide in-depth analysis (Hubert and Gardner, Webb 2009, Arnold and 
Zink, Driscoll, Still and Strang 2008). 
 
The implementation of benchmarking methodologies, as described by Hunsley and Lee 
(2007) incorporate four steps: 
1 – Identification of the population and treatment 
2 – Selection of a ‘best practice’ benchmark 
3 – Measurement of outcomes against the benchmark 
4 – Comparison of outcomes to the benchmark 
 144 
 
 
6.3.3. Identification of patient population 
The benchmarking study assessed inclusion of patient preference attributes within the 
ATLANTIS clinical trial design.  The population and treatment under consideration for the 
benchmarking exercise therefore mirrored the eligibility criteria for the trial. 
 
6.3.4. Selection of ‘best practice’ benchmark 
As demonstrated in Chapter 3, there is very sparse empirical evidence assessing patient 
preferences of genomic testing in precision cancer medicine trials, such as ATLANTIS, on 
which to base ‘best practice’ benchmarking.  This thesis identified and rated patient 
preference attributes of genomic testing.  This benchmarking study therefore utilized the 
identified preference attribute themes as the ‘best practice’ against which the ATLANTIS 
trial was compared. 
 
These preference attributes, in order of descending rating score are: 
 Regulatory/NHS approval 
 Test turnaround time 
 Invasiveness of testing 
 Physician approval 
 Test sensitivity/true positive 
 Test specificity/true negative 
 Prevalence of variant 
 Distance to travel 
 Implications for family 
 Family approval 
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6.4. Results 
Regulatory/NHS approval 
The ATLANTIS trial met the regulatory approval preference attribute benchmark meeting 
standard UK ethical and clinical trial conduct and governance frameworks.  The trial will 
was conducted in accordance with the World Medical Association Declaration of Helsinki 
(1964) and its revisions (Tokyo 1975, Venice 1983, Hong Kong 1989, South Africa 1996, 
Edinburgh 2000, Washington 2002, Tokyo 2004, Seoul 2008).  Each participating site 
required to comply with Good Clinical practice (GCP) and was not activated until local 
Clinical Trial Agreement is signed between Research and Development office and trial 
sponsor.  The accruing trial data was monitored by an Independent Data Monitoring 
Committee (IDMC) assessing any safety or efficacy issues that should be brought to 
participants’ attention or reasons for the trial recruitment to cease. 
 
The regulatory approval process enshrined in clinical trials in the UK supported 
ATLANTIS meeting the regulatory/NHS approval benchmark attribute.  Each participating 
site was required to meet these standards of conduct, supporting participants’ confidence 
on the trial.  This attribute was considered universal across UK clinical trials and is not 
unique to ATLANTIS.   
 
Test turnaround time 
The patient pathway in ATLANTIS incorporated genomic and other molecular testing 
throughout the pre-screening phase.  This design minimised the impact of test turnaround 
time by exploiting the opportunity to test during first line chemotherapy, which is around 
eighteen weeks for most patients.  This relied on early identification of potentially eligible 
patients to allow biomarker screening.  The anticipated test turnaround time in ATLANTIS 
is 14 days from receipt of sample at the central laboratory.  The central laboratory 
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processing of samples was anticipated to maintain consistency of test turnaround time 
across all participants in the trial, when compared to local testing.  One key strength of the 
ATLANTIS design is that test turnaround time did not defer treatment starting or 
randomisation. 
 
When benchmarking ATLANTIS against the best-practice attributes, test turnaround time 
was anticipated to meet patient preferences.  This was reliant on early patient identification 
throughout first line chemotherapy.  The central testing maintains parity of turnaround time 
across the whole study population, whilst not delaying time until randomisation or starting 
treatment. 
 
Invasiveness of testing 
Patients with UC had initial diagnostic biopsy performed as standard of care prior to 
commencement of first line chemotherapy.  Patients in ATLANTIS did not require 
additional tumour biopsy nor tissue collection, presuming sufficient archival tissue from 
diagnostic sample for molecular profiling.  Patients with insufficient archival tissue for 
molecular screening would be required to undergo repeat tissue biopsy if they wish to 
participate in the trial.  It was anticipated this would be a small number of participants.  
This contrasts some precision medicine trials, which mandate repeat tumour biopsies to 
determine genomic signature at different time points or for trial eligibility.  Patients in 
ATLANTIS had additional venepuncture tests compared to standard of care, where 
patients did not have further maintenance therapy.  Patients were be informed of this 
during the consent process and documented within the trial specific patient information 
sheet prior to embarking on any trial-related interventions. 
 
 147 
 
ATLANTIS incorporated the preference attribute theme for invasiveness of testing, given 
they were not required to undergo further invasive testing or re-biopsy prior to trial entry.  
This was balanced against the scientific premise that biomarker expression within an 
individuals’ tumour can change throughout its lifetime, including during cytotoxic 
chemotherapy. There was therefore, the possibility not repeating biopsy testing may result 
in errant genomic signatures that may not be truly reflective of the patients’ tumour at the 
screening and initiation of trial therapy.  The design in ATLANTIS reduced burden of 
repeat biopsy for patients and reflected the pragmatic study design.  This contrasts to some 
PCM studies, where repeated biopsy is necessary to meet eligibility criteria. 
 
Physician approval 
Investigators at each site were responsible for identifying potentially eligible patients, 
discussing the trial and screening processes.  This involved local research nurses and other 
clinical staff, including the patients’ own physician.  Patients were able to discuss the trial 
in detail with their physician and the merits of study enrolment prior to proceeding with 
molecular testing or entry into the main study.  It was therefore envisaged that participation 
in ATLANTIS will augment the patient-doctor relationship already in place at local 
centres, supporting decision-making around study entry.  This would lend itself to 
ATLANTIS having incorporated this preference attribute for testing. 
 
Test sensitivity/specificity 
The statistical design of ATLANTIS acknowledged test sensitivity and specificity need to 
be high to maintain scientific as well as patient-centric validity.  The test 
sensitivity/specificity is unique to each molecular subgroup within the study.  For patients 
enrolled in the trial, sensitivity or specificity of each molecular test will likely not be 
known at point of trial pre-screening.  This information may be discovered throughout the 
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lifetime of the trial.  Some arms of the study, such as the HRD biomarker arm, utilised pre-
existing data to inform on likely sensitivity/specificity based on experience from other 
disease settings but this was not be uniform across all subgroups. 
 
The ATLANTIS trial incorporated large volume molecular tumour profiling for patients 
entering the pre-screening stage.  The study aimed to determine predictive biomarkers of 
response, with data published as the study matures.  There was potential to align data 
produced in ATLANTIS with other biomarker studies in the UK.  It cannot be assumed 
this would provide information on test sensitivity or specificity for all patients enrolling in 
the study.  
 
Prevalence of genomic variant 
The adaptive design of ATLANTIS incorporated patients with molecularly defined 
subgroups of UC, alongside the cabozantinib arm for patients whose tumour profiling does 
not identify a novel agent-specific subgroup.  It was therefore anticipated all patients 
meeting study eligibility criteria, having provided informed consent, will potentially be 
eligible to enter a component sub-study.  The multi-arm design of the study allowed 
screening for multiple molecular signatures simultaneously.  The novel design meant 
patients were screened for multiple molecular variants, potentially with low individual 
prevalence, within the single adaptive design.  This leads to more efficient design for 
patients, including for low prevalence genomic variants.  Patient’s whose tumour do not 
meet pre-defined molecular subgroups, will still be eligible for inclusion in the 
cabozantinib component subgroup and were potentially be allowed to cross over if they 
meet eligibility for further molecular subgroups added in future.  
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The design of ATLANTIS favoured molecular signatures with low prevalence, tested 
simultaneously during the single pre-screening phase.  This aligned with the identified 
benchmarking preference attribute, which ATLANTIS incorporates.  This led to more 
efficient study design for patients, providing a platform for molecular testing rather than 
screening for discrete clinical trials of low prevalence molecular profiles. 
 
Distance to travel 
The ATLANTIS trial was conducted across more than 30 centres in the UK.  This allowed 
most patients access to study enrolment via their existing cancer centre.  Molecular 
screening for central biomarker analysis could be done on archival tissue and avoided 
complex specimen transfer for participating sites.  The study used drugs with an 
established safety profile, so participating sites did not require a centre specialising in early 
phase trials or comprehensive critical care facilities.  In the setting where a patients local 
cancer centre is not participating in ATLANTIS, patients may be required to travel to the 
nearest participating site.  This could lead to financial and time implications for patients 
participating in the study, although the anticipated number of patients for whom this would 
apply were small. 
 
ATLANTIS incorporated this benchmarking attribute by facilitating central testing of 
archival tissue retrieved from local pathology departments, removing the need for patients 
to travel for testing.  ATLANTIS was supported across multiple UK sites, facilitating 
patient recruitment across wide geographical section of the country.  This allowed 
representative national patient sample as well as reducing travel commitments for patients 
who wish to enrol in the study.  
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Implications for family 
There is an increasing awareness of potential for genomic testing to unmask molecular 
signatures reflecting germline mutations in an individual, which could have genetic 
implications for other family members.  Patients in ATLANTIS were tested for DNA 
repair deficit phenotype, resulting in defects in a variety of genes including BRCA1/2, 
BAP1, PALB2, FANCD2 and ERC2.  These DNA repair gene defects predict switching to 
maintenance therapy with PARP inhibitor in a BRCA-like patient subgroup may be 
beneficial.  Evidence supports the development of PARP (poly(ADP-ribose) polymerase) 
inhibitors in patients with either germline or somatic BRCA-like mutations and also a 
wider group of patients with evidence of homologous recombination deficiency (HRD) 
associated tumours (Farmer, H., McCabe, N., Lord, CJ., et al, 2005).  All patients in 
ATLANTIS had archival tumour tested for a composite HRD biomarker.  This may lead 
suggestion of germline mutation in BRCA genes in some patients, with associated 
implications for other family members.  This facilitates family members being 
appropriately screened for BRCA germline mutations, alongside therapeutic implications 
of prophylactic therapy or cancer screening.  The information also posed ethical challenges 
for patients and investigators around confidentiality and disclosure of such information to 
family members.  This was dealt with throughout the informed consent process for 
ATLANTIS, where patients were asked to opt in or out from discovering information 
which may pertain to possible inheritable cancer syndromes.   
 
Genomic testing across multiple clinical trials has potential to reveal germline mutations 
with potential wider implications for patients and family members.  Patients in ATLANTIS 
were tested for composite HRD biomarker, with potential implications for BRCA-type 
phenotype.  During the study screening phase, all patients were be informed of this prior to 
pre-screening via the study specific patient information sheet and asked to provide 
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informed consent.  Patients were offered the chance to opt in or out of receiving such 
information, though there is an appreciation this uncertainty still had potential to cause 
distress for patients. 
 
Family approval of testing 
Potential study participants were given time to consider the patient information sheet for 
ATLANTIS and sign informed consent prior to any trial-related activity.  It was anticipated 
this allowed individuals time to personally consider trial enrolment, as well as discussion 
with family members.  This preference attribute was not captured or recorded formally 
throughout the study, but may be reflected in the trial screening log of patient enrolment. 
 
The design of ATLANTIS allows prolonged pre-screening period during first line 
chemotherapy.  This allows participants time to consider the trial, discuss options with 
clinical staff and family members.  This reduced time pressure and allowed time to reflect 
on biomarker testing with family members.  It is not possible to empirically predict 
whether family members would endorsed the molecular testing within ATLANTIS.  This 
would require validation with further qualitative analysis in parallel with the study design. 
 
6.5. Discussion 
The aim of this benchmarking exercise was to assess and describe the benchmarking of 
patients’ preference attribute themes of genomic testing and how they are incorporated 
within the ATLANTIS trial.  ATLANTIS is a flagship UK study in patients with advanced 
UC and represents an opportunity for the UK to innovate in development of precision 
targeted therapies.  The novel adaptive design of ATLANTIS lends itself to incorporating 
multiple patient-centric factors laced throughout its architecture.  The ten preference 
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attribute themes demonstrated throughout this thesis were benchmarked against the 
ATLANTIS trial. 
 
The ATLANTIS trial incorporated many preference attribute themes.  The adaptive study 
design allowed features to evolve as evidence accrued throughout the study.  The study 
design and molecular testing lent itself to favourable benchmarking for test turnaround 
time.  It incorporated molecular screening during first line chemotherapy, reducing delay in 
potentially commencing study screening and maintenance treatment.  The adaptive 
umbrella design also favoured genomic variants with low prevalence, where patients were 
screened within the framework of a single study, reflecting an efficient design for patients.  
Within conventional study designs, patients with low prevalence genomic variants may 
have necessitated screening across multiple clinical trials, representing low yield of clinical 
trial entry and potential need for repeated tissue biopsy. 
 
The molecular testing in ATLANTIS was performed on archival tissue, reducing the need 
for invasive testing, particularly re-biopsy for patients.  This reduced number of screening 
tests performed compared screening for multiple targeted therapy trials.  ATLANTIS also 
compared favourably to the benchmark attributes for regulatory approval, as it has 
regulatory and NHS approval throughout the UK alongside local approval at participating 
sites.  This supported patient confidence the study is being conducted within regulatory 
governance frameworks within the UK and peer-reviewed throughout funding and 
regulatory processes. 
 
The ATLANTIS study minimised distance to travel for participants by opening at over 30 
centres with wide geographical distribution across the UK.  There remains potential some 
patients may have to travel greater distances to a participating site than their local cancer 
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centre, but it was anticipate these would be small numbers.  This attribute benchmark may 
be appreciated by assessment of the patient screening logs at participating sites and 
individual site feedback on recruitment.   
 
The benchmarking attribute of physician approval for the study was difficult to quantify.  
Local site investigators were expected to offer study screening to potential patients in 
whom they feel it would be appropriate, reflecting an element of physician approval.  It 
remains challenging quantifying this nor the impact it may have on patients suitable for the 
study.  Local investigators discuss study screening procedures and would be anticipated to 
have an established pre-existing patient-clinician relationship. 
 
Patients entering the ATLANTIS trial are unlikely to know the either sensitivity or 
specificity of testing, though it was possible in some subgroups.  This information is one of 
the primary research questions in conducting such trials.  The novel nature of the scientific 
and translational elements embedded within the study meant information would not 
necessarily be available to participants considering study enrolment.  It may be possible for 
some subgroups to extrapolate from previous studies where data for enrichment exists or 
availability of sensitivity/specificity data if agents with positive efficacy signal in the trial 
are transferred to standard of care paradigms. 
 
Molecular biomarker screening entailed HRD composite marker, with potential to select 
patients whose tumour displays a BRCA-like phenotype.  In some individuals, this 
suggested, but not specifically test, potential germline mutations in BRCA genes.  This has 
implications for other family members, with both positive and negative preference factors.  
Knowledge of germline BRCA mutations may allow other family members to be tested 
and potentially undergo prophylactic treatment or enhanced cancer screening.  It did, 
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though, have potential psychological and emotional burden for patients and families at a 
time when they are dealing with their own life-changing cancer diagnosis.  ATLANTIS 
biomarkers in future may highlight inheritable mutations pre-disposing to cancer or health 
conditions for which there are no therapeutic interventions available.  This is a challenging 
field across the breadth of genomic testing and not unique to the ATLANTIS trial.  This 
complex issue cannot be fully appreciated within the remits of this benchmarking exercise, 
but it is important it remains within the ATLANTIS informed consent process so that 
patients and family members can consider its implications prior to study screening. 
 
The long interval during first line chemotherapy for screening in ATLANTIS facilitated 
patient discussion with clinicians as well as other family members.  It is difficult to predict 
how family members perceived the ATLANTIS trial.  Some inferences can be made from 
site screening logs and anecdotal consultations with individual patients, but robust 
assessment of this attribute would require validation via parallel qualitative research 
alongside the trial. 
 
6.6. Conclusions 
This thesis identified and rated patient preference attribute themes of genomic testing in 
precision cancer medicine, also demonstrating preferences were influenced by cancer 
treatment intent.  The identified preference attribute themes were then utilised in a 
benchmarking exercise against the current ATLANTIS clinical trial, assessing patients’ 
preferences were incorporated by a novel clinical trial design.   
   
This benchmarking exercise demonstrated the novel design and research questions 
ATLANTIS incorporated many preference attributes of genomic testing in PCM.  The 
three preference attributes with the highest mean attribute rating were regulatory/NHS 
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approval, test turnaround time and invasiveness of testing.  The pragmatic adaptive study 
design incorporate these attributes, which reflected positively on the study design. 
 
The ATLANTIS trial failed to fully incorporate some preference factors of genomic 
testing.  These included attributes that were not fully predicted at the time of testing, such 
as test sensitivity/specificity or family implications of testing.  This in part reflected the 
innovative approach of molecular stratification for patients.  This information may become 
apparent throughout the lifetime of ATLANTIS, though the average life-expectancy of 
participants with advanced urothelial cancer means these individuals may never be aware 
of these results.  The role of genomic profiling and discussion of its implications remains a 
challenge for the wider precision medicine community in ATLANTIS as well as other 
precision medicine studies. 
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Chapter 7. Discussion and Conclusions 
7.1. Introduction 
This thesis added to current knowledge by exploring how, through mixed methods 
research, patients’ preferences of genomic testing in PCM were identified, rated and 
benchmarked against a current UK clinical trial.  This thesis explored the novel hypothesis 
that preference attributes and ratings were influenced by clinical treatment intent and time 
since completing therapy. 
 
This thesis demonstrated feasibility of identifying and rating preference attribute themes 
and benchmarked these against a current PCM clinical trial, providing empirical evidence 
for patient preferences of genomic testing in PCM clinical trials.  This thesis commenced 
by outlining the existing landscape of UK clinical trials, genomic testing and precision 
cancer medicine, then latterly defined primary thesis research questions (Chapter 1).  
Chapter 2 considered methodological approaches to answer the research questions of the 
thesis.  Following on from this, a systematic review of the literature (Chapter 3) was 
conducted, to identify and rate patient preference attributes of genomic testing in PCM. 
 
Throughout Chapter 4 and into Chapter 5, the thesis outlined employed methodology 
alongside results which identified and rated preference attribute themes of genomic testing.  
Chapter 6 benchmarked the identified preference attribute themes of genomic testing 
against a current PCM clinical trial. 
  
This concluding chapter will revisit the thesis research questions and summarise the key 
findings of each.  The links to wider literature and context will be discussed in parallel 
with strengths and limitations of the work.  Finally, this chapter will consider anticipated 
policy and clinical trial design implications of the work. 
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7.2. Revisiting the thesis research questions 
7.2.1. How are patient preferences of genomic testing in PCM defined and rated?  
This was the first empirical research identifying and rating patient preference attributes of 
genomic testing in the UK across a breadth of cancer subtypes.  The concepts underpinning 
genomic testing transcend the breadth of diagnostics and therapeutics with intertwined 
physician, policy-maker and patient preferences.  The systematic review in chapter 3 
illustrated lack of empirical evidence assessing patient preferences of genomic testing in 
the era of PCM.  The study by Issa et al demonstrated patient-centric attributes of genomic 
testing in specific clinical settings such as Oncotype DX in breast cancer and 
KRAS/UGT1A1 in colo-rectal cancer, though these may not be fully applicable to the 
wider cancer patient population out with these two tests.  The study by Najafzadeh was 
confounded by the fact that it only incorporated 38 patients and had 1,058 healthy 
volunteers from the population.  The employed hypothetical clinical scenarios were also 
aligned with treatment paradigms in treatment of patients with lymphoma, which may not 
be applicable to the wider cancer patient population. 
 
The study by Cuffe et al explored patient preferences of chemotherapy treatment but 
without consideration of genomic testing.  This study also considered the novel hypothesis 
that patient preferences were influenced by cancer treatment intent.  Patients who received 
adjuvant therapy put greater significance on cure rate and efficacy, whereas patients with 
metastatic cancer had higher preference for predicting response and test turnaround time.  
These identified studies were performed within North American participant groups and 
may, therefore, not be fully applicable to the UK cancer patient population. 
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Through collating and presenting the existing evidence identifying and rating patient 
preference attributes of genomic testing, chapter 3 identified that prior to assessing how 
current UK Clinical trials incorporate patient preferences of PCM, key patient preference 
attributes needed to be identified and rated.  The current evidence provided a clear 
directive that assessing patient preferences must also consider individual patient context 
such as clinical treatment intent influencing preference attributes and ratings.  This 
supported design of the mixed methods research study used throughout this thesis. 
 
Given these considerations and in order to answer the research questions of this thesis, an 
empirical study was required which identified and rated patient preference attributes of 
genomic testing in PCM.  Chapter 4 discussed the methodological considerations in order 
to answer these research questions.  The mixed methods research design employed 
Nominal Group Technique (NGT).  The complexity of genomic testing, paired with low 
patient experience of PCM, led to high cognitive burden for participants.  NGT 
methodology helped support participants through appropriate moderation and study design.   
 
Chapter 5 presented results of the NGT study and identified ten preference attribute themes 
with associated mean ratings.  The attribute ratings demonstrated patient preferences of 
genomic testing are influenced by clinical treatment intent.  Patients who received 
treatment with radical intent rated regulatory/NHS approval, test sensitivity and test 
specificity as the first, second and third highest order preference attribute themes, 
respectively.  Patients having received treatment with palliative intent rated invasiveness of 
testing, test turnaround time and physician approval as first, second and third highest order 
preference attribute themes, respectively. 
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This research provided empirical evidence the promise of genomic testing in PCM is not 
uniform across patient groups.  Clinical treatment intent should be considered when 
assessing its impact in the clinical arena.  This thesis added weight to existing evidence 
patients facing a life-limiting incurable illness have different preferences of genomic 
testing to those facing therapeutic decisions on radical cancer treatment.  Whilst 
acknowledging these results are subject to limitations, this provides an indication that, in 
answer to the thesis research questions, patient preferences of genomic testing are 
influenced by clinical treatment intent. 
 
7.2.2. Do current clinical trial designs incorporate patient preference attributes of 
genomic testing in PCM? 
Clinical trials remain the method for investigating and validating novel therapies and 
genomic tests prior to regulatory approval.  Having established evidence of key patient 
preference attributes of genomic testing, chapter 6 explored how these attributes were 
incorporated within a UK PCM clinical trial.  This thesis ran chronologically in parallel 
with design of the ATLANTIS clinical trial, so results did not directly inform the study 
design, but may inform future clinical trial design or amendments.   
 
The ATLANTIS trial is a flagship UK study for patients with advanced urothelial cancer 
and represented an opportunity for the UK to innovate in development of precision 
targeted therapies in this patient group.  The novel adaptive design of ATLANTIS lent 
itself to incorporating multiple patient preference attribute themes of genomic testing.  This 
thesis research ran in parallel with implementation of ATLANTIS, so its results were a 
retrospective narrative rather than informing study design.  The study benchmarked the 
ATLANTIS trial against the ‘gold standard’ preference attribute themes identified 
throughout this thesis. 
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The benchmarking exercise demonstrated the novel design of ATLANTIS incorporated 
many patient preference attribute themes of genomic testing.  The first, second and third 
highest order preference attribute themes were regulatory/NHS approval, test turnaround 
time and invasiveness of testing, respectively.  The pragmatic design of the trial, with 
genomic screening based on archival tissue, did not necessitate further invasive testing and 
minimised concerns of test turnaround time, given testing was performed during first line 
chemotherapy.  The highest order preference attribute, regulatory/NHS approval, was 
supported within a national clinical trial endorsed by the robust standards of clinical trial 
conduct and Good Clinical Practice (GCP) in the UK. 
 
The ATLANTIS trial did not fully incorporate the preference attributes of test 
sensitivity/specificity or family implications of testing.  This in part reflected these are 
primary research questions the study aimed to answer.  This evidence may become 
apparent throughout the lifespan of the trial, but such data would not always be known at 
the point of genomic testing for a patient entering the study.  The role of genomic profiling 
and its potential to confer germline or inheritable genomic profiles is a challenge for the 
wider precision cancer medicine community.  It may not be possible to identify presence or 
clinical relevance of all germline genomic genomic signatures at trial entry, with the 
potential uncertainty this could cause patients.  This was dealt with in ATLANTIS via the 
informed consent process.  Patients were offered the opportunity to opt in or out of 
discussions about potential inheritable or clinically significant genomic signatures 
identified by study pre-screening. 
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7.3. Implications for policy and clinical practice 
This thesis was the first in the UK to empirically identify and rate patient preferences of 
genomic testing across a spectrum of cancer subtypes and assess its incorporation in 
clinical trials.  This research identified ten patient preference attribute themes of genomic 
testing, along with providing evidence these attributes and preference ratings were context-
specific, being influenced by factors such as cancer treatment intent.  As a result, 
clinicians, clinical trialists and policy makers need to ensure they have a clear 
understanding of how individual patient context influences preferences of genomic testing.  
This thesis demonstrated patients receiving treatment with radical clinical intent identified 
different preference attributes themes and ratings compared to patients treated with 
palliative intent. 
 
This research demonstrated the identified preference attribute themes were all valued by 
patients, and thus, future provision of genomic testing supporting patient preferences 
should not exclude one attribute for another.  The number of identified attribute themes, 
paired with number of patients rating multiple, reflects the complex interaction between 
many preference attributes. 
 
As discussed in Chapter 1, PCM challenges existing clinical trial designs addressing large 
populations of patients.  This thesis outlined the sparse empirical evidence assessing 
patient preferences of genomic testing within PCM clinical trials.  The novel adaptive 
design of a single clinical trial design incorporated many preference attribute themes, 
whilst providing evidence of the challenges incorporating attributes including implications 
of inheritable mutations.  This thesis provided the first empirical evidence that novel 
pragmatic clinical trial designs can address many patient preference attributes of genomic 
testing. 
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7.4. Study strengths and limitations 
7.4.1. Study strengths 
This thesis was the first to study patient preferences of genomic testing within the UK 
healthcare setting and its incorporation within a PCM clinical trial.  This drew on 
qualitative identification of preference attribute themes followed by quantification of 
attribute ratings.  This built on existing literature assessing patient preferences of genomic 
testing and supported the hypothesis patient preferences are context-specific with regard to 
clinical treatment intent.  Using NGT allowed a realistic decision-making format for 
patients in order to identify preference attribute themes and ratings.  The use of mixed 
methods research incorporated both qualitative identification and quantitative rating of 
preference themes. 
 
This research involved patients across a wide spectrum of fourteen solid cancer subtypes 
including patients having received, or still receiving, an array of cancer treatment including 
surgery, radiotherapy, chemotherapy, immunotherapy, endocrine therapy, but the 
participant group had limited personal experience of precision cancer medicine.  Previous 
studies incorporated large numbers of healthy volunteers, which can lack robust 
application to cancer patient preferences.  This thesis recruited 102 patients, all of whom 
had personal experience of cancer diagnosis and therapy, making results more applicable 
to this population. 
 
Previous studies, conducted in North America, demonstrated preferences for specific tests 
such as Oncotype DX in breast cancer or KRAS in colo-rectal cancer, though these cannot 
readily be extrapolated to the wider cancer population, as preference attribute themes and 
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prioritisation may be unique to this subgroup or genomic test.  These attributes are also not 
directly comparable to the patient population within the UK healthcare system. 
 
This work further informs policy and clinical trial design by demonstrating patient 
preference attribute themes of genomic testing and benchmarked these against a current 
PCM clinical trial.  The clinical trial favourably incorporated many of these patient 
preference attributes, whilst also highlighting the challenges still facing novel clinical trial 
designs incorporating some others. 
 
7.4.2. Study limitations 
This thesis explored the current literature identifying patient preference attribute themes of 
genomic testing.  As discussed in Chapter 3, there were sparse empirical studies assessing 
patient preferences of genomic testing and none within the UK.  There were also no 
previous studies assessing incorporation of preference attributes within PCM clinical trials. 
 
The study sampling strategy included participants having received cancer therapy within a 
single centre in the West of Scotland.  The identified preference attributes and ratings were 
applicable to this patient population, but may not be fully representative of patients from 
out with this geographical region or healthcare setting.  Participants were also recruited to 
this study having either attended previous patient support groups or attending oncology 
follow-up clinics within the Beatson West of Scotland Cancer Centre.  This had potential 
to add patient selection bias, since participants were very motivated to attend and 
participate in the research project.  This had potential to recruit patients of higher socio-
economic group and those out with full-time employment.  These participants, having 
attended prior survivorship groups, may also have prior experience and greater 
understanding around clinical paradigms of PCM than the wider cancer patient population, 
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leading to bias.  The participants in this study, therefore, may not be fully representative of 
the wider cancer patient population across the UK. 
 
Allocation to subgroups within the study were based on participant-reported perception of 
cancer treatment intent.  This was done to reduce potential upset to participants of 
revisiting their cancer medical records and history, which may alter the relationship they 
have with the group moderator.  Given this study examined patient preferences, their 
perceptions of events have equal weight to the clinician-perceived outcomes of an 
individuals’ cancer care.   This, though, does not confirm the clinical validity of individual 
cancer treatment intent. 
 
This thesis explored patient preferences of genomic testing across a wide range of tumour 
subtypes, given the promise of PCM transcends tumour histologies.  This, therefore, does 
not focus on one specific genomic test, so may lack applicability for individual patients 
facing therapeutic decisions around a single genomic test in clinical practice.  This thesis 
did, though, add to existing literature by identifying transferrable preference attribute 
themes which could be considered when applying principles to a specific genomic test. 
 
This study employed mixed methods research design to identify and rate patient preference 
attribute themes of genomic testing in PCM.  One limitation of this design is that it did not 
allow exploration of potential interactions or trade-offs between different attributes.  The 
design was selected due to high cognitive burden of preferences within the infancy of the 
PCM paradigm for patients.  This allowed moderator involvement and support for 
participants addressing these complex issues, whilst ensuring the research questions were 
addressed throughout the Nominal Groups.  This did, though, lead to possibility of 
introducing further bias, by having a cancer clinician acting as group moderator.  It is 
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possible participant responses may have been influenced by the presence of a clinician.  
The study design attempted to mitigate this effect by always having a second moderator, 
who was a non-clinical member.  This study mirrored decision-making for patients around 
genomic testing in real-life, which would be performed in a clinical arena.  The design of 
this study reflected this paradigm. 
 
This thesis used a benchmarking exercise of the ATLANTIS trial.  The limitation of using 
this solitary study is that it involved a single tumour type and only incorporated patients’ 
treatment with palliative intent.  The use of ATLANTIS, a trial in which the thesis author 
is readily involved, had potential to introduce bias as non-independent assessment.  The 
author had involvement with the implementation of the trial, which may have altered 
perceptions of the applied benchmarking exercise.  The benchmarking exercise may, 
therefore, not be entirely applicable to other clinical trials.  One outcome of the 
benchmarking exercise, though, was to demonstrate the application of the ‘benchmark’ 
preference attributes identified throughout this thesis and how they could be applied to a 
single study.  This benchmarking exercise could, therefore, be applied to other clinical 
trials within the PCM arena, as was demonstrated by this thesis. 
 
7.5. Future research 
This thesis identified and rated patient preferences of genomic testing, then assessed how 
these were incorporated within a novel PCM clinical trial design.  The timeframes for 
clinical trial approval and conduct meant the thesis study could not be engrained within the 
trial or influence design.  It would be interesting to empirically examine whether 
preference attributes could be assessed in conjunction with a clinical trial, linking cohort 
data to the attributes identified in this thesis.  Such work may be suited to qualitative 
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methodology such as focus groups, structured interviews or longitudinal patient 
questionnaire.  
 
Following on from the work in this thesis, it would be interesting to research preferences of 
genomic testing by both funders and the general population.  This would give a comparator 
with patient preferences and potentially balance the priorities of different stake holders.  
The current study did not allow assessment of interaction and trade-offs between multiple 
inter-related attributes.  Future studies could consider this in defining trade-off thresholds 
for preference attribute themes. 
   
7.6. Conclusions 
This thesis contributed to the understanding of how patient preferences of genomic testing 
can be identified and rated in their own right as well as incorporation within a novel 
adaptive clinical trial design.  Involvement of patient preferences is seen as a barometer for 
high quality comprehensive clinical care, promoting empowerment and engagement.  This 
thesis identified the limitations of previous empirical evidence assessing patient 
preferences of genomic testing and incorporation in clinical trials.   Throughout the NGT 
and benchmarking studies, this thesis identified and rated preference attributes which can 
be used by clinical trialists and policy makers in order to ensure PCM retains patient-
centred values at its core and engrained throughout clinical trial design.   
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Appendix 1 – PRISMA CHECK LIST 
Appendix 1.  PRISMA Checklist for studies included in systematic review 
Section/topic # Checklist item Reported on page # 
TITLE 
Title 1 Identify the report as a systematic review, meta-analysis, or both. 55 
ABSTRACT 
Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; 
results; limitations; conclusions and implications of key findings; systematic review registration 
number. 
55 
INTRODUCTION 
Rationale 3 Describe the rationale for the review in the context of what is already known.  56 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
58 
METHODS 
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if 
available, provide registration information including registration number.  
N/A 
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Section/topic # Checklist item Reported on page # 
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale. 
58 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
56 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such 
that it could be repeated. 
57 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, 
and, if applicable, included in the meta-analysis).  
57 
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) 
and any processes for obtaining and confirming data from investigators. 
59 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any 
assumptions and simplifications made. 
56 
Risk of bias in individual 
studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of 
whether this was done at the study or outcome level), and how this information is to be used in 
any data synthesis. 
59 
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).  61 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis. 
N/A 
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Section/topic # Checklist item Reported on page # 
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication 
bias, selective reporting within studies).   
N/A 
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), 
if done, indicating which were pre-specified. 
N/A 
RESULTS 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram. 
61 
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations. 
61 
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see 
Item 12). 
N/A 
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data 
for each intervention group and (b) effect estimates and confidence intervals, ideally with a forest 
plot. 
62 
 
 
 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency. 
N/A 
 181 
 
Section/topic # Checklist item Reported on page # 
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). N/A 
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression 
[see Item 16]). 
N/A 
DISCUSSION 
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider 
their relevance to key groups (e.g., health care providers, users, and policy makers). 
69 
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., 
incomplete retrieval of identified research, reporting bias). 
73 
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications 
for future research. 
74 
FUNDING 
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review. 
N/A 
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Appendix 2 – Data extraction tables of studies included in systematic review 
 
Study Country Methodology Participant 
characteristics 
Attributes assessed Attribute levels Reported outcomes  
Najafzadeh 
et al 
2013 
Canada Discrete choice 
experiment of 
theoretical 
scenarios 
(aggressive 
curable versus 
non-aggressive 
incurable 
cancer) 
Total of 588 
participants 
550 healthy 
volunteer 
participants 
38 patient 
participants 
Invasiveness of testing Mouth swab, blood test, tumour, bone 
marrow or liver biopsy. 
Factors with greatest impact on 
patient decision-making were: 
Severity and likelihood of 
toxicity, sensitivity/specificity of 
testing, invasiveness of testing. 
Type and prognosis of cancer 
also affected preferences for 
genomically-guided treatment. 
 
Genomic test 
sensitivity 
5, 20, 35 and 50% 
Genomic test 
specificity 
5, 20, 35 and 50% 
Side-effects Mild, moderate or severe 
Test turnaround time 2, 7 or 12 days 
Cost of testing 
 
Can$50, $500, $1000 or $1500 
Privacy of results Patient and doctor, PD and insurance 
company, PDI and employer. 
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Study Country Methodology Participant 
characteristics 
Attributes assessed Attribute levels Reported outcomes 
Cuffe et 
al. 
2014 
Canada Hypothetical trade-off 
clinical scenario 
questionnaire (either 
metastatic or adjuvant 
setting).  Utilised 
probability trade-off 
testing. 
244 patient 
participants 
Primary attribute:  
Efficacy of therapy 
(adjuvant group) 
 
 
5-50% 
Factors with greatest impact on patient 
preferences were: 
Adjuvant group: efficacy of therapy 
Metastatic group: toxicity of therapy 
Median Willingness To Pay (WTP) 
across the study was CAD$1000-2000. 
Primary attribute: 
Toxicity of therapy 
(metastatic group). 
 
 
2.5-40% 
 
Both groups: cost of testing, 
waiting time and prevalence 
of genomic signal 
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Study Country Methodology Participant 
characteristics 
Attributes assessed Attribute levels Reported outcomes 
Issa et al 
2015 
USA Discrete 
choice 
experiment 
utilising 
genomic 
testing 
scenarios in 
breast and 
colorectal 
cancer 
300 patient 
participants 
(previous history 
of breast or 
colorectal cancer) 
Cost of genomic testing US$25, $100, $500, $1000, $2000, $4000 Factors with the greatest 
impact on patient 
preferences were: 
Probability of efficacy 
Predictive value of testing 
High willingness to pay for 
genomic testing 
Privacy of results Patient and doctor, PD and insurance 
company, PDI and employer. 
How test is used 
 
Doctor decides, patient decides or patient 
and doctor decide.  Insurance company 
use to determine coverage  
Predictive value of 
testing 
Positively predict response 55%, 70%, 
80%, 90%, 96% or 99%. 
What information will 
test provide 
Recurrence risk, recurrence/likelihood of 
benefit from chemotherapy, recurrence 
risk/likelihood of toxicity from 
chemotherapy, benefit from 
chemotherapy and likelihood of toxicity. 
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Appendix 3 – Mixed Methods Appraisal Tool (MMAT) methodological quality criteria 
Category of study 
design 
Methodological quality criteria.  Study: Genomic testing to determine drug response: measuring preferences of public 
and patients using a DCE (Najafzadeh). 
Responses 
Yes No Can’t tell 
Screening questions S1. Are there clear research questions? X   
S2. So the collected data allow to address the research questions? X   
Further appraisal may not be feasible or appropriate if answer is no to both questions    
Qualitative 1.1. Is the qualitative approach appropriate to answer research questions?     
1.2. Are the qualitative data collection methods adequate to address research questions?    
1.3. Are findings adequately derived from data?    
1.4. Is the interpretation of results sufficiently substantiated by data    
1.5. Is there coherence between qualitative data sources, collection, analysis and interpretation?    
Quantitative 
randomised 
controlled trials 
2.1. Is randomisation appropriately performed?    
2.2. Are the groups comparable at baseline?    
2.3. Are there complete outcome data?    
2.4. Are outcome assessors blinded to the intervention provided?    
2.5. Did the participants adhere to assigned intervention?    
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Category of study 
design 
Methodological quality criteria. Study: Genomic testing to determine drug response: measuring preferences of public 
and patients using a DCE (Najafzadeh). 
Responses 
Yes No Can’t tell 
Quantitative non-
randomised 
3.1. Are the participant’s representative of the target population?    
3.2. Are the measurements appropriate regarding both the outcome and intervention (or exposure)?    
3.3. Are there complete outcome data?    
3.4. Are the confounders accounted for in the design and analysis?     
3.5. During the study period, is there intervention administered (or exposure occurred) as intended?    
Quantitative 
descriptive 
4.1. Is the sampling strategy relevant to address the research questions?  X   
4.2. Is the sampling representative of the target population?  X  
4.3. Are the measurements appropriate? X   
4.4. Is the risk of non-response bias low? X   
4.5. Is the statistical analysis appropriate to answer the research question? X   
Mixed methods 5.1. Is there adequate rationale for using mixed methods design to address the research question?    
5.2. Are the different components of the study effectively integrated to answer the research question?    
5.3. Are outputs of integration of qualitative and quantitative components adequately interpreted?    
5.4. Are divergences and inconsistencies between quantitative and qualitative results adequately addressed?    
5.5. Do the different study components adhere to the quality criteria of each tradition of methods involved?    
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Category of study 
design 
Methodological quality criteria.  Study: A national study of breast and colorectal cancer patient’s decision-making for 
novel personalised medicine genomic diagnostics (Issa, Tufail, et al). 
Responses 
Yes No Can’t tell 
Screening questions S1. Are there clear research questions? X   
S2. So the collected data allow to address the research questions? X   
Further appraisal may not be feasible or appropriate if answer is no to both questions    
Qualitative 1.1. Is the qualitative approach appropriate to answer research questions?  X   
1.2. Are the qualitative data collection methods adequate to address research questions? X   
1.3. Are findings adequately derived from data? X   
1.4. Is the interpretation of results sufficiently substantiated by data X   
1.5. Is there coherence between qualitative data sources, collection, analysis and interpretation? X   
Quantitative 
randomised 
controlled trials 
2.1. Is randomisation appropriately performed?    
2.2. Are the groups comparable at baseline?    
2.3. Are there complete outcome data?    
2.4. Are outcome assessors blinded to the intervention provided?    
2.5. Did the participants adhere to assigned intervention?    
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Category of study 
design 
Methodological quality criteria.  Study: A national study of breast and colorectal cancer patient’s decision-making for 
novel personalised medicine genomic diagnostics (Issa and Tufail, et al). 
Responses 
Yes No Can’t tell 
Quantitative non-
randomised 
3.1. Are the participant’s representative of the target population?    
3.2. Are the measurements appropriate regarding both the outcome and intervention (or exposure)?    
3.3. Are there complete outcome data?    
3.4. Are the confounders accounted for in the design and analysis?     
3.5. During the study period, is there intervention administered (or exposure occurred) as intended?    
Quantitative 
descriptive 
4.1. Is the sampling strategy relevant to address the research questions?  X   
4.2. Is the sampling representative of the target population? X   
4.3. Are the measurements appropriate? X   
4.4. Is the risk of non-response bias low?  X  
4.5. Is the statistical analysis appropriate to answer the research question? X   
Mixed methods 5.1. Is there adequate rationale for using mixed methods design to address the research question? X   
5.2. Are the different components of the study effectively integrated to answer the research question? X   
5.3. Are outputs of integration of qualitative and quantitative components adequately interpreted? X   
5.4. Are divergences and inconsistencies between quantitative and qualitative results adequately addressed? X   
5.5. Do the different study components adhere to the quality criteria of each tradition of methods involved? X   
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Category of study 
design 
Methodological quality criteria.  Study: Cancer patients’ acceptance, understanding and willingness-to-pay for 
pharmacogenomics testing (Cuffe et al). 
Responses 
Yes No Can’t tell 
Screening questions S1. Are there clear research questions? X   
S2. So the collected data allow to address the research questions? X   
Further appraisal may not be feasible or appropriate if answer is no to both questions    
Qualitative 1.1. Is the qualitative approach appropriate to answer research questions?  X   
1.2. Are the qualitative data collection methods adequate to address research questions? X   
1.3. Are findings adequately derived from data? X   
1.4. Is the interpretation of results sufficiently substantiated by data X   
1.5. Is there coherence between qualitative data sources, collection, analysis and interpretation? X   
Quantitative 
randomised 
controlled trials 
2.1. Is randomisation appropriately performed?    
2.2. Are the groups comparable at baseline?    
2.3. Are there complete outcome data?    
2.4. Are outcome assessors blinded to the intervention provided?    
2.5. Did the participants adhere to assigned intervention?    
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Category of study 
design 
Methodological quality criteria.  Study: Cancer patients’ acceptance, understanding and willingness-to-pay for 
pharmacogenomics testing (Cuffe et al). 
Responses 
Yes No Can’t tell 
Quantitative non-
randomised 
3.1. Are the participant’s representative of the target population?    
3.2. Are the measurements appropriate regarding both the outcome and intervention (or exposure)?    
3.3. Are there complete outcome data?    
3.4. Are the confounders accounted for in the design and analysis?     
3.5. During the study period, is there intervention administered (or exposure occurred) as intended?    
Quantitative 
descriptive 
4.1. Is the sampling strategy relevant to address the research questions?  X   
4.2. Is the sampling representative of the target population? X   
4.3. Are the measurements appropriate? X   
4.4. Is the risk of non-response bias low? X   
4.5. Is the statistical analysis appropriate to answer the research question? X   
Mixed methods 5.1. Is there adequate rationale for using mixed methods design to address the research question? X   
5.2. Are the different components of the study effectively integrated to answer the research question? X   
5.3. Are outputs of integration of qualitative and quantitative components adequately interpreted? X   
5.4. Are divergences and inconsistencies between quantitative and qualitative results adequately addressed? X   
5.5. Do the different study components adhere to the quality criteria of each tradition of methods involved? X   
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Appendix 4 – Patient preference attribute summary tables 
Ten preference attribute themes emerged from the data generated in the nominal groups 
after the clarification stage.  There were thirty four attributes identified at the end of the 
round robin, which were taken into the clarification stage.  These preference attribute 
themes are shown below. 
Identified preference attributes 
theme after NGT clarification 
stage 
Preference attributes identified on whiteboard after 
round robin stage 
Invasiveness of testing 1 – ‘Soreness of test’ 
2 – ‘Whether biopsy or blood test’ 
3 – ‘Test to be simple and not intrusive’ 
4 – ‘The least painful test’ 
Regulatory/NHS approval 5 – ‘The test approved so my doctor can authorise it’ 
6 – ‘I know tests need NHS approval’ 
7 – ‘If a test is really good enough then I have faith the 
NHS would approve it, so I would feel more confident in it’ 
Test sensitivity/true positive 8 – ‘If I had the genetic thing being tested then I would 
want the test to find it’ 
9 – ‘I would want the test to pick up the variant almost all 
the time and not miss an opportunity that could benefit me’ 
10 – ‘The test should be accurate in showing me the 
problem’ 
Test specificity/true negative 11 – ‘I would want to know if I don’t have the thing being 
tested, rather than waste time with treatment that may not 
help me’ 
12 – ‘I would want to correctly know if I don’t have the 
variant, rather than waste anyone’s time’  
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Physician approval 13 – ‘I trust my doctor and if they feel it’s a good idea then 
I’d probably go for it’ 
14 – ‘My doctor knows me and my case best, so if she 
agreed then I’d try it’ 
15 – ‘If my consultant wanted to put me forward’ 
16 – ‘I trust my doctor to know what’s best for me.’ 
Family approval 17 – ‘I would not want to upset my family and if they 
pushed me then I would probably do it’ 
18 – ‘I know they care so I would think about it, my wife 
helps me with all the difficult decisions in my life’ 
19 – ‘My family go through everything with me, so I would 
need their support for this too.’ 
Distance to travel for testing 20 – ‘They can’t do some tests in my local hospital, another 
patient I knew had to travel to England and he found it 
hard’ 
21 – ‘I would like it to be near home if possible’ 
22 – ‘I would struggle to travel, that would make me 
anxious.’ 
23 – ‘I wouldn’t want to travel somewhere the medical 
team don’t know me.’ 
Test turnaround time 
 
 
 
 
 
 
 
24 – I remember so much worry at that time and the days 
went so slowly waiting for results’ 
25 – I wouldn’t want to wait for results’ 
26 – Don’t want it slowing down my treatment starting’ 
27 – ‘Time is precious to me and I don’t want to waste it 
waiting for results’ 
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Implications for family members 
of testing 
28 – ‘This may help my daughter being diagnosed sooner 
than I was’ 
29 – ‘I would feel so much guilt to know I may have passed 
something onto my children’ 
30 – ‘I do not know how I would tell my family, but would 
prefer to know’ 
31 – ‘As a parent, I would want to protect my children’  
Prevalence of variant 32 – ‘How commonly is the result positive’ 
33 – ‘How many people the test has a result that would help 
them’ 
34 – ‘The chance of actually having the genomic thing if 
it’s very rare’ 
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Appendix 5 – Pilot Nominal Group Study guide (v1.0) 
General Introduction 
Each nominal group will have the same set of interview questions and will be conducted 
by two moderators.  Demographic questionnaires will be collected prior to the beginning of 
the nominal groups. 
 
‘Welcome to our session.  We wish to thank you for taking the time to join us in talking 
about genomic testing in precision cancer medicine.  Introduce self (names of moderators).  
We would like to develop effective genomic tests that are valued by cancer patients.  In 
order to develop such tests, we need firstly to understand the attitudes of patients regarding 
cancer testing.  These nominal groups we are holding are a first step in this proceed.  We 
are going to have further similar discussions with groups of patients over the coming 
weeks. 
 
You have been invited to attend because you have each previously been diagnosed with 
cancer and received cancer treatment here in the West of Scotland.  In our discussions 
today, there are no right or wrong answers, but rather differing points of view.  Our hope is 
to gather all of these points of view, so please feel free to share yours, even if it is different 
to what has been suggested by the rest of the group.  Although you may not necessarily 
agree with the views of others, we would be grateful if you would listen respectfully as 
others share their views and that only one person talks at a time.  We would be very 
grateful if the discussions we have today remain in this room, in order to respect the 
confidentiality of everyone participating. 
 
We have placed name cards on the table in front of you, so please let us start by finding out 
some more about each other by going around the table.  Moderator to start and introduce 
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self, name and what you hope to achieve form today’s session.  Then invite next 
participant to follow suit until all participants have done so. 
 
Stage 1 - Silent generation of ideas 
Now we would like to ask some questions about your experiences of cancer, diagnosis, 
testing and treatment.  We would like you to take some time on your own to think about 
your personal experiences of cancer testing.  What were the main features/attribute of a 
genomic cancer test that you feel would have either a positive or negative effect on your 
preference towards having that test?    Please take a few minutes to think about this 
yourself and write down your answers.   
 
Stage 2 – Round robin 
After everyone has written down their answers and is ready, we will go around the table in 
turn and ask people to share one from their list until all the items have been heard.  As you 
read out the items, we will write them on the whiteboard as a record for us all to see.   
 
Stage 3 – Clarification 
Once all items have been shared, we will discuss each of them in turn and why they were 
selected.  Then we will have one long list of responses.  It is possible that different people 
may use similar terms to describe the same response, so we will discuss these with the 
whole group to come up with a final list and can combine some if they refer to the same 
response/attribute.  As a group, you will decide this. 
  
Stage 4 – Rating of preference attribute themes 
The group will have a full list from Stage 3 of the responses regarding the attributes of a 
genomic test from and at this point we will ask you each individually to rate each item by 
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writing these on the printed paper which we will provide for you.  This is done by giving a 
score of 9 to the item which you feel is most important to you, 8 to the item you feel next 
most important and so on.  You do not have to give a score to every item on the list if you 
do not feel it applies to you.  For this part, you do the rating on your own and can consider 
any of the information you have heard during the prior discussions. 
 
We will then collect the individual rating paper sheet from each of you and will collate all 
the information.  If you wish, then you can wait and we will discuss preliminary results of 
this with you, or you can attend a further update session at a later date if you wish more 
detailed summary of the group results. 
 
Conclusion 
We have come to the end of our nominal group session for today.  We would like to 
sincerely thank each of you for participating today and those who helped bring you to this 
group session.  Does anyone have any final questions? 
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Appendix 6 – Main Nominal Group Study Guide (v2.0)  
General Introduction 
Each nominal group will have the same set of interview questions and will be conducted 
by two moderators.  Demographic questionnaires will be collected prior to the beginning of 
the nominal groups. 
 
‘Welcome to our session.  We wish to thank you for taking the time to join us in talking 
about genomic testing in precision cancer medicine.  Introduce self (names of moderators).  
You have been invited to attend because you have each previously been diagnosed with 
cancer and received cancer treatment here in the West of Scotland and so have personal 
experience of cancer tests and treatment.  We appreciate that many patients will not have 
personal experience or possibly much awareness of precision cancer medicine.  Precision 
cancer medicine is an approach to patient care that allows doctors to select treatments that 
are most likely to help patients based on a genetic understanding of their cancer.  This idea 
is not new, but recent scientific advances have helped speed up the pace of this area of 
research.  In the past, when a patient is diagnosed with cancer, they usually receive similar 
treatment as others who have the same type and stage of cancer.  Even so, different people 
may respond differently and until recently doctors did not know why.  With emerging 
scientific discovery, doctors now understand that patients’ tumours have genetic changes 
that cause cancer to grow and spread.  These changes may occur in one individual but no 
another. 
 
If there is a targeted treatment that is approved for your type of cancer, you will likely be 
tested to see if the genetic change targeted by the treatment is present in your tumour.  This 
test can be done in many different ways.  We would like to develop these effective genetic 
tests that are valued by cancer patients.  In order to develop such tests, we need firstly to 
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understand the attitudes of patients regarding cancer testing.  These nominal groups 
discussions we are holding are a first step in this proceed.  We are going to have further 
similar discussions with groups of patients over the coming weeks. 
 
In our discussions today, there are no right or wrong answers, but rather differing points of 
view.  Our hope is to gather all of these points of view, so please feel free to share yours, 
even if it is different to what has been suggested by the rest of the group.  Although you 
may not necessarily agree with the views of others, we would be grateful if you would 
listen respectfully as others share their views and that only one person talks at a time.  We 
would be very grateful if the discussions we have today remain in this room, in order to 
respect the confidentiality of everyone participating. 
 
We have placed name cards on the table in front of you, so please let us start by finding out 
some more about each other by going around the table.  Moderator to start and introduce 
self, name and what you hope to achieve form today’s session.  Then invite next 
participant to follow suit until all participants have done so. 
 
Stage 1 - Silent generation of ideas 
Now we would like to ask some questions about your experiences of cancer, diagnosis, 
testing and treatment.  We would like you to take some time on your own to think about 
your personal experiences of cancer testing.  What were the main features/attribute of a 
genomic cancer test that you feel would have either a positive or negative effect on your 
attitude towards that test?    Please take a few minutes to think about this yourself and write 
down your answers.   
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Stage 2 – Round robin 
After everyone has written down your answers and is ready, we will go around the table in 
turn and ask people to share one from their list until all the items have been heard.  As you 
read out the items, we will write them on the whiteboard as a record for us all to see.   
 
Stage 3 – Clarification 
Once all items have been shared, we will discuss each of them in turn and why they were 
identified.  Then we will have one long list of responses.  It is possible that different people 
may use similar terms to describe the same idea, so we will discuss these with the whole 
group to come up with a final list and can combine some if the group feel they refer to the 
same response/attribute. 
  
Stage 4 – Rating of preference attribute themes 
The group will have a full list from Stage 3 of the responses regarding the attributes of a 
genomic test from and at this point we will ask you each individually to rate each item by 
writing these on the printed paper which we will provide for you.  This is done by giving a 
score of 9 to the item which you feel is most important to you, 8 to the item you feel next 
most important and so on.  You do not have to give a score to every item on the list if you 
do not feel it applies to you.  For this part, you do the rating on your own and can consider 
any of the information you have heard during the prior discussions. 
 
We will then collect the individual rating paper sheet from each of you and will collate all 
the information.  If you wish, then you can wait and we will discuss preliminary results of 
this with you, or you can attend a further update session at a later date if you wish more 
detailed summary of the group results. 
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Conclusion 
We have come to the end of our nominal group session for today.  We would like to 
sincerely thank each of you for participating today and those who helped bring you to this 
group session.  Does anyone have any final questions? 
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Appendix 7 – Ethics Approval 
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Appendix 8 – Participant Consent form 
 
CONSENT FORM FOR PARTICIPANTS IN RESEARCH STUDY 
 
Title of Project: 
Nominal group research to determine patient preferences for genomic testing in precision 
cancer medicine.  
           
 Please initial box 
1.    I confirm that I have read and understand the information sheet dated 23/05/20 
16 (v2.0) for the above research study, that I fully understand what is involved in 
taking part in this research study, and that I have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw  
at any time, without giving any reason, without my medical care or legal rights being 
affected. 
 
3. I understand that my information may be looked at by representatives of the  
study Sponsor (NHS Greater Glasgow and Clyde) for audit purposes. 
 
4. I understand that the focus groups sessions will be audio-recorded. 
 
5. I agree to take part in the above research study. 
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Please sign and date below: 
     
Name of Participant  Date  Signature 
     
Name of Person taking consent 
 
 Date  Signature 
 
When completed, 1 original for participant; 1 original for researcher; 
